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ABSTRACT 
Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine protein kinase 
which is engaged in a variety of signaling pathways, regulating a wide range of cellular 
processes. Due to its distinct regulation mechanism and unique substrate specificity in the 
molecular pathogenesis of human diseases, GSK-3 is one of the most attractive therapeutic 
targets for the unmet treatment of pathologies, including type-II diabetes, cancers, inflammation, 
and neurodegenerative disease. Recent advances in drug discovery targeting GSK-3 involved 
extensive computational modeling techniques. Both ligand/structure-based approaches have been 
well explored to design ATP-competitive inhibitors. Molecular modeling plus dynamics 
simulations can provide insight into the protein-substrate and protein-protein interactions at 
substrate binding pocket and C-lobe hydrophobic groove, which will benefit the discovery of 
non-ATP-competitive inhibitors. 
To identify structurally novel and diverse compounds that effectively inhibit GSK-3β, we 
performed virtual screening by implementing a mixed ligand/structure-based approach, which 
included pharmacophore modeling, diversity analysis, and ensemble docking. The sensitivities of 
different docking protocols to the induced-fit effects at the ATP-competitive binding pocket of 
GSK-3β have been explored. An enrichment study was employed to verify the robustness of 
ensemble docking compared to individual docking in terms of retrieving active compounds from 
a decoy dataset. A total of 24 structurally diverse compounds obtained from the virtual screening 
experiment underwent biological validation. The bioassay results showed that 15 out of the 24 
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hit compounds are indeed GSK-3β inhibitors, and among them, one compound exhibiting sub-
micromolar inhibitory activity is a reasonable starting point for further optimization. 
To further identify structurally novel GSK-3β inhibitors, we performed virtual screening 
by implementing another mixed ligand-based/structure-based approach, which included 
quantitative structure-activity relationship (QSAR) analysis and docking prediction. To integrate 
and analyze complex data sets from multiple experimental sources, we drafted and validated 
hierarchical QSAR, which adopts a multi-level structure to take data heterogeneity into account. 
A collection of 728 GSK-3 inhibitors with diverse structural scaffolds were obtained from 
published papers of 7 research groups based on different experimental protocols. Support vector 
machines and random forests were implemented with wrapper-based feature selection algorithms 
in order to construct predictive learning models. The best models for each single group of 
compounds were then selected, based on both internal and external validation, and used to build 
the final hierarchical QSAR model. The predictive performance of the hierarchical QSAR model 
can be demonstrated by an overall R
2
 of 0.752 for the 141 compounds in the test set. The 
compounds obtained from the virtual screening experiment underwent biological validation. The 
bioassay results confirmed that 2 hit compounds are indeed GSK-3β inhibitors exhibiting sub-
micromolar inhibitory activity, and therefore validated hierarchical QSAR as an effective 
approach to be used in virtual screening experiments.  
We have successfully implemented a variant of supervised learning algorithm, named 
multiple-instance learning, in order to predict bioactive conformers of a given molecule which 
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are responsible for the observed biological activity. The implementation requires instance-based 
embedding, and joint feature selection and classification. The goal of the present project is to 
implement multiple-instance learning in drug activity prediction, and subsequently to identify the 
bioactive conformers for each molecule. The proposed approach was proven not to suffer from 
overfitting and to be highly competitive with classical predictive models, so it is very powerful 
for drug activity prediction. The approach was also validated as a useful method for pursuit of 
bioactive conformers. 
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Chapter 1. INTRODUCTION TO GLYCOGEN SYNTHASE 
KINASE-3 AND RELEVANT DRUG DISCOVERY 
 2 
 
1.1. PHYSIOLOGICAL FUNCTION 
Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine protein kinase 
which is ubiquitously involved in the regulation of a wide range of cellular functions, including 
glucose metabolism, neuronal processes, chronic inflammations, cell proliferation and 
apoptosis.
1, 2
 Its involvement in many cellular processes is derived from the fact that GSK-3 
plays an important role in a variety of signaling pathways, most importantly Wnt signaling and 
insulin signaling pathway.
3
 The Wnts are a family of protein ligands that influence cell 
proliferation, differentiation, and migration. Wnt signal transduction ultimately results in the 
activation of genes regulated by transcription factors, and the activation should be realized by the 
binding of transactivator β-catenin to the transcription factors. GSK-3 phosphorylates the N-
terminal domain of β-catenin, resulting in ubiquitylation and proteasomal degradation of β-
catenin. So GSK-3 plays a key inhibitory role in the Wnt pathway, which is crucial for the 
specification of cell fate during embryonic development.
4
 The level of blood glucose is largely 
determined by the rate at which glucose is converted into glycogen by glycogen synthase, which 
is one of the important GSK-3 substrates.  
1.2. REGULATION MECHANISM 
It is interesting that the phosphorylation of glycogen synthase in insulin signaling 
pathway and β-catenin in Wnts signaling pathway are regulated through different mechanisms: 
insulin-induced inactivation of GSK-3 involves the phosphorylation of the serine residue in the 
glycine-rich N-terminal domain, whereas Wnts-induced inhibition of GSK-3 relates to the 
protein complex formation and displacement.
1, 5, 6
 The X-ray crystal structures revealed a 
phosphate binding site adjacent to the active site, which constitutes three positively charged 
residues (Arg96, Arg180 and Lys205) to bind the priming phosphate at P+4 position of the 
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substrate S/T-X-X-X-S/T(p) motif.
7-9
 This binding stabilizes the active conformation of the 
activation loop, which explains the primed substrate specificity of GSK-3 and suggests a 
mechanism for inhibitory serine phosphorylation (so-called autoinhibition).
9
 Insulin signaling 
promotes the phosphorylation of Ser21 in GSK-3α and Ser9 in GSK-3β near N-terminus, which 
transforms the N-terminus into a pseudo-substrate inhibitor that competitively occupies the same 
binding site and blocks the access for true primed substrate.
7
 In contrast, the phosphorylation of 
β-catenin in Wnts signal-transduction pathway is regulated through a different mechanism. The 
multiprotein complex consisting of GSK-3β, axin, and adenomatous polyposis coli (APC) 
protein is responsible for the phosphorylation of β-catenin, and thereby promotes its 
ubiquitylation and destruction. The Wnts triggers a signal-transduction pathway that involves the 
displacement of axin-APC scaffold with FRAT (frequently rearranged in advanced T-cell 
lymphomas), which leads to the dephosphorylation of β-catenin. The axin- and FRAT-binding 
sites of GSK-3 near the C-terminal end introduced a new binding pocket responsible for protein-
protein interaction.
10, 11
  
1.3. ISOFORMS AND TAU HYPERPHOSPHORYLATION 
There are two mammalian GSK-3 isoforms encoded in different genes: GSK-3α and 
GSK-3β.12 Although they are highly homologous, with 84% overall identity and 98% identity in 
the catalytic domain, they are not functionally identical.
1
 GSK-3β, also known as tau protein 
kinase I (TPK-I), has significant involvement in tau protein hyperphosphorylation, which has 
been observed in many neurodegenerative disorders such as Alzheimer‘s disease (AD).13 A new 
splice isoform, which contains a 13-residue insert within the kinase domain, has also been 
identified.
14
 Analysis of the kinase activity revealed that the new splice isoform GSK-3β2 has 
reduced tau protein phosphorylation compared with GSK-3β1. Since GSK-3β is highly 
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expressed in brain and is relevant to a variety of neurological disorders, it has attracted 
significant attention as a therapeutic target and as a molecular tool to understand the 
pathogenesis of these disorders. 
The disease association with AD was established when GSK-3β was isolated from brain 
extracts and shown to produce paired helical filament (PHF) epitopes on tau. Tau is a 
microtubule-associated protein expressed throughout the central nervous system (CNS), but 
predominantly in neuronal axons. Partially phosphorylated tau contains sequence motifs that 
promote association with tubulin, which leads to stabilization of microtubules. However, 
pathological hyperphosphorylation of these motifs prevents tubulin binding and thereby results 
in the destabilization of microtubules.
15
 There is strong evidence that GSK-3β co-localizes 
preferentially with insoluble neurofibrillary tangles and contributes to the formation of PHF in 
AD brain.
16
 GSK-3β has been shown to hyperphosphorylate tau both in transfected mammalian 
neuronal cells and in vivo.
17-19
  
1.4. STRUCTURAL INFORMATION 
The crystal structure of GSK-3β (Figure 1.1) consists of two domains: the N-terminal 
domain (N-lobe) and C-terminal domain (C-lobe), and the two domains form an in-between cleft 
which is the ATP-binding pocket. The conserved Asp200-Phe201-Gly202 (DFG) motif at the N-
lobe of the activation loop (A-loop) is in the active conformation (DFG-in conformation), where 
Asp200 coordinates γ-phosphate of ATP in the proper position for phosphate transfer and 
Phe201 makes hydrophobic contacts with the Met101 from αC-helix and the His179 in the 
conserved His179-Arg180-Asp181 (HRD) motif. The highly conserved Asp181 in the HRD 
motif at the catalytic loop is responsible for the correct configuration of the P-site 
serine/threonine in the peptide substrate, and most likely serves as the catalytic base to accept the 
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proton from the hydroxyl group of the substrate serine/threonine in a proposed dissociative 
phosphorylation mechanism.
20
 The tight electrostatic interaction between the Glu97 from αC-
helix and the Lys85 from β3-strand at N-lobe generates a lobe closure which is important in the 
active conformation. This polar contact combined with the hydrophobic spine consisting of 
Leu112 at N-lobe, Met101 at αC-helix, Phe201in DFG motif, and His179 in HRD motif are 
responsible for the activated GSK-3 structure.
21
 The triad of basic residues consisting of Arg96 
from αC-helix, Arg180 from catalytic loop, and Lys205 from A-loop forms a positively charged 
binding pocket to accommodate the priming phosphate, which is responsible for the unique 
substrate specificity. The C-lobe hydrophobic groove formed by αG-helix (Gly262-Leu273) and 
an extended loop (Asn285-His299) presents an interface for protein-protein interaction.  
 
Figure 1.1. A) cartoon representation of a crystal structure (PDB code: 1PYX) of GSK-3. Color 
codes: light blue for N-lobe; white for C-lobe; brown for hinge region; cyan for glycine rich loop 
(G-loop); pink for C-loop; wheat for αC-helix; magenta for DFG moiety; orange for HRD 
moiety; marine for activation loop (A-loop); yellow for αG-helix; violet for extended loop; Small 
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molecule ADPPNP is in stick representation; B) Important residues highlighted in stick 
representation (PDB code: 1O9U). 
1.5. DRUG DISCOVERY TARGETING GSK-3 
Due to its distinct regulation mechanism and unique substrate specificity in the molecular 
pathogenesis of human diseases, GSK-3 is one of the most attractive therapeutic targets for the 
treatment of unmet pathologies, including type-II diabetes, cancers, inflammation, and 
neurodegenerative disease.
2, 22
 The inhibition of GSK-3 phosphorylation can promote the 
conversion of glucose to glycogen, overcoming the resistance to insulin, which may be beneficial 
for the treatment of type-2 diabetes. The involvement of GSK-3 in cellular signaling pathways 
makes it essential in cell apoptosis and survival. The neuropathological characteristics of AD are 
defined by the presence of intracellular neurofibrillary tangles (NFTs) and extracellular amyloid 
plaques. NFTs are insoluble accumulations of hyperphosphorylated tau in the filamentous form, 
and amyloid plaques are dense deposits of β-amyloid (Aβ) peptides metabolized from β-amyloid 
precursor protein (APP). GSK-3 contributes to tau hyperphosphorylation and regulates APP 
processing, and inhibition of GSK-3 attenuates tau phosphorylation and Aβ levels.23  
The aberrant regulation of GSK-3 in a variety of human diseases stimulated the 
development of selective and potent GSK-3 inhibitors as promising new drug candidates with 
great therapeutic potentials.
24
 Numerous research efforts both in academy and pharmaceutical 
companies have shown solid evidence of preclinical and clinical efficacy for these new drug 
candidates in the modulation of glycogen metabolism, gene transcription and 
neurodegeneration.
23, 25
 Most of these compounds are ATP-competitive inhibitors and none of 
them have demonstrated isoform selectivity. Several successful representatives (Figure 1.2) of 
GSK-3 inhibitors include SB 216763 and SB 415286, reported to normalize blood glucose levels 
in human liver cells and induce gene expression in HEK293 cells,
26
 CHIR 98023 and CHIR 
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99021, reported to promote the activation of glycogen synthase and stimulate glycogen 
deposition in the liver,
27
 and cazpaullones (1-azakenpaullone derivatives), reported to stimulate 
pancreatic β-cell replication and protection in isolated rat islets.28 Those compounds might be 
useful for the treatment of diabetes.
25
 Other useful GSK-3 inhibitors include 6-bromoindirubin-
3‘-oxime, which reduces the β-catenin phosphorylation on a GSK-3 specific site,29 
hymenialdisine, which blocks the phosphorylation of the microtubule-binding protein tau,
30
 and 
AR-A014418, (aminothiazole) which was also shown to inhibit tau phosphorylation at a GSK-3 
specific site.
31
 Those compounds could be developed as anti-cancer agents
32
 or neuroprotective 
agents.
33
 
 
Figure 1.2. Representatives of small molecule GSK-3 inhibitors advanced into preclinical or 
clinical trials.  
 
Since all kinase enzymes share a common binding site for ATP and most of the current 
GSK-3 inhibitors competitively interact with the ATP-binding site, design of potent inhibitors 
with high degrees of selectivity during drug discovery remains a challenge. To better address 
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selectivity issues, kinase inhibitors without direct interaction with ATP-binding site provide 
promise of therapeutic interventions with fewer off-target side effects. A class of non-ATP-
competitive GSK-3β inhibitors that have been reported as new disease-modifying agents for the 
effective treatment of AD and other tauopathies are thiadiazolidinones (TDZD) and derivatives 
(Figure 1.2).
34
 Although their structure-activity relationships have been studied,
35
 a clear 
understanding of the binding mode and inhibition mechanism is still unavailable. The substrate-
competitive inhibitor L803-mts (N-Myristol-GKEAPPAPPQS(p)P) has demonstrated promising 
preclinical merit through in vivo inhibition of GSK-3, including antidepressant-like activity 
based on the evidence of up-regulated β-catenin in mouse hippocampus;36 insulin mimetic action 
based on the facts of elevated glycogen synthase activity and increased glucose uptake.
37
 
Furthermore, long-term administration of L803-mts into mice can reduce blood glucose levels, 
improve glucose tolerance and homeostatis in a diabetic model.
38
 
Although a number of GSK-3 inhibitors have emerged and several of them are fairly 
potent, none of them have been developed as effective drug candidates nor approved by the US 
Food and Drug Administration. The major reasons frustrating all the efforts are kinase selectivity 
issues and poor pharmacokinetic profile including factors such as CNS bioavailability. Hence 
there is still a great need to identify and develop structurally novel and diverse GSK-3β 
inhibitors as potential therapeutic interventions. Various efforts have been made in the discovery 
and development of potent and selective GSK-3 inhibitors and the most fruitful one has been 
computer-aided drug design (CADD), which accelerated the lead evolution and optimization for 
the pursuit of structurally novel and diverse GSK-3 inhibitors. CADD approaches can typically 
be divided into two classes: ligand-based approaches and structure-based approaches. For ligand-
based approaches, the inhibitory activities of thousands of compounds against GSK-3 have been 
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reported, along with extensive quantitative structure-activity relationship (QSAR) studies. QSAR 
has been employed to correlate the biological activities with the structural or physicochemical 
properties, and the correlations subsequently provided the distinguishing and favorable 
characteristics. For structure-based approaches, around 30 crystal structures of GSK-3 currently 
have been deposited in Protein Data Bank (PDB
39
) (1GNG,
11
 1H8F,
7
 1I09,
8
 1J1B,
40
 1J1C,
40
 
1O9U,
10
 1PYX,
41
 1Q3D,
41
 1Q3W,
41
 1Q41,
41
 1Q4L,
41
 1Q5K,
42
 1R0E,
43
 1UV5,
44
 2O5K,
45
 
2OW3,
46
 2JLD,
47
 3DU8,
48
 3F7Z,
49
 3F88,
49
 3GB2,
50
 3I4B,
51
 3L1S,
52
 3M1S,
53
 and 3PUP
54
), 
which were utilized to predict the binding modes and affinities of new inhibitors.  
Several successful high throughput virtual screening experiments were conducted via 
ligand-based approaches, especially quantitative structure-activity relationship (QSAR) analyses 
and pharmacophore screening.
55-57
 The reason that previous researchers preferred ligand-based 
virtual screening rather than structure-based virtual screening is that the X-ray crystal structures 
only provide a static picture of ligand-protein complexes and give limited information as to how 
protein flexibility can be exploited for the purpose of drug discovery. Docking and enrichment 
studies in the adaptive ATP-binding site of six GSK-3β crystal structures have shown the poor 
prediction accuracies of docking poses without considering the significant induced fit effects.
58
 
However, structure-based approaches not only give us information regarding the best possible fit 
of a molecule in the binding site, but also provide insight into the important binding features 
essential to the ligand-protein interaction that can be used to address selectivity problems 
especially against highly homologous kinases.
59, 60
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Chapter 2. RECENT ADVANCES IN COMPUTATIONAL 
MODELING TARGETING GSK-3 FOR DRUG DISCOVERY 
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2.1. COMPUTATIONAL MODELING TARGETING ATP-BINDING 
POCKET 
2.1.1. LIGAND-BASED APPROACHES 
2.1.1.1. QSAR ANALYSIS 
Extensive QSAR studies have been applied on GSK-3 inhibitors (Appendix: A), 
including 3-anilino-4-arylmaleimides,
61
 indirubins,
44, 62, 63
 paullones, 
64
 aloisines,
65
 2,4-
disubstituted thiadiazolidinones (TDZD),
34, 35
 pyrazolopyrimidines,
66, 67
 pyrazolopyridazine,
68, 69
 
pyrazolopyridines,
70-72
 and benzofuran-3-yl-(indol-3-yl)maleimides.
73
 Exploration of QSAR 
entails statistically significant correlation between structural and physicochemical properties (so-
called independent variables) and biological activities (so-called dependent variables) of the 
chemical structures. 
Katritzky et al. reported a 2D-QSAR study of 277 GSK-3 inhibitors using geometrical, 
topological, quantum mechanical, and electronic descriptors.
74
 The study compared both a linear 
QSAR method using multiple linear analysis (MLA) and a nonlinear QSAR method using 
artificial neural networks (ANN). Based on internal validation, the MLA produced highly 
predictive models for 3-anilino-4-arylmaleimides, moderately predictive models for 
pyrazolopyridines, and weakly predictive models for pyrazolopyridazines and 
pyrazolopyrimidines. In comparison, nonlinear QSAR modeling of the whole collection of 
compounds using ANN yielded acceptable predictions for both training set and test set. 
However, the interpretability was compromised in the nonlinear model. Sivaprakasam et al. also 
reported a 2D-QSAR study using Fujita-Ban and Hansch analysis, which explored the 
physicochemical and structural requirements for a set of 3-anilino-4-phenylmaleimides toward 
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GSK-3α binding.75 The interpretability of Fujita-Ban and Hansch analysis is high and they 
agreed on the conclusion that hydrophobic interaction at the 3-anilino ring as well as steric and 
electronic interactions on the 4-phenyl ring are crucial for inhibitory activities.  
To improve interpretability, 3D-QSAR using comparative molecular field analysis 
(CoMFA) and comparative molecular similarity indices analysis (CoMSIA) is very helpful. One 
of the most crucial steps for CoMFA and CoMSIA methods is structural alignment, which 
requires a reference as putative bioactive conformation. Sivaprakasam et al. reported a 3D-
QSAR study using CoMFA and CoMSIA to further examine the structural requirements toward 
GSK-3α binding of 3-anilino-4-arylmaleimides.76 Two structural alignment strategies were 
employed and compared, which were ligand-based alignment using the lowest energy 
conformation of the most active compound and structure-based alignment using the locally 
minimized conformation of co-crystallized compound. Based on statistical results, the structure-
based alignment produced the best models for both CoMFA and CoMSIA. Two alignment 
strategies have also been employed by Zeng et al. to carry out CoMFA and CoMSIA for 
aloinsines as GSK-3 inhibitors.
77
 In comparison, structure-based alignment which utilized a high 
energy conformation extracted from a co-crystallized structure of aloisine B with CDK2 yielded 
much better statistical parameters for both CoMFA and CoMSIA. So the bioactive conformation 
is not usually the lowest in energy. Another 3D-QSAR study using CoMFA and CoMSIA was 
carried out by Zhang et al. for indirubins, and it also compared two alignment rules.
78
 However, 
the comparison was performed in a different way. The same template conformation of indirubin-
3‘-oxime extracted from a co-crystallized structure was employed, and two different sets of 
conformations for the compounds in the training set were used in two alignment rules for 
comparison. In the so-called receptor-based method, the docking poses of compounds in the 
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training set were used for superimposition. In the so-called ligand-based method, the minimum 
energy conformations for the compounds in the training set were superimposed on the same 
template conformation of indirubin-3‘-oxime. The comparison showed evidence that the 
minimum energy conformations produced better predictions for both CoMFA and CoMSIA. 
Since the differences of statistical results for the two alignment rules were not significant, both 
methods are suitable to build reliable 3D-QSAR models.  
When the binding modes are not available from crystal structures, the 3D-QSAR analysis 
can be imperative to explore the structural requirements for ligand-protein binding. TDZDs are 
identified as the first ATP-noncompetitive GSK-3 inhibitors, which block phosphorylation 
without targeting ATP binding. These compounds are of great interest since they did not show 
inhibitory activity against other kinases and the mechanism of their inhibitory action is still not 
clear. A CoMFA study based on the alignment of minimum energy conformations produced a 
predictive model for TDZDs, which was externally validated using an independent test set.
35
 3D-
QSAR can be also very important in selectivity studies to explore the correlations between the 
chemical structures and the multiple biological activities. Paullones exhibited multiple inhibitory 
activities against CDK1, CDK5, and GSK-3. Three CoMSIA models were established and 
compared. Since the structural alignment was based on the minimized docking poses at the 
CDK1 ATP-binding site, the statistical results obtained for the CDK1 model were clearly 
superior to the ones for the CDK5 model and the GSK-3 model. The 3D contour maps for the 
inhibitory activities of paullones with respect to CDK1, CDK5, and GSK-3 indicated that the 
electronic fields between the models should be taken into account for the development of GSK-3 
selective paullones
64
. 
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A 3D-QSAR study using CoMFA and CoMSIA followed by molecular docking can be 
used as a conventional approach to unveil the structural requirements for ligand-protein 
interactions, which is beneficial for medicinal chemists to optimize lead compounds with high 
interpretability. However, the structural alignment of 3D-QSAR requires the molecules to have a 
similar scaffold, which typically limits the predictiveness of the models especially for a large 
dataset consisting of structurally diverse compounds. Also, sometimes the conformations used 
for alignments are significantly different from the bioactive conformations, which can reduce the 
accuracy and relevance of the model. In contrast to 3D-QSAR methods, classical QSAR methods 
based on structural and physicochemical descriptors are independent of structural alignment, so 
they can be expected to perform well with large, diverse data sets. Furthermore, with the 
development of machine learning algorithms and artificial intelligence methods which can be 
implemented for both model construction and feature selection, modern QSAR methods which 
can produce highly predictive linear or nonlinear models play an increasingly important role in 
the drug discovery process, especially in virtual screening studies to identify novel hit 
compounds.
79
 
Taha et al. extensively surveyed the literature and compiled a large group of diverse 
GSK-3 inhibitors, including 3-anilino-4-arylmaleimides,
61
 pyrazolopyridazine,
68, 69
 and 
pyrazolopyridines.
70-72
 The biological activities of these compounds were obtained by testing 
against the human GSK-3α isoform under the same experimental protocol, so their bioactivities 
are comparable. Two subsets of compounds carefully selected from the collection of 152 diverse 
GSK-3 inhibitors were employed to explore the pharmacophoric space using the HYPOGEN 
module from CATALYST software package, which yielded in total 60 different pharmacophore 
models having satisfactory statistical results. Although pharmacophore models can be used to 
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explain ligand-protein interactions, their predictive abilities to correlate the chemical structures 
to the bioactivities are limited by steric shielding and auxiliary substituent groups that can either 
enhance or reduce the bioactivity. So a self-consistent QSAR analysis using a genetic function 
algorithm and multiple linear regression (GFA-MLR-QSAR) was performed to search for the 
best combination of pharmacophore models and physicochemical descriptors. To reduce 
redundancy, the 10 best scoring pharmacophore models selected from 10 clusters of 60 models 
were combined with quantitative physicochemical descriptors to construct the descriptor space. 
GFA-MLR produced a highly predictive QSAR model, which contained two orthogonal 
pharmacophore models and seven different physicochemical descriptors. The optimal QSAR 
model obtained from GFA-MLR was subsequently employed in virtual screening to select 
potential GSK-3β inhibitors from an in-house-built structural database of established drugs. The 
top three ranked drugs, namely, hydroxychloroquine, cimetidine, and gemifloxacin, were 
validated to have GSK-3β inhibitory activities in both in vitro and in vivo models.80 Goodarzi et 
al. performed a series of QSAR studies using the same set of 152 diverse GSK-3 inhibitors with 
the same division of training and test set.
81
 Their linear and nonlinear QSAR models exhibited 
the powerful predictivenessof modern QSAR analysis using artificial intelligence and machine 
learning algorithms. The artificial intelligence algorithm named fuzzy rough set ant colony 
optimization combined with multiple linear regression and support vector machines yielded the 
best linear predictive model and the best nonlinear model, which had highpredictiveness. 
Most recently, 3D-QSAR analysis has emerged as a useful post-filtering predictor that 
can be used to predict the bioactivities of structurally similar hit compounds obtained from 
docking screening. The incorporation of 3D-QSAR prediction into the virtual screening protocol 
has been validated to be reliable and beneficial to search for lead compounds inhibiting 
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epidermal growth factor receptor.
82
 Fang et al. proposed and validated a virtual screening 
protocol that combined structure-based and ligand-based approaches to search for new lead 
compounds inhibiting GSK-3β.83 The ligand-based 3D-QSAR analysis using CoMFA and 
CoMSIA was performed on a data set of benzofuran-3-yl-(indol-3-yl)maleimides. The best 
CoMFA and CoMSIA models were then externally validated using two different test sets, and 
the best CoMSIA model was selected as the most predictive for the structurally diverse 
compounds. Then, the best CoMSIA model was combined with molecular docking in their 
virtual screening protocol, which yielded a hit rate greater than 20%. Finally, an enrichment 
study was performed to validate that the proposed virtual screening protocol using combined 
molecular docking and 3D-QSAR prediction was reliably able to retrieve active compounds from 
a virtual library. It was proven that the proposed virtual screening protocol indeed improved the 
hit rate by approximately 1.5 times during screening of one fifth of the compounds of the virtual 
library, compared with a virtual screening protocol without ligand-based 3D-QSAR prediction. 
2.1.1.2. PHARMACOPHORE MODELING 
Since a variety of GSK-3 inhibitors have been reported recently, information regarding 
the chemical structures of known GSK-3 inhibitors could be well utilized to identify novel 
scaffolds using a pharmacophore mapping strategy. A 3D common feature pharmacophore 
model unveils crucial information regarding the 3D arrangement of essential common features to 
be recognized by the active site during ligand-protein binding. Dessalew et al. carried out a 
pharmacophore mapping study using a set of 21 potent and structurally diverse GSK-3 
inhibitors.
56
 The top-ranked pharmacophore model was subsequently used as a query to screen a 
chemical database. Pharmacophore-based virtual screening followed by molecular docking 
yielded five hits with novel scaffolds, which, however, were not biologically validated. 
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Exploration of pharmacophoric space carried out by Taha et al. produced various putative 
pharmacophore models, which can be complementary to each other indicating distinct binding 
modes accessible for GSK-3 inhibitors.
80
 So the validation and selection of pharmacophore 
models will be essential in pharmacophore-based virtual screening. Patel et al. developed a 
specific pharmacophore model for selective GSK-3 inhibitors using the distance comparison 
method (DISCO), which was validated by two strategies: 1) overlap of pharmacophore features 
on important interactions for ligand-protein binding; 2) searching a database containing selective 
and non-selective GSK-3 inhibitors as well as inactive molecules.
84
 The two important 
interactions that a pharmacophore model should demonstrate included a hydrogen bond acceptor 
interacting with Val 135 and a hydrogen bond donor interacting with Asp 133. The validation 
database contained a set of 378 compounds, including 130 selective inhibitors, 216 non-selective 
inhibitors, and 32 inactive compounds. The specific pharmacophore model finally selected as a 
query for virtual screening demonstrated satisfactory discriminatory ability by picking 96 out of 
130 selective inhibitors, only 5 out of 216 non-selective inhibitors, and only 2 out of 32 inactive 
molecules. The final specific pharmacophore query containing 8 features was selected to be used 
for virtual screening. The hits were docked into GSK-3β ATP-binding pocket (1Q4L), and 9 
potential lead compounds were identified exhibiting high docking scores and putative docking 
poses. Biological validation was not performed. 
Pharmacophore mapping alone is important but not sufficient to adequately account for 
distinct binding modes and provide effective discrimination between active and inactive 
compounds. So it usually is used in combination with other ligand-based approaches. For 
instance, Taha et al. proposed a self-consistent QSAR analysis searching for the best 
combination of pharmacophore models and physicochemical descriptors to discriminate active 
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and inactive molecules.
80
 Kim et al. carried out sequential ligand-based virtual screening by 
combining common feature pharmacophore mapping and recursive partitioning (RP) 
classification to identify novel GSK-3β inhibitors.55 The pharmacophore models were derived 
from six known GSK-3β inhibitors and validated through evaluating hit rates in an artificial 
virtual screening experiment against a collection of 287 known GSK-3β inhibitors and 994 
inactive compounds. The best common feature pharmacophore model provided effective 
discrimination between active inhibitors (hit rate=45%) and inactive compounds (hit rate=18%). 
An optimal RP classification model constructed using nine E-state keys and one topological 
index was applied sequentially after pharmacophore-based virtual screening to further filter the 
database. The final 56 hits were carefully selected considering docking pose, structural diversity, 
and synthetic accessibility. They were then subjected to biological validation, and three 
compounds exhibited low micromolar GSK-3β inhibitory activities. 
2.1.2. STRUCTURE-BASED APPROACHES 
2.1.2.1. VIRTUAL SCREENING AND DE NOVO DESIGN 
High throughput virtual screening using molecular docking has been widely applied in 
structure-based drug discovery.
85
 Kang et al. successfully identified TDZDs as submicromolar 
ATP-competitive GSK-3β inhibitors using structure-based virtual screening.86 Out of 170 
TDZDs, five compounds were selected based on Hammerhead docking scores and structural 
diversity. Most interestingly, out of five compounds that were bioassayed, the two most active 
compounds demonstrated ATP-competitive inhibition and high selectivity over other 
homologous kinases. 
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The direct comparison of the performance between virtual screening using molecular 
docking and experimental high throughput screening was first carried out by Polgár et al. as part 
of a lead discovery project.
87
 Due to the conformational flexibility of Gln185 at the ATP-binding 
pocket (Figure 2.1) of GSK-3β crystal structures, three representative structures with different 
Gln185 conformations (1Q4L, 1UV5, and 1Q3D) were selected for docking studies. In 
accordance with the artificial enrichment study, FlexX-Pharm which incorporates 
pharmacophore constraints into molecular docking produced the highest enrichment factor and 
demonstrated an improved ability to filter out false positives in the decoy dataset. Hence, FlexX-
Pharm was subsequently employed in the direct comparison of virtual and experimental high 
throughput screening, which was performed in a real enrichment experiment using a corporate 
collection of 16,299 diverse molecules. The experimental screening yielded 90 validated hit 
compounds (hit rate = 0.55%). The best structure-based virtual screening achieved a 23-fold 
improvement of enrichment factor for the top 1% of the ranked database. However, the 69 
validated hit compounds could not be identified by the virtual screeing algorithm (false 
negatives). Even if the whole ranked database was considered, FlexX-Pharm could not generate 
reasonable docking poses for 49 of the validated hit compounds, so these false negative 
compounds would be lost by virtual screening. It was also demonstrated that the correlation 
between the docking scores and the inhibitory activities was extremely low, and even the 
distributions of the docking scores and the experimental measures were different. So there 
existed significant uncertainty in the prediction of inhibitory activities using structure-based 
virtual screening. The results suggested that virtual screening can be useful for filtering out false 
positives and can be complementary to the experimental screening in lead identification from a 
very large database.  
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Structure-based Ludi de novo design, which is a fragmental approach applying the 
principle of complementarity, has been demonstrated as a useful tool to identify structurally 
novel compounds predicted to be GSK-3 inhibitors.
88
 The method first calculates interaction 
sites within the binding pocket, providing information about steric, hydrophobic, electrostatic, 
van der Waals, and hydrogen bonding interactions; and then searches for fragments that 
complement the binding sites, which are subsequently ranked based on the Ludi empirical 
scoring function. Dessalew et al. carried out de novo design experiments and identified 10 
potential leads sharing a 2,4-diaminopyrimidine scaffold and 5 potential leads sharing a 2,4-
diaminoquinazoline scaffold. Visual examination of the docking poses and comparative analysis 
of docking scores provided further confidence on the prediction, but the hits were not 
biologically validated. 
2.1.2.2. DOCKING PREDICTION AND INDUCED FIT EFFECTS 
To better understand the protein flexibility and induced fit effects in structure-based drug 
discovery, Gadakar et al. investigated the prediction accuracies of docking poses for GSK-3β 
inhibitors in the binding site of 6 crystal structures (1H8F, 1PYX, 1O9U, 1Q4L, 1Q5K, and 
1UV5), using the Glide module from the Schrödinger suite.
58
 Glide SP, Glide XP, and induced 
fit docking (IFD) were utilized to carry out self-docking, cross-docking, and enrichment studies. 
Both Glide SP and XP exhibited acceptable abilities to reproduce the co-crystallized binding 
poses in a self-docking experiment and Glide XP performed slightly better than Glide SP. 
However, most of the cross-docking predictions could not reproduce the co-crystallized binding 
poses, and the large deviations of the docking poses indicated significant induced fit effects in 
the binding of GSK-3β to various ligands. To support this observation, IFD was carried out using 
3 crystal structures (1Q5K, 1O9U, and 1Q4L) to compare the cross-docking predictions. IFD, 
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which can simulate the conformational flexibility of the protein binding site during ligand-
protein recognition, consistently improved the docking predictions based on the markedly 
reduced RMSD values. The subsequent enrichment study also demonstrated the utility of 
induced fit models in the binding prediction based on the improved retrieval of active inhibitors 
seeded in a decoy database.  
The induced fit effects are attributed to the conformational flexibility of the protein as 
well as the bridging water molecules at the binding site. The sensitivity of docking prediction to 
the presence of bridging water molecules has been well investigated, which indicated the 
significance of including water molecules in a docking simulation.
89
 Furthermore, the 
displacement of water molecules with a small molecule at the binding site is a major contribution 
to molecular recognition, and this favorable contribution to the binding free energy has been 
quantitatively described by capturing the hydration map (so-called water map) of the 
thermodynamic properties (especially enthalpy and entropy) of the active site solvent.
90
 The 
enthalpic and entropic contributions characterized by the expulsion of hydrophobically enclosed 
solvent by the complementary small molecules has been well correlated to the binding free 
energy differences as part of structure-activity relationship analysis.
91
 Most recently, the water 
map of the location and energetics of the active site solvent was found to be able to explain 
quantitatively the kinase selectivity SAR for four pairs of kinase systems (Src/GSK-3β, Abl/c-
Kit, ZAP-70/Syk, CDK2/CDK4).
92
 Some of the enclosed active site water molecules constitute a 
conserved structural element contributing to the extended network of hydrogen bonds at the 
kinase ATP-binding site.
93
 The examination of 13 protein kinases with active conformations has 
revealed the presence of conserved water molecules as essential structural elements 
interconnecting the protein structures and stabilizing catalytic residues.
94
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Figure 2.1. The ATP-binding pocket with important residues and conserved water molecule 
highlighted in stick representation; protein is in cartoon representation; hinge region is 
highlighted in orange (PDB code: 1Q5K). 
Lu et al. extensively investigated the roles of conserved bridging water molecules in the 
binding of GSK-3β to inhibitors using 10 crystal structures of ligand-protein complexes (1Q3D, 
1Q3W, 1Q41, 1Q4L, 1Q5K, 1R0E, 3DU8, 3F7Z, 3GB2, and 3I4B) 
95
. ONIOM-based quantum 
mechanics/molecular mechanics (QM/MM) calculations were used to optimize the co-
crystallized structures and identified the conserved bridging water molecules at the GSK-3β 
ATP-binding site that form hydrogen bonds with the side chain hydroxyl group of Thr138 and 
the backbone carbonyl group of Gln185 (Figure 2.1), except 1R0E for which only hydrogen 
bonds with Thr138 were observed. Thy fully optimized geometries of the QM layer which 
included inhibitors, bridging water molecules, and two residues (Thr138 and Gln185) did not 
undergo significant structural changes compared with the original crystal structures. The theory 
of atoms in molecules (AIM) was employed to examine the properties at the hydrogen bond 
critical points which confirmed the existence of water-mediated hydrogen bonding networks. 
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The subsequent molecular dynamics (MD) simulations (6 ns) were performed to compare two 
complex systems based on crystal structure 1R0E with and without the bridging water molecule, 
which demonstrated that the bridging water molecule was locked in the binding site and 
stabilized the protein structure via water-mediated hydrogen bonding interactions. Finally, 
molecular docking studies using 8 crystal structures (1Q3D, 1Q3W, 1Q41, Q4L, 1Q5K, 1R0E, 
3F7Z, and 3I4B) demonstrated that the inclusion of bridging water molecules can improve both 
docking pose prediction and binding affinity prediction.  
2.1.2.3. SELECTIVITY STUDIES 
Since all the protein kinases share a common ATP-binding pocket, development of 
specific and selective ATP-competitive kinase inhibitors is highly challenging. Structure-based 
approaches may shed light on rational drug design of selective and specific kinase inhibitors 
using spatial information related to subtle differences at the ATP-binding pocket. Vulpetti et al. 
carried out a comparative study using GRID/CPCA and GRIND/CPCA (CPCA=consensus 
principal component analysis; GRIND=Grid-Independent Descriptors) on a set of 10 crystal 
structures including 4 complexes of CDK2/cyclin A bound to inhibitors, and 6 complexes of 
GSK-3β bound to inhibitors.96 GRID/CPCA requires structural alignment and GRIND/CPCA is 
alignment-independent. The direct comparison of 3D structures of the ATP-binding pockets 
highlighted the regions and interactions useful to gain selectivity against specific targets of 
interest. Inclusion of multiple crystal structures took into account protein flexibility. In order to 
identify the most discriminative interactions between the ATP-binding pockets of CDK2 and 
GSK-3β, CPCA was employed to analyze the multivariate descriptions obtained from molecular 
interaction fields (MIFs) calculations. 3D visualization of the GRID/CPCA contour plots 
superimposed on the crystal structures of CDK2 with bound benzodipyrazole defined a precise 
 24 
 
spatial position of a hydrophobic site in the back of ATP-binding pocket that can be exploited to 
improve selectivity. The sequence and structural alignment identified the two residue differences 
which contribute to the discriminative regions: Phe80 in CDK2 compared to Leu132 in GSK-3β, 
and Ala144 in CDK2 compared to Cys199 in GSK-3β (Figure 2.1). The computational insights 
helped the design of a 4,4-gem-dimethyl derivative as a selective inhibitor for CDK2, which was 
subsequently biologically validated. GRID/CPCA was also carried out to explain the fact that a 
6-bromo substituent on indirubin-3‘-oxime increases the selectivity for GSK-3β over CDK2. It is 
interesting that the selectivity region for GSK-3β is very close to the selectivity region for 
CDK2. The selectivity profile can be explained by the subtle difference of hydrophobic 
interactions in the back of the ATP-binding pocket, while the increased width of this pocket 
better suited the bromine substituent to achieve selectivity for GSK-3β and the increased depth of 
this pocket complemented well the dimethyl groups to achieve selectivity for CDK2. 
GRIND/CPCA without superimposition confirmed the same selectivity regions. The good 
agreement of the two different analyses supports the reliability of the results. Another study has 
successively exploited the structural difference between Leu132 in GSK-3β and Phe80 in CDKs 
to design a series of 7-substituted aminoindazoles as potent GSK-3β inhibitors with high 
selectivity against CDK1 and CDK2.
97
  
Besides the aforementioned statistical approach, MD simulations combined with binding 
free energy calculations and decomposition analysis can also provide insight into the selectivity 
profile. Molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) binding free energy 
calculations and molecular mechanics/generalized Born surface area (MM/GBSA) free energy 
decomposition analysis were carried out by Chen et al. to explore the selectivity profile of 
paullones.
98
 Six ligand-protein complexes of three paullones (alsterpaullone, 1-azakenpaullone, 
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and 2-azakenpaullone) binding to protein crystal structures (1O9U for GSK-3 and 1UNL for 
CDK5) were constructed. A detailed analysis of energy components contributing to the binding 
affinities revealed that van der Waals interactions contributed to the major favorable binding free 
energies. But the small variance of van der Waals contributions among the six complexes cannot 
explain the selectivity profiles of paullones. The sequence and structural alignment demonstrated 
that two parallel residues at the conserved position may distinguish the selectivity of paullones in 
favor of GSK-3: Val135 in GSK-3 and Cys83 in CDK5, and Tyr138 in GSK-3 and Asp86 in 
CDK5. A residue-based MM/GBSA decomposition analysis was carried out to calculate the 
interaction of each residue-ligand pair, which indicated that the net electrostatic contribution of 
alsterpaullone with Val135 in GSK-3 was indeed much stronger than the one of alsterpaullone 
with Cys83 in CDK5, and the same variances were observed for azapaullones. However, 
different electrostatic contributions were not useful for structural optimization to gain selectivity, 
since the hydrogen bond interactions occurred between the ligands and the backbone of Val135 
and of Cys83. Another observation from the energy decomposition analysis can be used to 
explain the selectivity gain of 1-azapaullone that occurs when substituting nitrogen for carbon at 
the 1-position. The substitution resulted in the reduction in pairwise interaction between Asp86 
and 1-azapaullone compared to that between Asp86 and alsterpaullone, which was consistent 
with the reduction in the occupancies of hydrogen bonds of N12 in 1-azapaullone with Asp86 
compared to N12 in alsterpaullone with Asp86. In contrast to the interaction between ligands and 
CDK5, the substitution did not change much the interaction between ligands and Tyr138 in 
GSK-3. So the substitution did not change much the inhibitory activity for 1-azapaullone against 
GSK-3, but reduced the inhibitory activity significantly for 1-azapaullone against CDK5. Hence, 
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the interaction toward Asp86 in CDK5 was able to be employed to improve the selectivity 
profile in structural optimization, especially for paullones. 
2.2. COMPUTATIONAL MODELING TARGETING THE SUBSTRATE 
BINDING POCKET 
Considering the unique substrate specificity of GSK-3, it is worthwhile to explore 
carefully the substrate binding pocket to design small peptide inhibitors such as L803-mts (N-
Myristol-GKEAPPAPPQS(p)P), which exhibited promising preclinical values. To identify the 
interaction sites located within the substrate binding cleft, Ilouz et al. carried out molecular 
modeling combined with biological studies.
99
 The sequence alignment identified three residues 
of interest at the substrate binding site: Gln89 and Asn95 in the N-lobe are conserved in GSK-3 
but not conserved in other homologous kinases including mitogen-activated protein kinase 
(MAPK), cyclin-dependent kinase 2 (CDK2), and protein kinase A (PKA); Phe67 from the 
glycine-rich loop (G-loop, also known as the P-loop) is conserved in GSK-3 and PKA but is 
mutated to tyrosine in MAPK and CDK2. The biological studies demonstrated that the mutations 
of the three residues will result in various reductions in levels of GSK-3 phosphorylation. To 
understand the substrate recognition mechanism at the atomic level, the ternary complex 
structures of phosphorylated GSK-3β (pTyr216), ATP, and the substrates, the phosphorylated 
cAMP responsive element binding proteins (pCREBs), were constructed by protein-protein 
docking. The docking studies verified that the polar residues, Gln89 and Asn95, participated in 
hydrogen bond interactions with various polar/charged residues at the P+6 position in the 
substrates; and the Phe67 in the conserved G-loop pointed toward the substrate binding cleft to 
stabilize the G-loop conformation through hydrophobic contact with substrates. However, the 
two polar residues (Gln89 and Asn95) are far away from the catalytic site at the P position, so 
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they were rarely explored for the design of potent substrate-competitive inhibitors. Figure 2.2 
shows the key residues involved in the unique substrate specificity of GSK-3. 
 
Figure 2.2. The primed substrate binding pocket with important residues highlighted in stick 
representation (PDB code: 1O9U). 
The unique substrate specificity of GSK-3 is derived from the fact that the priming 
phosphate is well accommodated by three positively charged residues. The mutation of Arg96 to 
lysine or alanine severely impaired the phosphorylation of primed substrates without affecting 
non-primed substrates. To explain the mutagenesis study, Zhang et al. performed MD 
simulations on three systems: wild type (WT), R96K and R96A mutants of GSK-3β-ATP-pSer 
complexes, followed by MM-GBSA binding free energy analysis.
100
 MD simulations 
demonstrated that Arg96 was important to induce a slight closure of the N- and C-lobes. The 
lobe closure involving a closed conformation of the C-loop, A-loop, and G-loop may facilitate 
substrate binding and ATP positioning. The mutation of Arg96 which is located on the αC-helix 
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caused the open motion of the disordered C-loop and G-loop, and subsequently twisted the 
conformation of ATP‘s flexible triphosphate moiety. Abnormal conformational changes which 
occurred on the G-loop were related to the high mobility of β and γ phosphate groups in two 
mutants during MD simulations. Binding free energy analysis provided evidence that the 
mutation indeed reduced the binding affinities, and especially disturbed the electrostatic 
interaction between Arg96 and pSer, which was a dominant favorable contribution to the binding 
energy. 
To obtain an atomic level description of the activation mechanism by Tyr216 
phosphorylation, MD simulations were carried out by Buch et al. on both the inactive form of the 
unphosphorylated GSK-3β-ATP complex (derived from 1PYX) and the active form of the 
phosphorylated GSK-3β(p)-ATP complex (derived from 1O9U).101 The unphosphorylated 
Tyr216 in the crystal structure 1O9U points into the priming phosphate binding pocket and 
blocks the access of the primed substrate, while the phosphorylated Tyr216 in the crystal 
structure 1PYX points in the opposite direction and forms polar contacts with Arg220 and 
Arg223 (Figure 2.2). The intramolecular electrostatic interactions at the active site were further 
monitored throughout MD simulations on both active and inactive forms. Due to the different 
orientation of Tyr216, Arg220 can form different polar contacts controlling the accessibility of 
the catalytic groove. In the inactive form, Arg220 interacts with the γ-phosphate group of ATP 
and Asp181 from the conserved HRD motif. In addition to another electrostatic interaction 
between Arg96 from αC-helix and Asp200 from the conserved DFG motif, the catalytic groove 
was in the closed conformation with limited accessibility. However, in the active form, Arg220 
and Arg223 were neutralized by phosphorylated Tyr216 and the catalytic cleft was in the open 
conformation with full substrate access. Buch et al. also constructed two ternary complexes of 
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phosphorylated GSK-3β(p)-ATP binding with substrate peptide (KEEPPSPPQS(p)P) and 
inhibitor L803 (KEAPPAPPQS(p)P) at the substrate binding site through molecular docking, and 
carried out MD simulations on the two bound complexes. The conserved Phe67 from the G-loop 
played an important role for substrate and inhibitor binding by stabilizing the active 
conformation and ATP positioning. Typically, the binding modes for the substrates and 
inhibitors were similar with pSer strongly interacting with the positively charged triad (Arg96, 
Arg180, and Lys205). The analysis of RMSD (for all the Cα‘s of GSK-3β) and hydrogen bonds 
indicated a slightly tighter binding of the inhibitor 803, which was consistent with the 
experimental results. The observation was explained by the mutation of Glu in the substrate to 
Ala in the inhibitor at the P-3 position. However, a detailed binding energy analysis to explain 
the different binding affinities was not presented.  
To better understand the primed substrate specificity, Lu et al. modeled the ternary 
complex structures of GSK-3β binding with ATP and substrate peptides with and without primed 
phosphorylation, and carried out MD simulations and binding free energy calculations on the 
constructed complex systems.
102
 The ternary complexes consisting of GSK-3β with 
phosphorylated Tyr216, ATP, and 8-residue glycogen synthase peptides (ACE-RHSSPHQS(p)-
NME and ACE-RHSSPHQS-NME) were constructed. The two complexes were referred to as p-
Tyr216/GSK-3β/ATP/pGS and p-Tyr216/GSK-3β/ATP/GS for simplicity. During the MD 
simulations, the conformational changes of the C-loop, αC-helix, and A-loop were monitored. 
Although the active conformation of the A-loop of GSK-3β was observed for both primed and 
non-primed substrates, they had different impacts on the relative motions of the C-loop and the 
β-turn secondary structure of the A-loop: a closed conformation with low flexibility was induced 
by the primed substrate and an open conformation with high flexibility was presented in the non-
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primed substrate system. The priming phosphorylation at the P+4 position properly aligned the 
primed substrate into the active site, and the priming phosphate group stabilized the triad of 
positively charged residues through strong electrostatic interactions. The electrostatic potential 
generated by the triad could not be effectively neutralized by the non-primed substrate, and the 
electrostatic repulsion resulted in high flexibility of the side chains of the triad. The movement of 
the Arg96 side chain led to an open conformation with an enlargement of the cavity volume. 
Radial distribution function (RDF) analysis revealed that the water molecules around the side 
chains of the triad participated in the hydrogen bonding and disturbed the interactions between 
the triad and the non-primed substrate. Furthermore, the distance between the oxygen of the P-
site serine and the γ-phosphorus of ATP (S0-Oγ…Pγ-ATP) of the primed substrate was much 
shorter than that of the non-primed substrate. The shortened distance resulting from the tighter 
binding could facilitate the phosphate transfer reaction. MM-GBSA analysis was further 
performed, and large differences of binding free energies were observed for p-Tyr216/GSK-
3β/ATP/pGS and p-Tyr216/GSK-3β/ATP/GS. Residue-based decomposition analysis further 
revealed that major favorable contributions were gained from Arg96, Arg180, Lys205, and 
Val214. 
2.3. COMPUTATIONAL MODELING TARGETING THE C-LOBE 
HYDROPHOBIC GROOVE 
The scaffolding peptide axin and FRAT bind competitively to GSK-3 at the same 
hydrophobic groove formed by the αG-helix (Gly262-Leu273) and an extended loop (Asn285-
His299) near the C-lobe. The binding of the two peptides to GSK-3 is involved in the specific 
regulation mechanism in the Wnts signaling pathway. The substrate peptides adopted α-helical 
secondary structures in packing against the hydrophobic channel mainly through hydrophobic 
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but also with a few polar interactions. The protein-substrate interface revealed a typical 
hydrophobic helix-helix ridge-groove interaction involving residues Val263, Leu266, Val267, 
and Ile270 from the αG-helix of GSK-3 (Figure 2.3) and helically disposed residues of the 
substrates, which are residues Leu212, Ala216, and Leu220 of FRAT and Phe388, Leu392, 
Leu396, and Val399 of axin. The significant difference in the binding modes of axin and FRAT 
involved distinct interactions with the extended loop in the C-lobe. There is a sharp turn in the 
FRAT peptide structure, which occurs at Gly210-Asn211 and breaks the FRAT α-helical 
segment into two parts. The second α-helix of FRAT occupies the same hydrophobic groove as 
axin does which adopts a single intact α-helix. As a result, the peptide NH groups of residues 
Leu212, Ile213, and Lys214 from the second α-helix of FRAT form hydrogen bond interactions 
with the side chains of Tyr288 and Glu290 from the extended loop in GSK-3 (Figure 2.3). 
However, such hydrogen bonds were not observed in the binding of axin to GSK-3. 
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Figure 2.3. The C-lobe hydrophobic groove with important residues highlighted in stick 
representation (PDB code: 1GNG). 
The experiments cannot fully explain the fact that different mutations of GSK-3 residues 
result in selective reduction in binding affinities of different substrates. Molecular modeling, 
especially MD simulation, provides a powerful tool to better understand the dynamic features of 
the structural motions and changes, so it can be incredibly helpful in terms of interpreting the 
experimental results of mutagenesis. Zhang et al. performed MD simulations on three systems: 
WT GSK-3β with bound axin, the V267G mutant of GSK-3β with bound axin, and GSK-3β with 
the bound L392P mutant of axin, followed by MM-GBSA binding energy calculations.
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Throughout the MD simulations of different systems, GSK-3β did not undergo significant 
conformational changes, but the substrate axin exhibited distinct dynamical behavior. In the WT 
system, axin was well maintained in the hydrophobic groove. However, the mutant V267G 
resulted in a packing defect at the hydrophobic interface, which was demonstrated by the upward 
motion of axin toward αG-helix. The mutation destroyed the integrity of the hydrophobic 
interactions of Val267 from GSK-3β with Leu392 and Leu396 from axin, which triggered the 
positional shift of axin and impaired the important salt bridge interaction between Asp264 from 
GSK-3β and Arg395 from axin. Furthermore, the mutant L392P on axin resulted in partial helix 
distortion, which was observed based on the evidence of abnormal dihedral angles and decreased 
intra-helix hydrogen bond occupancies. The conformational distortion of axin impaired the 
hydrophobic interactions as well as the salt bridge between Asp264 and Arg395. The binding 
free energy analysis provided further evidence of the packing defect of hydrophobic interactions 
introduced by the mutations. Two mutations reduced significantly the van der Waals energy 
term, which was the dominant favorable contribution to the binding affinity for the wildtype. 
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The single-point mutation of Val267 to Gly on GSK-3β selectively abolished the binding 
affinity toward axin without impact on FRATide binding, whereas single-point mutation of 
Tyr288 to Phe on GSK-3β selectively abolished the FRATide binding without affecting axin 
binding. To provide atomic-level evidence of the mutagenesis studies, Tang et al. carried out 
MD simulations on the different GSK-3β structures bound to GSKIPtide (GSK-interacting 
peptide), which binds GSK-3β in a manner similar to axin.104 The sequence alignment of three 
substrates (AxinGID, FRATide, and GSKIPide) revealed a common L/A-X-X-R-L motif that 
played an important role in protein-substrate interactions. The Leu or Ala residue at the first 
position participated in the hydrophobic helix-helix ridge-groove interaction, and the Arg residue 
formed an important salt bridge interaction with Asp264 on GSK-3β. Since GSKIPtide binds 
GSK-3β in a similar manner compared to AxinGID, it is not surprising that the V267G mutant of 
GSK-3β reduced the binding affinity of GSKIPtide by 70% and abolished the binding affinity of 
AxinGID. The experimental results can be explained by the observation that the reduction in 
volume of the hydrophobic side chain from Val to Gly distorted the hydrophobic interface and 
caused the positional shift of GSKIPtide residues. However, the mutation of Val267 to Gly did 
not affect the binding affinity of FRATide. This can be explained by the observation that Ala216 
of FRATtide, which is in the corresponding position to Leu126 of GSKIPtide and Leu392 of 
AxinGID, contributed minimal binding affinity without any hydrophobic contact with the αG-
helix of GSK-3β, because of its short side chain. Hence, the reduction in volume caused by the 
side chain mutation implied a packing defect for GSKIPtide and AxinGID, but not for FRATide. 
Another mutation of Tyr288 to Phe abolished the binding affinity for FRATide without any 
impact on GSKIPtide and AxinGID binding. The experimental results can be explained by the 
different binding modes with the extended loop on GSK-3β‘s C-lobe. In the complex of GSK-3β 
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bound to GSKIPtide, the Tyr288 on GSK-3β interacted with Arg119 on the substrate in two 
ways: a) a hydrophobic interaction between the ring moiety of Tyr288 and the aliphatic moiety 
of Arg119; b) an electrostatic interaction between the hydroxyl group of Tyr288 and the 
positively charged guanidino group of Arg119. The mutation of Tyr288 to Phe only affected the 
electrostatic interaction, so it induced insignificant conformational change. In the complex of 
GSK-3β bound to AxinGID, the aromatic ring of Tyr288 on GSK-3β was sandwiched by the 
aliphatic moiety of Pro385 and the aromatic ring of Phe388 on AxinGID. So the mutation of 
Tyr288 to Phe did not have any impact on the hydrophobic interaction among the three residues. 
However, in the complex of GSK-3β bound to FRATide, the hydroxyl group of Tyr288 as well 
as the carboxyl group of Glu290 were strongly involved in the hydrogen bond interactions with 
the backbone NH group of the residues Leu212, Ala216, and Leu220 on the FRATide second α-
helix. The mutation destroyed the hydrogen bonds, and subsequently impaired the FRATide 
binding. Electrostatic potential analysis supported the evidence that the binding modes of 
GSKIPtide and AxinGID are similar, but they are different from the binding mode of FRATide. 
The structure-based knowledge may benefit the rational design of small peptides which can 
selectively inhibit GSK-3 phosphorylation towards different substrates.   
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3.1. INTRODUCTION 
In the present research project, we explored the performance of implementing a mixed 
ligand-based/structure-based approach in the virtual screening procedure to identify structurally 
novel and diverse ATP-competitive GSK-3β inhibitors. For the ligand-based approach, we 
employed the Phase
105
 module from Schrödinger 2010 to construct a common binding 
hypothesis for a collection of structurally diverse and highly potent GSK-3β inhibitors. The 
generated 3D pharmacophore model was used for preliminary screening of large databases to 
preclude selection of compounds lacking the key structural features necessary to be kinase 
inhibitors. To achieve maximum coverage of the activity space and reduce structural redundancy 
in the screening process, diversity analysis was used to ensure identification of a diverse set of 
compounds. Finally, molecular docking studies were performed to estimate the binding strengths 
of ligand-protein complexes. To address the protein flexibility issues, we used the ensemble 
docking protocol which has been shown to be superior to individual docking. 
3.2. MATERIALS AND METHODS 
3.2.1. PHARMACOPHORE MODELING 
A collection of 22 active GSK-3β inhibitors or substrate derivatives with distinct 
structural features was selected for development of the 3D pharmacophore model to be used as a 
query to screen large databases. Figure 3.1 shows the chemical structures and the published 
GSK-3β inhibitory activities of those compounds. The numbering for the compounds is retained 
from the original publications and the references can be found in Table 3.1. The collection 
contains 10 compounds directly extracted from X-ray co-crystal structures with GSK-3β. In the 
pharmacophore model building they were restricted to have rigid conformations exactly 
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matching the ones in the crystal structures. The rest of the compounds in the collection are highly 
potent and structurally distinct GSK-3β inhibitors. They have flexible conformations and so it 
was necessary to search for their minimum conformations before pharmacophore model 
generation. The MacroModel
106
 module from Schrödinger 2010 was used to generate 
conformers. The mixed Monte Carlo multiple minimum (MCMM)/low-mode conformational 
search method was used, followed by 100 minimization steps with the OPLS-2005 force field. 
After the search the conformers which were similar within a root-mean-square deviation 
(RMSD) of 1.0 Å were considered as redundant conformers and eliminated. The maximum 
number of conformers per compound was limited to 1000. The possible pharmacophore features 
considered included hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H), 
negatively charged group (N), positively charged group (P), and aromatic group (R). 
Pharmacophore models were generated which satisfied two requirements: 1) at least three 
features were included in the model; 2) the model needed to match all the active compounds in 
the collection. Finally, the models were examined and ranked by survival score, which is 
calculated by the following equation: 
Survival Score = Vector Score + Site Score + Volume Score + 1 (3.1) 
The vector score is the average of the cosines of the angles formed by corresponding pairs of A, 
D, or R vector features. The site score is computed based on alignment score which is the RMSD 
in the site-point positions. The volume score is calculated based on the overlap of van der Waals 
(VDWs) models of the non-hydrogen atoms in each pair of structures.  
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Figure 3.1. The chemical structures and biological activities of representative GSK-3β 
inhibitors. (a) 10 compounds directly extracted from X-ray co-crystal structures with GSK-3β; 
(b) compounds used only for pharmacophore modeling; (c) compounds used only for enrichment 
study; Compounds without superscripts are without known bioactive conformation and so 
underwent conformational search; they were used in both pharmacophore modeling and in the 
enrichment study. 
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Figure 3.1. Continued. 
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Table 3.1. Pharmacophore modeling results including the best alignments of the chosen active 
compounds. 
No. Name IC50 
(nM) 
Confs Fitness Relative 
Energy 
PDB and 
Reference 
1 ADP n.a. 1 2.24 0 1J1C
40
 
2 staurosporine
a
 15 1 2.24 0 1Q3D
41
 
3 alsterpaullone 4 1 2.07 0 1Q3W
41
 
4 indirubin-3‘-monoxime 22 1 1.73 0 1Q41
41
 
5 I-5
a
 26 1 1.65 0 1Q4L
41
 
6 AR-A014418
a
 104 1 1.67 0 1Q5K
31
 
7 3-indolyl-4-arylmaleimide n.a. 1 1.72 0 1R0E
43
 
8 6-bromoindirubin-3‘-oxime
a
 5 1 1.75 0 1UV5
29
 
9 bis-(indole) maleimide 
pyridinophane
a
 
3 1 1.68 0 2OW3
46
 
10 NMS-869553A n.a. 1 3.00 0 3DU8
48
 
11 hymenialdisine
a
 10 2 2.31 0 30 
12 3,5-disubstituted azapurine 25b
a
 13 12 1.69 0.325 107 
13 5-aryl-pyrazolo[3,4-b]pyridine 22
a
 11 4 1.91 0.127 72 
14 6-aryl-pyrazolo[3,4-b]pyridine 23
a
 1 3 1.78 0 70 
15 heterocycle-substituted pyrimidine 
15
a
 
60 13 1.27 0.315 108 
16 pyrazolopyrimidine 26
a
 8.5 2 2.32 0 109 
17 3-imidazo[1,2-a]pyridin-3-yl-4-
(1,2,3,4-tetrahydro-[1,4]diazepino-
[6,7,1-hi]indol-7-yl)pyrrole-2,5-dione 
10
a
 
1.3 31 1.77 2.597 110 
18 1-(4-aminofurazan-3-yl)-5-
dialkylaminomethyl-1H-
[1,2,3]triazole-4-carboxylic acid 
derivative 6b
a
 
100 66 2.17 2.400 111 
19 4-acylamino-6-arylfuro[2,3- 5 8 2.14 3.834 112 
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d]pyrimidine 24
a
 
20 CHIR 98014
a
 0.58 68 1.58 1.086 113 
21 3-(benzofuran-3-yl)-4-(indol-3-
yl)maleimide 2b
a
 
7 8 1.77 0.934 114 
22 3-(7-azaindolyl)-4-arylmaleimide 
17c
a
 
26 71 1.82 3.495 115 
a
 Compounds used for both pharmacophore modeling and enrichment study. 
 
3.2.2. DIVERSITY ANALYSIS 
Structurally similar compounds are likely to exhibit similar activity, and hence maximum 
coverage of the activity space should be achieved by selecting a structurally diverse set of 
compounds. To measure shape similarity, linear hashed binary fingerprints were calculated. This 
has been shown to be an efficient approach to cluster large data sets and evaluate the diversity of 
compound libraries.
116
 Since the database to be screened is large (>400,000 compounds), the 
shape fingerprints were calculated at 64-bit precision with maximum linear path equaling 14 in 
order to be able to distinguish molecules in the database to a large extent. After the shape 
fingerprints calculations, dissimilarity-based compound selection (DBCS) was performed, which 
was based on the calculated pairwise Soergel distances between compounds. The sum of the 
distances between each compound and the selected subset was evaluated at each round and the 
compound with the largest total distance from the selected subset was added. This method is 
called maximum sum of distances and is initialized by selecting representative compounds. This 
is the most efficient and effective non-hierarchical clustering method.
117
 After diversity analysis, 
about 8,000 structurally distinct compounds were selected to conduct docking screening. The 
shape-fingerprint calculations and DBCS analysis were performed using Canvas
118
 implemented 
in Schrödinger 2010. 
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3.2.3. DOCKING STUDIES 
The structural features of ligand-protein interactions provide insight into the important 
binding features which can be useful for discovering and designing novel potent and selective 
inhibitors for GSK-3β. To estimate the reliability and prediction accuracy of various docking 
protocols, several validation experiments have been conducted including self-docking and cross-
docking. In self-docking, the native ligand (from a protein-ligand co-crystallized structure) is 
docked back into its corresponding receptor structure, whereas in cross-docking every extracted 
ligand is docked into all the receptor structures in the collection. In the present study, a total of 
20 crystal structures have been culled for GSK-3β either with or without ligands in the ATP 
binding pocket. The list of all the crystal structures with their Protein Data Bank (PDB) code, 
ligands and references are tabulated in Table 3.2. If the crystal structure contained more than one 
GSK-3β chain, then only chain A was considered. The apo PDB structures 1GNG, 1H8F, and 
1I09 were not included in the following docking investigations since they do not have important 
water molecules in the binding sites, and their local conformational features around the binding 
pockets are different from the ligand-bound protein structures especially in the glycine rich loop 
and hinge region because of the absence of induced fit effects. Since 1J1B and 1PYX have the 
same ligands in the binding pocket, only 1PYX was included in the following studies. The PDB 
structure 2JLD demonstrates the binding of GSK-3β to a ruthenium complex but the 
corresponding force field parameters for ruthenium are not available in the docking programs. 
The PDB structure 3F88 contains a ligand missing important connection bonds. So those two 
crystal structures were excluded in the self-docking and cross-docking experiments, but they 
were included in the enrichment studies since the receptor structures had undergone induced fit 
effects to accommodate their native ligands. The PBD structures 1J1C, 1O9U, and 1PYX have as 
 43 
 
native ligands ADP, ADZ, and ANP, respectively. These are ATP derivatives and have highly 
negatively charged functional groups which are surrounded by a number of water molecules in 
the crystal structures, so they have different induced fit compared to the structures containing 
small molecule inhibitors. Hence those three crystal structures were not included in the cross-
docking experiments. To evaluate the prediction accuracy, the RMSD between the docking poses 
and experimental structures of the ligands were calculated, and the lower RMSD indicates the 
better docked pose. In order to determine which docking algorithm is best for these proteins, 
several leading docking programs were examined and compared, including Glide 5.6,
119
 GOLD 
4.0,
120-122
 AutoDock 4.2,
123, 124
 and MOE 2010.10 Dock.
125
 Then ensemble docking was also 
carried out in contrast to individual docking to probe sensitivity to induced fit effects during 
ligand-protein recognition. 
Table 3.2. Available GSK-3β X-ray crystal structures from PDB 
PDB code Substrate Resolution
b
 Release Date Reference 
1GNG none 2.60 2002-10-03 11 
1H8F none 2.80 2002-01-31 7 
1I09 none 2.70 2002-01-01 8 
1J1B
a
 ANP 1.80 2003-12-03 40 
1J1C
a
 ADP 2.10 2003-12-03 40 
1O9U ADZ 2.40 2003-08-15 10 
1PYX
a
 ANP 2.40 2003-10-21 41 
1Q3D
a
 Staurosporine 2.20 2003-10-21 41 
1Q3W
a
 Alsterpaullone 2.30 2003-10-21 41 
1Q41
a
 Indirubin-3'-monoxime 2.10 2003-10-21 41 
1Q4L
a
 I-5 2.77 2003-10-14 41 
1Q5K
a
 AR-A014418 1.94 2004-08-10 31 
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1R0E
a
 3-indolyl-4-arylmaleimide 2.25 2004-10-12 43 
1UV5 6-bromoindirubin-3‘-oxime 2.80 2004-01-29 29 
2O5K 7-hydroxy-1H-benzoimidazole 3.20 2007-10-23 45 
2OW3
a
 
bis-(indole)maleimide 
pyridinophane 
2.80 2008-02-19 46 
2JLD
a
 Ruthenium complex 2.35 2008-12-09 126 
3DU8
a
 NMS-869553A 2.20 2009-03-03 48 
3F7Z
a
 1,3,4-oxadiazole 2.40 2009-03-10 127 
3F88
a
 1,3,4-oxadiazole 2.60 2009-03-10 127 
a 
Only chain A was considered. 
b
 In Å. 
Glide 5.6. Before performing the docking experiments, the receptor crystal structures 
went through protein structure preparation, which included deleting crystallographic water 
molecules beyond 5 Å from the native ligands, adding hydrogens, assigning bond orders and 
ionization states, optimizing hydrogen bond networks, and finally minimizing protein structures. 
All the preparation jobs were conducted using the Protein Preparation Wizard implemented in 
Schrödinger 2010 with default setup. The ligand structures were prepared using the LigPrep 
module. The ionization states and stereochemistry of the ligands were maintained to be the same 
as reported. The docking program Glide (Grid-based Ligand Docking with Energetics) uses a 
series of hierarchical filters to determine the possible locations of the ligand in the binding site of 
the receptor. The hierarchy includes an initial exhaustive search of all possible conformations of 
ligands followed by greedy scoring and refinement using the Schrödinger discretized version of 
the ChemScore empirical scoring function, subsequently followed by grid minimization and final 
scoring using GlideScore. A grid which represents the shape and properties of the receptor by 
various sets of VDWs and electrostatic fields is used to align and score the ligand poses in the 
binding site. To generate the scoring grids, the default VDW radius scaling factor (1.0) and 
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partial charge cutoff (0.25) were used. The grids were centered around the centroid of native 
ligands in the structures, with enclosing box (outer box) dimensions of 34 Å  34 Å  34 Å and 
ligand diameter midpoint box (inner box) dimensions of 14 Å  14 Å  14 Å. No constraints 
were imposed on any of the receptor structures. To perform docking experiments, the VDW 
radius scaling factor (0.8) and partial charge cutoff (0.15) were kept unchanged. There are three 
options of docking precision, which are HTVS (high-throughput virtual screening), SP (standard 
precision), and XP (extra precision). The Glide HTVS is fast and intended for the rapid screening 
of very large databases, but it has restricted conformational sampling which can result in an 
unsatisfactory docking pose. The Glide SP is appropriate for screening ligands in large numbers 
and is the default option. The Glide XP scoring function is designed to identify ligand poses that 
are supposed to have unfavorable energies, which is useful to exclude false positives and to 
provide a better correlation between good poses and good scores. It includes additional terms 
relative to the SP scoring function to deal with hydrophobic interactions and is designed for use 
only on good ligand poses. It is a powerful and discriminating procedure, but takes much more 
computational effort. 
GOLD 4.0. GOLD (Genetic Optimisation for Ligand Docking) is a genetic algorithm for 
docking flexible ligands into the binding pockets of receptors. The structures for both receptors 
and ligands were prepared using the same procedures as were used in Glide docking. Since water 
molecules play key roles in ligand-receptor recognition, all the crystallographic water molecules 
remaining in the receptor structures were switched on and the orientation of the hydrogen atoms 
of active water molecules were optimized automatically using the GOLD software. To reward 
water displacement in the binding pocket, an additional parameter (Sbar) is added to the fitness 
function for both GoldScore (GS) and ChemScore (CS), except for in the Astex Scoring 
 46 
 
Potential (ASP). The number of genetic algorithm runs was set to 10 and the default early 
termination option was turned on to stop docking runs as soon as the top three solutions were 
within the RMSD values of 1.5 Å. To define the binding site, all protein atoms within 10 Å of 
the native ligand and their associated residues were considered. The LIGSITE cavity detection 
algorithm was used to restrict the region of interest to the solvent accessible surfaces. Finally, the 
docking analyses were carried out for all three fitness functions, GS, CS, and ASP. The GS 
fitness function has been optimized for the prediction of ligand binding poses, so it can be used 
to discriminate between different binding modes of the same ligand molecules. However, 
obtaining a significant correlation between a fitness score and the biological activities is not 
guaranteed. Unlike the GS fitness function which is based on force field parameters, the CS 
fitness function is derived empirically from a regression model based on a set of 82 protein-
ligand complexes for which biological activities are available. In contract to the GS and CS 
fitness function, ASP is an atom-atom potential derived from the statistical potentials generated 
by analyzing existing ligand-protein structures in the entire PDB database. 
AutoDock 4.2. AutoDockTools implemented in MGLTools 1.5.4 developed at the 
Molecular Graphics Lab (MGL) of the Scripps Research Institute were used to set up, run and 
analyze AutoDock 4.2 dockings. To prepare the receptor structures, hydrogens were added, 
Kollman United atomic charges were assigned, and non-polar hydrogens were merged with their 
parent carbon atoms. To prepare the ligand structures, partial atomic charges were assigned using 
the Gasteiger method after all hydrogens were added and torsion trees were set up for the 
rotational bonds using AutoTors. Grid boxes of 40 points in each dimension with spacing of 
0.375 Å between grid points were constructed for all the receptors using AutoGrid, centering on 
the centroid of the native ligands. To perform docking studies, three search methods were used 
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including the Solis & Wets algorithm for local search, the Genetic Algorithm (GA) for global 
search, and the Lamarckian GA (LGA) for hybrid global-local search. The maximum iterations 
were set to 300 for the Solis & Wets local search. The number of individuals in the population of 
150, the maximum number of generations of 27,000 and the maximum number of energy 
evaluations of 2,500,000 were set up for the GA global search. Ten runs of hybrid LGA search 
were performed with the local search frequency set to 0.06. Finally energy-ranked cluster 
analyses were carried out on the docking results with the RMSD cluster tolerance of 2.0 Å. The 
free-energy scoring function of AutoDock 4.2 is based on linear regression analysis of a large set 
of diverse protein-ligand complexes with known biological activities using the AMBER force 
field. 
MOE 2010.10 Dock. To add hydrogens to the receptor and ligand structures, Protonate 
3D was used with default settings. Then partial charges for both receptors and ligands were 
calculated using the MMFF94 force field
128
. To generate conformations for the rotatable bonds, 
the Triangle Matcher placement method was used. It works by systematically superimposing 
ligand atom triplets to the triplets of receptor site points. The receptor site points are alpha sphere 
centers which represent locations of tight packing. The default London dG (LdG) scoring 
function was used to estimate the free energy of binding of the ligand from a given pose. The top 
ten ranked docking poses were retained for further refinement. Two refinement schemes were 
carried out after scoring. One is ForceField refinement (FFR) by which energy minimization of 
the system is performed using the current forcefield (MMFF94) and the final energy is evaluated 
using the Generalized Born solvation model (GB/VI); the other one is GridMin refinement 
(GMR) in which a grid is used for electrostatic calculations during the minimization process 
which can speed up the process. The VDW interactions are treated explicitly and the distance-
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dependent dielectric model is used. The final electrostatic energy is calculated using the explicit 
Coulomb form instead of the grid. 
Ensemble Docking. An ensemble of 13 protein structures was used for docking studies, 
including 1Q3D, 1Q3W, 1Q4L, 1Q41, 1Q5K, 1R0E, 1UV5, 2JLD, 2O5K, 2OW3, 3DU8, 3F7Z, 
and 3F88. For each ligand, the top-ranked pose against each receptor structure was saved, and 
the ensemble of docking poses for each ligand was sorted by GlideScore. Since for some ligands 
we could not obtain a reasonable docking pose against certain receptor structures using Glide, 
the number of members of the ensemble of the top-ranked docking poses for each ligand is less 
than or equal to 13. After ranking, only the pose with the lowest GlideScore was retained for 
each ligand, and the other poses were eliminated. The post-docking processes, including pooling, 
sorting, and redundancy elimination, were conducted using the utility program ‗glide_merge‘ 
implemented by Schrödinger. This docking protocol is called ensemble docking. In contrast to 
individual docking in which only a single receptor structure is used, ensemble docking takes into 
account the protein flexibility to some extent. The performance in terms of the docking 
predictions of both individual docking and ensemble docking was evaluated using enrichment 
studies. 
3.2.4. ENRICHMENT STUDIES 
A collection of 22 highly active GSK-3β inhibitors with distinct structures was selected 
and seeded into a 1,000 decoy dataset created by Schrödinger.
129, 130
 The random hit rate was 
2.2%, which means without any assistance of predictive algorithm, the compound randomly 
selected from the combined dataset has a 2.2% chance to be an active inhibitor. The collection of 
highly active GSK-3β inhibitors (Figure 3.1) includes 17 compounds used in the pharmacophore 
modeling and 5 other compounds, which are 7-hydroxy-1H-benzoimidazole derivative 6h,
45
 bis-
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7-azaindolylmaleimide 28,
131
 1,3,4-oxadiazole derivative 20x,
127
 9-cyano-1-azapaullone 2b,
28
 
and 2,5-diaminopyrimidine 29a.
107
 The decoy dataset was created by selecting ligands from a 
library containing one million compounds that exhibit ‗drug-like‘ properties. To evaluate the 
effectiveness of the different virtual screening protocols using individual docking and ensemble 
docking, the hit rates (Hits%) and enrichment factors (EF) of the known active compounds 
within 1, 5, and 10% of the top-ranked compounds were calculated.  The hit rate is calculated 
using the following equation: 
        
          
           
    100 (3.2) 
Hitsactive is the number of known active compounds in the top-ranked list, and Totalactive is the 
number of total known active compounds, which is 22. The enrichment factor is represented by: 
   
                        
                      
 (3.3) 
Hitsdecoy is the number of decoy compounds in the top-ranked list, and Totaldecoy is the number of 
compounds in the total decoy dataset, which is 1,000. The enrichment curves were also obtained 
for both individual docking and ensemble docking. The Hits% and EF were calculated based on 
the assumption that all the compounds in the decoy dataset are inactive against GSK-3β, 
however, that cannot be guaranteed. There may be some compounds in the decoy dataset that 
actually are active against the target protein. Thus, an enrichment study is just an estimate of the 
screening effectiveness. 
3.2.5. HIGH THROUGHPUT VIRTUAL SCREENING 
The ChemBridge EXPRESS-Pick
TM
 database consisting of more than 480,000 small 
synthetic compounds was selected for performing virtual screening, which is illustrated in Figure 
3.2. The 3D structures of those compounds were generated using the LigPrep
132
 module 
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implemented in Schrödinger 2010. To filter the compounds for drug-likeness, the modified 
Lipinski‘s rules were used, which are as follows: molecular weights are in the range of 200 to 
600; number of hydrogen bond donors is from 0 to 6; number of hydrogen bond acceptors is 
from 0 to 12; calculated logP values are from 1 to 5; and the number of rotatable bonds is from 0 
to 15. A set of 441,612 compounds survived into the next stage, which was screened using the 
common pharmacophore hypothesis. The hypothesis filtered out about half of the screened 
compounds. The remaining compounds underwent diversity analysis which reduced the number 
of compounds to ~12,000. Those compounds were subjected to the last stage of the virtual 
screening procedure, ensemble docking using the 13 protein crystal structures mentioned above. 
The hit compounds with preferable Glide SP scores and reasonable docking poses were selected 
and subjected to the enzyme inhibition assays. 
 
Figure 3.2. Flowchart for high throughput virtual screening. 
 
3.2.6. BIOLOGICAL VALIDATION 
The Invitrogen Z-Lyte kit was used to screen for potential GSK-3β inhibitors through 
fluorescence resonance energy transfer (FRET) between the donor, coumarin, and the acceptor, 
fluorescein. The donor and acceptor are on each end of the peptide substrate, constituting the 
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FRET pair. The Z‘-LyteTM Ser/Thr 9 peptide is used since it is designed with a priming 
phosphate which satisfies the substrate specificity of GSK-3β. The inhibitors were screened in a 
two-step reaction. In the first step, the kinase reaction proceeds, in which the γ-phosphate of ATP 
is transferred to a single serine or threonine residue in the synthetic peptide substrate. In the 
second step, the development reaction occurs, in which a site-specific protease recognizes and 
cleaves non-phosphorylated peptides. The cleavage disrupts FRET between the donor and 
acceptor fluorophores on the peptide, giving off a high emission ratio. The phosphorylated 
peptides remain uncleaved and maintain FRET, giving off a low emission ratio. Therefore, the 
kinase inhibition can be recognized by a high emission ratio which means the low 
phosphorylation by GSK-3β. This ratiometric approach reduces the effects of well-to-well 
variation, and provides a quick and reliable approach for the assessment of GSK-3β inhibition.  
The enzyme inhibition assays were performed in 384-well Greiner Bio-One flat bottom 
microplates. First, three control solutions were prepared. The maximum emission ratio was 
established based on the 100% inhibition control, which yields 100% cleaved peptide in the 
development reaction. The 100% inhibition control contained 2.5 μL of 4% DMSO, 5 μL of 
kinase/peptide mixture, and 2.5 μL of diluted kinase buffer. The original buffer, which was 
prepared by mixing 250 mM HEPES, 50 mM MgCl2, 5 mM EGTA, and 0.05% BRIJ-35 at pH 
7.5, was diluted by 3.76-fold. The minimum emission ratio was established as the 0% inhibition 
control, which is designed to produce a recommended 20-40% phosphorylated peptide in the 
kinase reaction and to yield 60-80% cleaved peptide in the development reaction. The 0% 
inhibition control contained 2.5 μL of 40 μM ATP instead of 2.5 μL of kinase buffer, resulting in 
a 10 μM final ATP concentration. The 100% phosphorylation control, consisting of 5 μL 
synthetically phosphorylated peptide instead of 5 μL of kinase/peptide mixture, is designed for 
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calculation of percent phosphorylation. This control yields a very low percentage of cleaved 
peptide in the development reaction. The inhibitory activities of the hit compounds against GSK-
3β were assayed by reading the fluorescence signals of the reaction mixture, which contained 2.5 
μL of 40 μM hit compound dissolved in 4% DMSO, 5 μL of kinase/peptide mixture, and 2.5 μL 
of 40 μM ATP. The final concentration of each compound to be tested in the assay was 10 μM, 
and the final concentration of DMSO never exceeded 1%.  The percent inhibition is calculated 
by the following equation: 
                       
                                  
                                          
  (3.4) 
The percent phosphorylation can be calculated based on the emission ratio. 
To determine the IC50 of the hit compounds with percent inhibition greater than 50% at 
10 μM concentration, 10 concentration points were prepared using 3-fold dilutions, ranging from 
10 μM to 0.5 nM, and were used for the nonlinear regression analysis of the dose response curve. 
For a proper comparison, indirubin-3‘-monoxime (IC50 = 190 nM
133
) was employed as the 
reference standard. 
3.3. RESULTS AND DISCUSSION 
3.3.1. PHARMACOPHORE MODELING 
After clustering and scoring, three pharmacophore models were generated, all of which 
have the same three features (‗A‘, ‗D‘, and ‗R‘) with different relative positions. The 
pharmacophore models and their scores are listed in Table 3.3. The model with the highest 
survival score (2.87) was selected as the pharmacophore model to be used for screening of large 
molecular databases, for which the 3D coordinates and inter-feature distances and angles are 
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listed in the Tables 3.4 and 3.5. The pharmacophore features ‗A‘ and ‗D‘ represent the hydrogen 
bond interactions with the hinge region and co-crystallized water molecule within the ATP-
binding pocket. The backbone amides of the hinge region residues, including Tyr134, Val135, 
and Pro136, strongly interact with the ligands, and this interaction plays a key role in the ligand-
protein interaction at the ATP-binding pocket.
134
 The planar aromatic group (‗R‘) is buried into 
the adenine-binding domain and interacts with the protein through hydrophobic interactions. The 
superimpositions of the pharmacophore model with representative compounds are shown in 
Figure 3.3. The best alignments of the selected active compounds and their inhibitory activities 
are tabulated in Table 3.1. Although the correlations between the biological activities and fitness 
values are low, this common pharmacophore model matches all of the diverse GSK-3β 
inhibitors, so it is suitable to be used as the pre-filter in database screening. 
Table 3.3. Generated pharmacophore models. 
No. Features 
Survival 
Score 
Vector 
Score 
Site Score  
Volume 
Score 
Matches 
1 ADH 2.870 0.859 0.660 0.348 22 
2 ADH 2.738 0.817 0.590 0.333 22 
3 ADH 2.435 0.730 0.410 0.297 22 
 
Table 3.4. The xyz coordinates for the best feature-based pharmacophore model, which was used 
for virtual screening. 
 X
a 
Y
a 
Z
a 
A 24.313 −14.622 −9.8282 
D 23.569 −13.511 −11.878 
R 21.293 −16.493 −9.5971 
 
a
 In Å. 
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Table 3.5. The inter-feature distances and angles for the best feature-based pharmacophore 
model, which was used for virtual screening. 
Features Distance (Å) Features Angles (°) 
A—D 2.447 D—A—R 92.0 
A—R 3.560 A—D—R 54.1 
D—R 4.391 A—R—D 33.8 
 
 
 
Figure 3.3. Overlap of representative GSK-3β inhibitors with the pharmacophore model having 
the highest survival score. A. alsterpaullone; B. pyrazolopyrimidine 26; C. 4-acylamino-6-
arylfuro[2,3-d]pyrimidine 24; D. staurosporine. The pharmacophore features ‗ADR‘ (acceptor, 
donor, and aromatic) are represented by the blue ball with arrow, red ball with two arrows, and 
orange ring, respectively. The color codes for the inhibitors are as follows: green (carbon), red 
(oxygen), blue (nitrogen), and white (hydrogen). 
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3.3.2. DOCKING VALIDATION 
The RMSD values which show the displacement of docking poses relative to the 
experimental structures are listed in Table 3.6. For Glide 5.6, the prediction accuracies were 
improved with increased accuracy of docking scoring function from HTVS (high-throughput 
virtual screening) to SP (standard precision) to XP (extra precision). However, the computational 
effort increased at the same time. It is clear that Glide SP and Glide XP outperformed other 
docking protocols as measured by lower RMSD values. For Gold 4.0, the GoldScore (GS) 
scoring function gave the best performance. Some of the docking poses generated by Gold were 
far from the experimental structures. So using default parameters, the heuristic genetic algorithm 
did not identify the correct docking pose in an efficient manner. AutoDock 4 produced very good 
docking poses using the global search and hybrid search methods. For MOE 2010.10 Dock, the 
refinement processes after scoring significantly boosted the docking performance. The means 
and medians were obtained for all of the docking protocols, and we found that Glide XP gave the 
lowest values for both mean (0.84 Å) and median (0.37 Å). Glide SP was the second best 
protocol, with mean and median of RMSD values of 0.89 Å and 0.44 Å, respectively. Glide XP 
requires significantly increased computational effort compared to Glide SP. In the context of 
virtual screening, not only the accuracy but also the efficiency needs to be considered. Thus, 
Glide SP was selected as the optimal docking protocol for performing further studies including 
virtual screening.  
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Table 3.6. RMSD values for docking validation studies. 
RMSD (All atoms) 
PDB 
Code 
Glide Gold MOE AutoDock 
HTVS SP XP GS CS ASP LdG FFR GMR LGA GA LS 
1J1C 1.27 1.01 1.58 1.12 1.19 0.85 3.63 3.69 3.07 0.51 2.35 1.20 
1O9U 15.94 3.43 3.45 4.80 4.69 4.76 3.11 0.65 3.79 3.97 3.96 4.42 
1PYX 12.19 1.69 1.70 1.37 1.01 1.42 2.42 0.89 3.03 0.93 1.00 6.17 
1Q3D 0.21 0.19 0.15 0.35 0.49 0.48 1.62 0.17 0.88 0.38 0.32 1.15 
1Q3W 0.08 0.07 0.13 0.61 0.27 0.21 7.08 0.16 0.44 0.25 0.22 0.90 
1Q41 2.93 0.55 0.36 0.68 0.59 0.42 1.12 0.42 0.85 0.43 0.44 2.04 
1Q4L 0.90 2.04 0.13 1.13 0.51 0.53 6.93 1.39 2.86 0.43 0.41 3.19 
1Q5K 0.14 0.14 0.51 0.74 9.06 0.41 7.10 1.44 1.19 0.46 0.41 1.40 
1R0E 6.19 0.08 0.10 1.60 6.55 6.36 6.01 6.68 6.14 0.87 2.95 3.49 
1UV5 0.23 0.30 0.34 0.56 0.71 0.25 6.42 0.45 0.37 0.48 0.59 3.40 
2O5K 4.36 1.74 1.73 2.91 2.18 1.18 4.25 3.45 2.60 2.33 2.00 3.89 
2OW3 0.15 0.54 0.38 0.45 0.72 0.74 1.01 0.59 0.76 0.59 0.61 0.61 
3DU8 6.87 0.33 0.26 0.53 0.68 0.67 3.55 0.28 0.85 0.37 0.38 5.00 
3F7Z 0.91 0.28 0.94 4.63 5.72 5.80 7.16 3.58 4.25 4.15 0.73 3.45 
Mean 3.74 0.89 0.84 1.53 2.46 1.72 4.39 1.70 2.22 1.15 1.17 2.88 
Median 1.09 0.44 0.37 0.93 0.87 0.71 3.94 0.77 1.90 0.50 0.60 3.30 
 
Color 
Code 
RMSD < 1.5 1.5 < RMSD < 3.0 3.0 < RMSD < 4.5 4.5 < RMSD 
 
To study the induced fit effects on ligand-protein binding, the significance of the co-
crystallized water molecules within the ATP-binding pocket was examined (Figure 3.4). In the 
crystal structure 1Q3W, there is one water molecule interacting with both alsterpaullone and 
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residue Tyr134 in the hinge region. In the crystal structure 1R0E, a water molecule located in 
another position plays an important role in the connection of 3-indolyl-4-arylmaleimide with 
residues Glu97 and Asp200.  In the crystal structure 1Q3D, a hydrogen bonding network 
consisting of three water molecules bridges the interaction between staurosporine and residues 
Val135, Glu137, and Gln185, at the bottom of the binding pocket. In the crystal structure 1UV5, 
a distinct hydrogen bonding network consisting of three water molecules bridges the interaction 
between 6-bromoindirubin-3‘-oxime and residues Thr138, Arg141, and Gln185. So the co-
crystallized water molecules indeed play key roles in the ligand-protein interactions, and due to 
the induced fit effects the ligands with distinct structures may have different numbers of and 
locations of water molecules to enhance ligand-protein binding. 
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Figure 3.4. Different locations and interactions of co-crystallized water molecules within the 
ATP-binding pocket. A. 1Q3W; B. 1R0E; C. 1Q3D; D. 1UV5. The proteins are represented by 
cartoons, while the residues on the hinge region are represented by sticks. The carbons of the 
proteins are colored grey, while the carbons of the inhibitors are highlighted in green. The other 
atoms have the color codes: red (oxygen), blue (nitrogen), and white (hydrogen). 
The conformational flexibility of the residues around the ATP-binding pocket can also be 
seen by overlapping five crystal structures, including 1Q41, 1Q4L, 1UV5, 2O5K, and 2OW3 
(Figure 3.5). The co-crystallized ligands were removed before alignment for clear comparison, 
and the superimposition was based on the alignment of the backbone amino-acids. From the 
overlap, it is apparent that only Tyr134 in the hinge region has relatively little flexibility, and the 
side-chains of the other residues, Arg141, Glu185, and Phe67, are highly flexible. Those residues 
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play important roles in the ligand-protein binding through hydrogen bonds and hydrophobic 
interactions. 
 
Figure 3.5. Overlap of five crystal structures, including 1Q41, 1Q4L, 1UV5, 2O5K, and 2OW3. 
The proteins are represented by cartoons. The residues Tyr134, Arg141, Glu185, and Phe67 are 
represented by sticks. The color codes are as follows: grey (carbon), red (oxygen), and blue 
(nitrogen). 
To assess the induced fit effects on the docking disposition, self-docking and cross-
docking studies were conducted using Glide SP docking. The compound bis-(indole)maleimide 
pyridinophane from the crystal structure 2OW3 could not be docked into the receptor in the 
crystal structures 1Q4L, 1Q41, and 1UV5 with a reasonable docking pose. The RMSD values of 
the self-docking and cross-docking of the other compounds were tabulated in Table 3.7. It is 
clear that self-docking yielded proper binding poses similar to the ones in the crystal structures 
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with average RMSD equal to 0.57 Å, but the cross-docking produced binding poses far from the 
ones in the crystal structures with average RMSD equal to 5.04 Å. Therefore, the induced fit 
effects have significant influence on the docking disposition, and docking into a single crystal 
structure alone is not sufficient to be used to predict the binding poses of structurally diverse 
compounds. 
Table 3.7. RMSD values for self-docking and cross-docking studies. Each row represents the 
ligand and each column represents the protein. 
 
1Q3D 1Q3W 1Q4L 1Q5K 1Q41 1R0E 1UV5 2O5K 2OW3 3DU8 3F7Z 
1Q3D 0.19 5.56 3.93 10.17 8.40 7.20 9.54 4.57 6.55 4.23 6.37 
1Q3W 2.05 0.07 1.27 8.66 6.99 0.91 1.78 5.22 1.20 1.06 0.95 
1Q4L 7.78 3.74 0.55 8.60 3.09 2.01 3.34 3.91 4.26 5.78 5.01 
1Q5K 2.46 2.83 9.72 2.04 2.03 1.35 2.08 8.69 9.25 9.02 8.41 
1Q41 1.78 6.84 1.12 10.71 0.14 1.19 0.39 1.07 1.68 6.16 6.50 
1R0E 6.37 5.76 3.55 7.21 6.53 0.08 3.74 6.04 1.32 5.70 5.89 
1UV5 1.77 2.73 1.17 9.68 0.31 7.14 0.30 6.43 1.93 1.83 6.91 
2O5K 4.49 6.96 11.64 12.23 3.92 2.59 2.36 1.74 2.99 3.36 2.62 
2OW3 7.28 8.61 n.a.
a
 10.02 n.a.
a
 5.58 n.a.
a
 10.00 0.54 7.51 7.81 
3DU8 1.39 6.72 6.81 3.53 5.85 5.79 6.00 6.17 2.00 0.33 0.34 
3F7Z 4.33 4.57 7.65 9.25 6.35 5.88 5.89 1.64 7.21 2.12 0.28 
a 
No reasonable docking pose was found. 
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To address the induced fit effects, the ensemble docking approach described in the 
methods section was used. In contrast to the induced fit docking approach
135
 implemented in 
Schrödinger 2010, the ensemble docking method does not require protein sampling, which costs 
huge computational effort and is inappropriate for high throughput virtual screening. Meanwhile, 
ensemble docking takes into account both interactions with the water molecules and the 
conformational flexibility of the residues, based on evidence from the experimental crystal 
structures. In order to validate that ensemble docking is superior to individual docking and is 
appropriate to address the induced fit effects, the enrichment study described in the methods 
section was conducted. The performance of individual docking and ensemble docking in 
retrieving known active compounds from large decoy datasets was evaluated and the results are 
listed in Table 3.8. It is clear that only one individual docking protocol, based on crystal structure 
2OW3, slightly outperformed ensemble docking, and that was only for screening of 1% of the 
compounds; otherwise ensemble docking significantly outperformed all the individual dockings 
at both 5% and 10% of the screened compounds. The enrichment curve in Figure 3.6 also shows 
that the ensemble docking method has the best enrichment among all the docking protocols, 
especially from 5% to 45% of the screened database. The cut-off line for virtual screening 
usually lies within this range. Thus, based on the enrichment study, ensemble docking is believed 
to be the most effective and accurate docking method and was used in the last stage of the virtual 
screening procedure. 
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Table 3.8. Enrichment Study. 
  1% 5% 10% 
Protein No. Hits% EF No. Hits% EF No. Hits% EF 
1Q3D 5 23 23.2 11 50 10.0 12 55 5.5 
1Q3W 4 18 18.6 5 23 4.6 6 27 2.7 
1Q4L 5 23 23.2 7 32 6.4 10 45 4.6 
1Q5K 1 5 4.6 2 9 1.8 3 14 1.4 
1Q41 3 14 13.9 7 32 6.4 7 32 3.2 
1R0E 4 18 18.6 8 36 7.3 11 50 5.0 
1UV5 3 14 13.9 7 32 6.4 7 32 3.2 
2JLD 1 5 4.6 7 32 6.4 10 45 4.6 
2O5K 4 18 18.6 5 23 4.6 7 32 3.2 
2OW3 7 32 32.5 11 50 10.0 13 59 5.9 
3DU8 1 5 4.6 6 27 5.5 9 41 4.1 
3F7Z 3 14 13.9 7 32 6.4 10 45 4.6 
3F88 2 9 9.3 6 27 5.5 8 36 3.6 
Ensemble 6 27 27.9 13 59 11.8 16 73 7.3 
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Figure 3.6. Enrichment Curve for the individual docking into different PDB structures (PDB 
labels given) and for ensemble docking. 
3.3.3. VIRTUAL SCREENING AND BIOLOGICAL VALIDATION 
To verify the reliability of the proposed mixed ligand/structure-based approach in the 
virtual screening procedure from the experimental perspective, 24 hit compounds were selected 
based on the ensemble docking score and on visual inspection, in which we verified the presence 
in the docking poses of the essential hydrogen bond interactions with the hinge region of the 
receptor. The compounds were purchased from ChemBridge Corp. and the GSK-3β inhibitory 
activities of these compounds were tested according to the experiments described above. Their 
chemical structures and biological activities are listed in Table 3.9. The functional groups 
highlighted in red are predicted to be the moieties that establish hydrogen bond interactions with 
the residues in the hinge region of the receptor. Fifteen structurally diverse compounds with 
inhibition greater than 50% at 10 μM concentration were selected for IC50 determination. Among 
them, 9 compounds had IC50 values less than 10 μM. Furthermore, compound 23, with molecular 
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weight of 286 and logP of 1.68, exhibited sub-micromolar activity, and hence can be used as a 
good starting point for further drug development. 
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Table 3.9. Biological activities for binding to GSK-3β of the hit compounds. 
No. Structure 
Docking 
Score 
(PDB 
code) 
%inhibition 
at 10 μM 
(%) 
IC50 
(μM) 
reference 
 
 100 0.19 
1 
 
–9.119 
(2OW3) 
13 N.A.
a 
2 
 
–9.121 
(1Q3D) 
44 N.A.
a 
3 
 
–9.433 
(1UV5) 
12 N.A.
a 
4 
 
–9.401 
(1R0E) 
30 N.A.
a 
5 
 
–9.149 
(1Q5K) 
65 39.51 
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6 
 
–8.818 
(1Q4L) 
25 N.A.
a 
7 
 
–8.923 
(1Q4L) 
100 15.79 
8 
 
–8.941 
(1UV5) 
34 N.A.
a 
9 
 
–9.241 
(1UV5) 
25 N.A.
a 
10 
 
–9.297 
(1Q4L) 
41 N.A.
a 
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11 
 
–10.566 
(1Q5K) 
84 2.06 
12 
 
–9.381 
(1Q41) 
65 67.07 
13 
 
–10.269 
(1Q41) 
30 N.A.
a 
14 
 
–10.682 
(1UV5) 
75 1.05 
15 
 
–10.236 
(1UV5) 
100 1.76 
16 
 
–10.021 
(1R0E) 
100 2.40 
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17 
 
–9.511 
(1UV5) 
61 72.73 
18 
 
–9.876 
(1Q4L) 
85 7.48 
19 
 
–9.716 
(1R0E) 
83 27.32 
20 
 
–9.752 
(1Q41) 
69 5.13 
21 
 
–9.571 
(1Q4L) 
75 10.02 
22 
 
–10.067 
(2JLD) 
100 2.80 
23 
 
–9.461 
(1Q41) 
100 0.51 
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24 
 
–8.839 
(2OW3) 
65 1.58 
a
 N.A.: not active. 
To examine the predicted ligand-protein interactions, the best docking poses of the four 
most active hit compounds (compounds 14, 15, 23, and 24) are demonstrated in Figure 3.7. All 
four of the compounds satisfy the basic requirements of ATP-competitive GSK-3β inhibitors, 
which include functional groups which interact with the residues in the hinge region and an 
aromatic group which fits into the narrow ATP binding pocket. Furthermore, they all have 
additional interactions either with co-crystallized water molecules or with other protein residues. 
For instance, 14, which was docked into the structure 1UV5, has a hydrogen bond interaction 
with one co-crystallized water molecule located on the bottom of the ATP-binding pocket 
through the carbonyl group on the indolone moiety; 15, which was docked into the same crystal 
structure, has two hydrogen bonding interactions: one is between the hydroxyl group and the 
residue Asn64 and the other one is between the sulfur on the thiazole ring and the co-crystallized 
water; the carbonyl group on the amide moiety of 23, which was docked into the structure 1Q41, 
has a hydrogen bonding interaction with one co-crystallized water molecule; while the cyano 
group of 24, which was docked into the structure 2OW3, has a hydrogen bonding interaction 
with a different water molecule deeply buried in the ATP-binding pocket. These additional 
hydrogen bond interactions explained the high activities of the corresponding hit compounds. 
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Figure 3.7. Docking poses of the four top active hit compounds. A. 14; B. 15; C. 23; D. 24. The 
protein surface is colored light blue, while the surface of the residues which have hydrogen bond 
interactions with the hit compounds are colored pink. The hit compounds and the co-crystallized 
waters have the same color codes: green (carbon), red (oxygen), blue (nitrogen), yellow (sulfur), 
and white (hydrogen). 
3.4. CONCLUSIONS 
In order to identify structurally novel and diverse GSK-3β inhibitors, we designed and 
validated a mixed ligand/structure-based virtual screening protocol. In terms of ligand-based 
approaches, we constructed a common pharmacophore hypothesis to be used for preliminary 
screening of large databases to make sure to include only compounds containing the key 
structural features needed to be GSK-3β inhibitors, and we performed diversity analysis to 
achieve maximum coverage of the activity space and reduce the structural redundancy in the 
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screening process. In terms of a target-based approach, we systematically investigated various 
docking protocols and showed that ensemble docking is an efficient and effective technique to 
address the induced-fit effects in ligand-protein recognition. The hit compounds obtained from 
virtual screening underwent experimental validation. The bioassay results showed that 15 out of 
24 hit compounds are indeed GSK-3β inhibitors when tested at 10  M, and among them, 8 
molecules exhibited low micromolar activities (IC50 < 10  M) and one molecule exhibited sub-
micromolar activity. The high hit rate demonstrated the success of the proposed mixed 
ligand/structure-based virtual screening protocol. Upon closely examining the predicted binding 
poses, we concluded that the additional hydrogen bond interactions with co-crystallized water 
molecules in the ATP binding pocket are required for the high binding affinity. 
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4.1. INTRODUCTION 
Since 3D-QSAR using CoMFA and CoMSIA methods requires structural alignment, 
which is crucial and requires the molecules to have a similar scaffold. So the size of data set in 
one particular modeling project is typically limited. And sometimes, the conformations used for 
alignments are different from the bioactive conformations, which can reduce the accuracy and 
relevance of the model. In contrast to 3D-QSAR methods, classical QSAR methods based on 
structural and physicochemical descriptors are independent of structural alignment, so they can 
be expected to perform well with large data sets. Furthermore, with the development of machine 
learning algorithms and artificial intelligence methods which can be implemented for both model 
construction and feature selection, modern QSAR methods which can produce highly predictive 
linear or nonlinear models play an increasingly important role in the drug discovery process, 
especially in virtual screening studies to identify novel hit compounds.
79
 
The predictive performance of the QSAR models are highly dependent on the consistency 
of the experimental bioactivities, in other words, the data homogeneity. The different bioassay 
protocols can conceivably yield distinct biological activities for the same compound inhibiting 
GSK-3 (Table 4.1). The systematic errors from the experiments can significantly reduce the 
predictive accuracies of the QSAR models if compounds with biological activities determined 
under different bioassay protocols are collected into one large data set.
136
 To deal with this 
circumstance, we constructed a hierarchical QSAR model which adopts a multi-level structure to 
take into account the data heterogeneity. Figure 4.1 illustrates the multi-level structure of the 
hierarchical QSAR model. In the lower level of the model, each regression model is built on data 
collected by a single research group using a particular bioassay. The labels to be used in building 
regression models are the single-protocol bioactivities. In the upper level of the model, all the 
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compounds culled from different research groups are collected in a single data set, and a multi-
class classification model is constructed to separate compounds into different subclasses. The 
labels of the classification models are the group numbers (from I to VII) which are used to 
indicate the heterogeneity in the data. State-of-the-art machine learning algorithms, support 
vector machines (SVM) and random forests (RF), were used to construct a multi-class 
classification model at the higher level and multiple regression models at the lower level. The 
performance of the two algorithms was systematically investigated and compared. The best 
models with the highest predictive ability were employed, combined with ensemble docking, in a 
mixed ligand-based/structure-based virtual screening study to identify structurally novel GSK-3 
inhibitors. 
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Table 4.1. GSK-3 inhibitors and their different reported biological activities. 
Structure Biological Activities 
 
SB-216763 
Coghlan et al.
137
 IC50 = 34.3 nM 
Kozikowski et al.
138
 IC50 = 50 nM 
 
SB-415286 
Coghlan et al.
137
 IC50 = 77.5 nM 
Smith et al.
61
 IC50 = 104±10 nM 
Kozikowski et al.
138
 IC50 = 1.3 μM 
 
AR-A014418 
Bhat et al.
42
 IC50 = 104±27 nM 
Gaisina et al.
73
 IC50 = 41.8±6.4 nM 
 
Staurosporine 
Leclerc et al.
62
 IC50 = 15 nM 
Engler et al.
139
 IC50 = 56±6.9 nM 
 
Indirubin-3‘-monoxime 
Meijer et al.
44
 IC50 = 22 nM 
Bain et al.
140
 IC50 = 0.19 μM 
 
Alsterpaullone 
Leost et al.
141
 IC50 = 4 nM 
Bain et al.
140
 IC50 = 0.11 μM 
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Kenpaullone 
Leost et al.
141
 IC50 = 23 nM 
Bain et al.
140
 IC50 = 0.23 μM 
 
 
 
Figure 4.1. The multi-level structure of the hierarchical QSAR model. Level I constitutes a 
multi-class classification model and Level II constitutes regression models. The group numbers 
highlighted in red were used in model construction, indicating the data heterogeneity. The 
subclass numbers highlighted in blue were used in the classification models, indicating the 
corresponding groups. 
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4.2. MATERIALS AND METHODS 
4.2.1. COLLECTION OF HETEROGENEOUS DATA SETS 
A collection of seven groups of compounds were compiled from the literature. To 
demonstrate the difference of the bioassay protocols under which the inhibitory activities of each 
group of compounds was tested, we describe and compare some experimental details here, 
especially regarding the isoforms and organisms of the target proteins, the substrate peptide, and 
the concentration of ATP cofactors. For each dataset we included from the corresponding papers 
all the reported compounds except for those without reported activity and or without well-
defined stereochemistry. The chemical structures of the collected 728 GSK-3β inhibitors from 
seven research groups, associated with the experimental and predicted pIC50 values, are provided 
(Appendix: B-H). 
Meijer et al. studied the structure-activity relationships (SAR) of hundreds of compounds 
against GSK-3α/β. The compounds typically belonged to three chemical classes, indirubins,62, 63, 
142
 paullones,
64, 143
 and aloisines.
65
 A total of 214 of the molecules constitute the Group I dataset. 
The GSK-3α/β was purified from porcine brain by affinity chromatography on immobilized axin 
and purified from insect Sf9 cells. The kinase activity was assayed using the pGS-1 peptide as a 
substrate, at a final ATP concentration of 15 μM. 
Ward et al. studied the binding affinity of several sets of compounds again human GSK-
3α (hGSK-3α). The compounds defined as the Group II dataset consist of the analogs of 3-
anilino-4-arylmaleimides,
61
 the analogs of 5-aryl- pyrazolopyridines and 5-aryl-
pyrazolopyridazines,
68, 72
 and the analogs of 6-aryl- and 6-heteroaryl-pyrazolopyridines.
70, 71
 A 
total of 157 molecules were collected. The hGSK-3α isoform was expressed using the 
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baculovirus expression system and recovered from cells by homogenization and purification 
using NiNTA superflow. The hGSK-3α was assayed on the substrate peptide (Biotin-
KYRRAAVPPSPSLSRHSSPHQSpEDEEE) in the presence of 10 μM ATP. 
Thomas et al. reported the in vitro biological activities for the inhibition of human GSK-
3β (hGSK-3β) by the pyrazolopyrimidine derivatives,66, 67 and Maeda et al. reported the same 
inhibitory activities by the furopyrimidine derivatives.
112
 A total of 91 molecules based on these 
two chemotypes constitute the Group III dataset. The hGSK-3β enzyme assays for the two sets of 
compounds were carried out by Schweiker et al. from GlaxoSmithKline Inc. under the same 
scintillation proximity assay (SPA) protocol. The hGSK-3β was assayed on the substrate peptide 
(Biotin-Ahx-AAAKRREILSRRPSpYR-amide) in the presence of 2.5 μM ATP. 
Kozikowski et al. investigated the SAR of a set of potent and selective GSK-3β inhibitors 
based on the chemotypes of 1H-indazol-3-yl-(indol-3-yl)maleimides and benzofuran-3-yl-(indol-
3-yl)maleimides.
73, 138, 144
 A total of 85 of the molecules gathered from the literature define the 
Group IV dataset. The in vitro kinase assay was performed on the pGS peptide 
(RRRPASVPPSPSLRHSSpHQRR) in the presence of 10 μM ATP. 
Arnost et al. identified a series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-ones as potent 
GSK-3β inhibitors,52 of which a total of 62 molecular derivatives constitute the Group V dataset. 
The compounds were tested against GSK-3β using the standard coupled enzyme assay, which 
was carried out in the presence of substrate peptide (HSSPHQSpEDEEE) and 10 μM ATP. 
Saitoh et al. reported the design, synthesis and SAR analysis of a novel series of 1,3,4-
oxadiazole derivatives as GSK-3β inhibitors.49, 50 A set of 61 of the compounds exhibiting good 
 79 
 
potency and selectivity constitute the Group VI dataset. The human GSK-3β expressed using 
baculovirus expressing system was assayed in the presence of 0.5 μM ATP. 
Lesuisse et al. reported the rational design of potent and selective GSK-3β inhibitors via 
structural modifications to lead compounds identified through high throughput screening.
97
 The 
lead compound contains an aminoindazole moiety interacting with the hinge region of the kinase 
binding pocket, and a total of 58 derivative molecules constitute the Group VII dataset. The 
enzymatic activity was measured by the SPA approach, in which the recombinant human GSK-
3β was assayed on pGS-2 substrate peptide in the presence of 1 μM ATP. 
4.2.2. CALCULATION OF MOLECULAR DESCRIPTORS 
The 3D structures were built and preoptimized using the LigPrep module
132
 from 
Schrödinger Suite 2010. In order to obtain reasonable conformers of the compounds which were 
to be employed to calculate relevant 3D descriptors, ensemble docking
145
 was performed to 
generate the predicted binding poses for all the compounds in the QSAR study. The resulting 
conformations were found to be consistent for structurally similar compounds and are close to 
biologically significant conformers, comparing to the co-crystallized structures. The 3D 
structures were further optimized until the root-mean-square gradient reached 0.0001 kcal mol
-1
 
and partial charges were obtained with the semiempirical AM1 method implemented in MOE 
software.
146
 The optimized structures associated with the partial charges were then subjected to 
molecular descriptor calculations using DragonX software
147
 which generates up to 3224 
descriptors (Table 4.2). In order to remove descriptors that would likely be unhelpful for 
generating high quality models, several preprocessing steps were performed, including the 
elimination of descriptors with the same values for all molecules in the training set for the model 
being built, descriptors with too many zero values (>90%), and descriptors with very small 
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standard deviations (0.05). After preprocessing, the feature values were scaled to have 0 as mean 
and 1 as standard deviation before they were applied in the SVM modeling. The normalization 
step is necessary for SVM, since the ranges of feature values vary greatly from one category to 
another, and the large variations have a big impact on the quality of SVM models. However, the 
normalization step is not required for RF, so the initial feature values were used in the RF 
modeling.  
Table 4.2. Twenty-two Categories of molecular feature descriptors generated using DragonX 
software.  
2D or 3D Category Number of descriptors 
2D 
constitutional descriptors 48 
topological descriptors 119 
walk and path counts 47 
connectivity indices 33 
information indices 47 
2D autocorrelations 96 
edge adjacency indices 107 
Burden eigenvalue descriptors 64 
topological charge indices 21 
eigenvalue-based indices  44 
functional group counts  154 
atom-centered fragments  120 
molecular properties 29 
2D binary fingerprints  780 
2D frequency fingerprints  780 
3D 
Randic molecular profiles 41 
geometrical descriptors 74 
RDF descriptors 150 
3D-MoRSE descriptors 160 
WHIM descriptors 99 
GETAWAY descriptors 197 
charge descriptors 14 
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Table 4.3. Data set summary. 
Group 
Research 
Group 
Chemical Classes Ntrain 
pIC50 
range 
(train) 
Ntest 
pIC50 
range 
(test) 
I Meijer et al. 
Indirubins 
Paullones 
Aloisines 
174 3.0-8.5 40 4.6-8.0 
II Ward et al. 
3-Anilino-4-arylmaleimides 
5-Aryl- pyrazolopyridines 
5-Aryl-pyrozolopyridazines 
6-Aryl-pyrazolopyridines 
6-Heteroaryl-pyrazolopyridines 
128 5.3-9.1 29 5.3-8.3 
III 
Thomas et al. 
Maeda et al. 
Pyrazolopyrimidines 
Furopyrimidines 
75 4.5-8.8 16 4.5-8.4 
IV 
Kozikowski et 
al. 
1H-Indazol-3-yl-(indol-3-
yl)maleimides 
Benzofuran-3-yl-(indol-3-
yl)maleimides 
66 4.9-9.6 19 5.6-9.3 
V Arnost et al. 
3-Aryl-4-(arylhydrazono)-1H-
pyrazol-5-ones 
49 5.4-9.4 13 6.6-8.7 
VI Saitoh et al. 1,3,4-Oxadiazoles 49 5.0-8.6 12 6.1-8.2 
VII Lesuisse et al. Aminoindazoles 46 4.0-8.3 12 4.6-8.0 
 
4.2.3. DIVISION INTO TRAINING AND TEST SETS 
K-mean clustering analysis was employed in the division of each group of compounds 
into the training and test sets (Table 4.3).
148
 As an unsupervised learning algorithm, the method 
partitions the data set into k mutually exclusive clusters, with k any integer, and from each 
cluster, the compound with the median biological activity was selected for the test set and the 
rest of the compounds in the cluster were selected for the training set. Hence, the number of 
clusters defines the number of compounds in the test set, which is usually about one fifth of the 
overall data set for each group. Furthermore, such a split guarantees that the distribution of 
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biological activities for the test set is similar to that for the training set. The feature values were 
scaled to the range [0, 1] before they were used to calculate the squared Euclidean distance, 
which then was minimized for each cluster during the k-mean analysis. For each group of 
compounds, the same division into training and test sets was applied for both the multi-class 
classification and regression models. 
4.2.4. MEASUREMENT OF THE PREDICTION PERFORMANCE 
For the multi-class classification models, the quality of the models was estimated using 
the classification accuracy.  
         
                                       
                         
      (4.1) 
Confusion tables were also used to illustrate the prediction ability of the models in more 
detail. 
For the regression models, three statistical measures were employed to evaluate the 
predictive accuracies of the models, including the squared Pearson‘s correlation coefficient (R2), 
residual mean square error (RMSE), and F-ratio. The goodness-of-fit R
2
 is defined by: 
   
               
 
     
              
         
 (4.2) 
where    represents the observed bioactivities and    represents the predicted bioactivities. 
Meanwhile, the subscript representations are adopted to indicate whether the relevant statistic 
refers to the training set (      
 ), leave-one-out cross-validation (    
 ), 5-fold cross-validation 
(   
 ), or prediction of the test set (     
 ). 
The RMSE or residual variance is calculated as follows: 
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(4.3) 
where      is equivalent to      
 , the squared standard deviation of the estimate. The same 
subscript representations are adopted as above. The squared deviation of the regression line (  
 ) 
is defined as: 
  
         
  (4.4) 
where   represents the average of the observed bioactivities. The     
  and   
  combined together 
can be used to calculate the F-ratio, according to the equation: 
  
  
 
     
 (4.5) 
where   has the degree of freedom 1 and n–2 for   
  and     
 , respectively. This ratio is used in 
hypothesis testing with the assumption that the model predicts better than a prediction using an 
average value, α, at a certain significance level (α = 0.05). So the higher the value of the F-ratio, 
the better the predictiveness of the model.
149
 The same subscript representations are adopted as 
above. 
The robustness and predictive power of the regression models were further examined 
using the Y-randomization test which is a widely used validation technique. The test is carried 
out by rebuilding the new regression models using the original independent variable matrix (the 
feature values) but using a randomly permuted dependent variable vector (for the bioactivities). 
This process is repeated 100 times, and the mean values and standard deviations of the 
measurements of the new models are evaluated and compared with the original models. It is 
expected that the new models obtained with the randomized bioactivities should generally yield 
poor prediction performance in terms of both internal and external validation. If the best 
 84 
 
resulting models in the Y-randomization test exhibit high prediction ability, then it implies that a 
reliable regression model cannot be obtained for the given data set using the current modeling 
method. The Y-randomization test was applied to the seven regression models using the selected 
methods. 
4.2.5. SUPPORT VECTOR MACHINES 
SVM have been developed by Vapnik
150
 and his co-workers, based on the statistical 
learning theory derived from the structural risk minimization principle and Vapnik-Chervonenkis 
(VC) dimension. SVM involves the attempt to minimize the upper bound of the expected test 
error, and it is superior in terms of generalization over the traditional empirical risk minimization 
principle employed in conventional neural networks, which just minimize the error on the 
training data. SVM was initially developed in the context of binary (two-class) classification 
problems, in which a linear classifier with the smallest empirical risk and VC dimension is 
constructed to correctly separate the data into either the positive or negative class. Geometrically, 
this classifier is termed the optimal separating hyperplane with the maximum margin for a given 
set of learning data. The largest margin corresponds to the smallest empirical risk and smallest 
VC dimension. 
The current standard formulation is soft margin SVM
151
 which introduces a penalty for 
misclassified data, denoted by ξ and called a slack variable. In the case of binary classification, 
given n points of training data placed in the matrix X = (x1, x2, …, xn), where each point xi is a 
m-dimensional real vector, xi   R
m
, for i = 1, 2, …, n, and each object  xi  belongs to a class yi   
{–1, +1}, the construction of a linear classifier actually is equivalent to solving the following 
primal optimization problem: 
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 (4.6) 
                      
                    
        
  (4.7) 
where   is a norm vector perpendicular to the hyperplane, and   is a tuning parameter that can 
be adjusted by the user. Minimizing the first term can be translated into finding the maximum 
margin hyperplane and minimizing the second term can be translated into minimizing the error 
of misclassified data. So the tuning parameter   represents a trade-off between the expected test 
error, or generalization error, and the error of the misclassified learning data, or training error. 
This is a quadratic programming problem, which minimizes a quadratic function under linear 
constraints. The problem can be solved based on the use of a Lagrange function, transforming 
the primal problem into its dual formulation. After solving the dual problem, the optimal values 
for the vector   and threshold   can be used to construct an optimal separating hyperplane for 
the classification of new data. 
In the case of multi-class classification, the ‗one-versus-one‘ approach is involved. This 
approach first decomposes the training set into several binary classification problems, and then 
trains a binary classifier for every two-class problem from the training set. So a k-class problem 
would result in k*(k–1)/2 binary classifiers. In the prediction phase, a voting strategy is engaged 
to assign the class of the data points and a data point is designated to be in the class with the 
maximum number of votes. If two classes have an identical number of votes, the data point is 
assigned to the class appearing first in the storage array. 
In the case of hard-to-separate classes, a nonlinear kernel function ϕ(xi) is introduced in 
order to map the original feature space into a feature space of a higher dimension, and then a 
linear classification is performed in that higher dimensional feature space. By transforming the 
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feature space, the nonlinear separable classes having a complex relationship between the original 
input variables (xi) and the corresponding classes (yi) can be efficiently separated by a linear 
classifier. One of the most widely used kernel function, the radial basis function (RBF) kernel in 
the Gaussian form, was used in the present study: 
                      
 
      (4.8) 
where the tuning parameter   controls the shape of the separating hyperplane. It can be 
optimized with a suitable cross-validation procedure. 
Initially developed for classification, SVM was extended by Vapnik and his co-
workers
152
 to be able to establish regression models. The transformation from a sign function in 
SVM classification to a real function in SVM regression is realized by incorporating an ε-
insensitive loss function: 
              
                                         
                                  
   (4.9) 
where   represents the maximum margin for the deviation between the experimental values (  ) 
and predicted values (     ), and it should be optimized during the model construction. Based on 
this linear loss function, the loss penalty for the deviation within   is zero, and the loss penalty 
for the deviation beyond   is calculated by the difference between the deviation and  . The loss 
penalty corresponds to the slack variable in the soft margin SVM classification models. 
However, in regression models, overestimation and underestimation cause distinct prediction 
errors. So two slack variables are introduced, which are ξ+ and ξ–, and the primal formulation for 
soft margin SVM regression models is: 
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  (4.11) 
In the present work, the Matlab
153
 interface of LIBSVM 3.0
154
 was employed for the 
SVM classification and regression analysis using a Gaussian RBF kernel in the hierarchical 
QSAR modeling. There are two tuning parameters for SVM classification models ( ,  ) and 
three tuning parameters for SVM regression models ( ,  ,  ), which balance the trade-off 
between data fit and model complexity. The tuning parameters were determined by a grid search. 
100 replications of 5-fold cross-validation were performed to access the classification accuracies 
or regression    
  at each point over a fixed grid of parameter values. The median values for the 
100 replications were used as the optimal tuning parameters. 
In order to demonstrate the influence of redundant or irrelevant features to SVM, the 
computationally intensive wrapper-based feature selection method was implemented. Wrapper 
methods incorporate model assessment within the feature selection procedure, which usually 
provides superior performance and can be used to find the optimal or suboptimal subset of 
features specifically for certain learning models,
155
 such as for multiple linear regression, 
artificial neural networks, or SVM. Since the number of subsets of features is 2
M
 where M is the 
total number of features, there is no way to do an exhaustive search. However, randomized 
heuristic search methods provide a promising feature selection mechanism, especially when 
implemented with evolutionary algorithms from artificial intelligence, such as the particle swarm 
algorithm used in the present study. After the wrapper-based feature selection, one post-
processing step was employed in order to further reduce the redundancy and refine the models, 
 88 
 
which was to eliminate features which are highly correlated (Pearson‘s correlation coefficient R 
> 0.9) with others and hence would be expected to be of low importance to the models.  
4.2.6. BINARY PARTICLE SWARM ALGORITHM 
The particle swarm (PS) algorithm is a part of evolutionary computing, which belongs to 
artificial intelligence. The algorithm, introduced by Kennedy and Eberhart in 1995,
156, 157
 
simulates the collective behavior of a flock of birds or a school of fish looking for the shortest 
route from their current position to a food source. PS optimization, like other swarm intelligence 
algorithms such as ant colony optimization, is a stochastic, population-based optimization 
algorithm which explores the search space without the provision of a global model. The 
randomly initialized particles with an original velocity and position proceed through the search 
space, remembering the best position encountered; then they accelerate towards the position of 
the best performing particles as well as towards their personal best previous position. So it is a 
valuable heuristic algorithm updating the velocities and positions according to the historic 
behaviors of the particles themselves or of their neighbors. During each update, the velocity is 
adjusted by two elements, the cognitive part and social part. Later, Shi and Eberhart proposed 
another improved model, introducing the inertia weight to achieve a fast convergence.
158, 159
 The 
position is adjusted using the updated velocity.  
The binary particle swarm representation
160
 was used in the present study, which is 
widely used to search the feature space in modern QSAR studies.
161, 162
 The features are encoded 
in a population (P) of binary strings, indicating the positions of particles. Each binary string 
represents a point in M-dimensional space, in which M is the total number of candidate features. 
The position of the ith particle is represented by a vector    = (   ,    , …,    ), where     (i = 
1, 2, …, P and d = 1, 2, …, M) can be either 0 representing an unselected feature or 1 
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representing a selected feature. The velocity of the ith particle is represented by a number   , 
where    (i = 1, 2, …, P) can be a positive integer, varying between 1 and Vmax, based on how 
many bits in the string should be changed from 0 to 1 or from 1 to 0 in each iteration. The 
maximum velocity Vmax serves as a constraint to control the trade-off between the local and 
global exploration of a particle swarm. According to Wang et al,
160
 the Vmax should be neither 
too low nor too high, and a moderate value such as M/3 is recommended. The velocity can be 
initialized by a random number generated from a uniform distribution from 1 to M, and if the 
velocity is larger than Vmax, it will be set back to the maximum velocity. The positions of the 
particles are initialized by probabilistic selection. A set of random numbers between 0 and 1 are 
first generated from the uniform distribution. Then probability thresholds (δ) are used to convert 
continuous numbers to a binary representation, via mapping the random numbers in the interval 
(0, δ) to 1 and other values to 0. Since there are thousands of candidate features, and only a few 
of them (10-40) are expected to be selected in a particular QSAR model, a small threshold 
interval (<0.1) is used to determine the subset membership.  
Once the particles are constructed, the velocity and position of each particle are updated 
on every iteration according to the following equations: 
                                                 (4.12) 
            (4.13) 
where    and    are cognitive and social acceleration constants, contributing to the balance 
between local and global exploration; rand1 and rand2 are two random numbers, generated in the 
range (0, 1) from a uniform distribution;     represents the best previous position of the ith 
particle, and     represents the overall best position of all the particles in the population. The 
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inertia weight ( ) is introduced to limit the number of iterations needed for convergence. It is 
linearly decreased along with the iteration (k) for each update: 
           
         
    
   (4.14) 
where      and      are predefined maximum and minimum values of inertia weight, and 
     is the predefined maximum number of iterations. The starting point    equals     . After 
the predefined number of iterations, the inertia weight reduces to     . 
Within each iteration, a fitness value indicating the goodness of the particular subset of 
features is computed for every particle as follows: 
         
                       
   
 
                    
  (4.15) 
where μ
  
 is the measure of goodness describing how well the model fits the observation. For 
multi-class SVM classification models, it is calculated based on the median classification 
accuracy for 9 replications of 5-fold cross validation; and for SVM regression models, it is 
calculated based on the median    
  for the 9 replications of 5-fold cross validation. The actual 
number of selected features is represented by m and the desired number of selected features is 
represented by α. Since a smaller number of selected features give higher interpretability and 
generalization power to the model, the optimal particle position is the feature subset with the 
shortest length and the highest measure of goodness of fit. The piecewise fitness function 
employs the exponential function to penalize solutions containing a large number of selected 
features. 
After preliminary studies (results not shown), the tuning parameters controlling the 
performance of the PS feature selection algorithm were determined (Table 4.4), including the 
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population size (P), the maximum number of iterations (    ), the cognitive acceleration 
constant (  ), the social acceleration constant (  ), the maximum value of inertia weight (    ), 
the minimum value of inertia weight (    ), the maximum velocity (Vmax), and the probability 
threshold (δ). Some of them were determined based on the recommended values according to 
Wang et al.
160
 The tuning parameters for SVM were also defined for the feature selection 
process. 
Table 4.4. The parameters controlling the performance of PS feature selection algorithm as well 
as SVM classification and SVM regression models. 
Group P kmax c1 c2 ωmax ωmin Vmax δ C γ ε 
multi-class SVM classification 
– 500 2000 2.0 2.0 1.4 1.4 452 0.02 30 0.08 – 
SVM regression 
I 400 6000 2.0 2.0 1.4 0.4 428 0.05 50 0.05 0.08 
II 500 2000 2.0 2.0 1.4 0.4 430 0.04 50 0.05 0.08 
III 500 2000 2.0 2.0 1.4 0.4 383 0.03 30 0.05 0.06 
IV 400 4000 2.0 2.0 1.4 0.4 406 0.04 30 0.05 0.06 
V 400 3000 2.0 2.0 1.4 0.4 369 0.03 30 0.08 0.08 
VI 400 3000 2.0 2.0 1.4 0.4 393 0.03 30 0.08 0.08 
VII 400 3000 2.0 2.0 1.4 0.4 387 0.03 30 0.08 0.08 
 
4.2.7. RANDOM FORESTS 
Decision trees are commonly used for data mining. The most popular kind is 
classification and regression trees (CART), which is a greedy method based on a recursive 
partitioning algorithm. CART has a combination of several advantages over other machine 
learning algorithms including the ability to ignore irrelevant descriptors, the ability to handle 
mixed data structures (continuous and discrete variables), and the simplicity of the results which 
can be represented by simple tree models rather than by elaborate equations. CART can be used 
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to construct nonparametric and nonlinear models in order to predict either continuous or 
categorical dependent variables. However, the major drawback of CART is its low prediction 
accuracy caused by the overfitted tree-based structure, especially when it is used to deal with a 
large dataset. To avoid overfitting, different approaches have been applied including 
computation-intensive pruning methods based on cross-validation or ensemble learning methods 
such as random forests (RF). Developed by Leo Breiman
163
, RF has been demonstrated as one of 
the most powerful tools for data exploration, delivering improved prediction accuracy while 
retaining the appealing properties of decision tree methods.
164
 The RF algorithm used in the 
present study is available in the Matlab implementation.
165
 
The random forests are a collection of CART-like trees, which are grown from bootstrap 
samples of the original training data. A total number of ntree trees are grown following the CART 
algorithm until the maximum size of each tree is reached, and the trees are not pruned back. The 
prediction of the new data is made based on the aggregated outputs of the ensemble trees. For 
classification problems it is the class with the majority of votes and for regression problems it is 
the value of the average prediction.  
 In the process of training, each CART-like tree is grown using a bootstrap sample of n 
molecules drawn from the training data with replacement. Since bootstrapping is random 
sampling with replacement, some of the molecules from the training data will appear multiple 
times in the bootstrap sample, while some others will be left out of the sample. The ‗left out‘ 
molecules account for one-third of the training set molecules on average and they constitute the 
out-of-bag (OOB) sample. The OOB molecules which have not been used in tree construction 
will be used as the internal test set (validation set) to estimate the prediction performance. This 
internal OOB error estimate has been proven to be unbiased and in good agreement with k-fold 
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cross-validation.
164
 So there is no need to perform additional cross-validation which would be 
computationally intensive, to get an unbiased estimate of the RF performance. 
Three tuning parameters can be optimized by users to boost the performance of RF 
models: the number of trees (ntree), the minimum node size and the number of randomly selected 
subsets of descriptors used for splitting at each node (mtry). ntree should be sufficiently large so 
that the OOB error estimate can be stabilized, and the default value of 500 is usually large 
enough. The minimum node size determines the minimum size of nodes below which no split 
will be applied, and it controls the maximum size possibly reached for each tree. The default 
value for classification is 1 and the default value for regression is 5. mtry ranges from 1 to M, the 
total number of features available, and it serves as a trade-off between the impacts of two factors: 
the correlation between any pair of trees in the forest and the strength of each individual tree in 
the forest. The default value of mtry for classification is    and the default value for regression is 
   . It has been found that the performance of RF models is insensitive to changes in the three 
tuning parameters, and the default values are good enough in most cases.
164
 So the default values 
for the classification and regression model tuning parameters were used in the present study.  
The RF algorithm can handle thousands of features via an embedded feature selection 
algorithm built into the process of model construction. The approach can serve to evaluate how 
much a single feature contributes to the prediction accuracy based on how many times the same 
feature is used in the ensemble of trees. With the intrinsic feature selection algorithm, RF is 
generally insensitive to the presence of redundant or irrelevant descriptors, and there is no need 
to perform extra feature selection algorithms such as those which should be implemented in 
SVM models. As an illustration, the commonly used feature reduction method recursive 
backward elimination (RBE) was used and the results were compared with the original model. 
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The method, introduced by Svetnik et al.,
164
 is based on the ranking of feature importance 
calculated by the RF algorithm itself during model construction. In each step of reduction, the 
least important half of the features is removed. The 100 replications of 5-fold cross-validation on 
the training set were calculated to access classification accuracies or regression    
 , and the best 
median values indicate the optimal number of features. 
4.2.8. MIXED LIGAND/STRUCTURE-BASED VIRTUAL SCREENING 
The commonly used QSAR-based virtual screening approaches usually employ QSAR 
models based on a single group of data, which limits the exploration of ligand-based structural 
information. With the employment of the hierarchical QSAR model described above, we can 
fully exploit the usefulness of the structural information of many groups of small molecules 
obtained through extensive literature search. The hierarchical QSAR model was built in a 
bottom-up way, from the lower level to the upper level, and it is employed in the virtual 
screening study in a top-down way. The compounds from the chemical database first undergo 
multi-class classification at the upper level. Once a compound is classified into a certain 
subclass, its bioactivity is predicted using one of the regression models at the lower level. The 
multi-level structure of the hierarchical QSAR model guarantees that the molecular bioactivities 
are predicted using the most reliable model.  
In order to obtain reliable predictions, a QSAR model should be used within its 
applicability domain,
166
 which defines the acceptable interpolation regions in the multivariate 
space. The interpolation estimates the values within the endpoints. In one dimensional space, an 
interpolation region is simply the interval between the minimum and maximum values. In 
multivariate space, an interpolation region is defined by a convex hull which is the smallest 
convex area containing all the training data points. The simplest method to estimate a convex 
 95 
 
hull, which is also used in the present study, is taking the ranges of the individual feature values. 
The ranges define a multi-dimensional hyper-rectangle encompassing the convex hull.
166
 The 
compounds with feature values outside the extremes of the training set are considered as outliers 
which are out of the applicability domain, and the prediction of activities of the outliers are 
considered unreliable. 
Ensemble docking has been extensively investigated and employed in the virtual 
screening study effectively.
145
 Herein, we employed the ensemble docking approach to further 
examine the predicted binding affinities of the hit compounds obtained from the hierarchical 
QSAR screening. The protocol and procedure of selecting and preparing the protein X-ray 
crystal structures for ensemble docking have been discussed in detail before.  In the present 
work, 18 protein structures were selected, including 1Q3D, 1Q3W, 1Q41, 1Q4L, 1Q5K, 1R0E, 
1UV5, 2O5K, 2OW3, 2JID, 3DU8, 3F7Z, 3F88, 3GB2, 3I4B, 3L1S, 3M1S, and 3PUP. The 
ensemble docking was performed using the Glide XP
119
 scoring function implemented in the 
Schrödinger Suite 2010.  
The final virtual screening protocol is illustrated in Figure 4.2. The screening chemical 
database is the KINASet collection of more than 12,000 drug-like small molecules, rationally 
selected from ChemBridge‘s EXPRESS-PickTM collection via desirable chemical group filtering 
and 3D pharmacophore query. The compounds in the chemical database underwent the same 
process of structural minimization and partial charge calculation. The hit compounds with high 
predicted pIC50 values and reasonable docking scores were selected and subjected to the GSK-3β 
inhibition bioassays as described before.
145
 The same reference compound, indirubin-3‘-
monoxime with reported IC50 value as 190 nM, was employed to verify the reliability of the 
bioassay protocol. 
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Figure 4.2. The flowchart for high throughput virtual screening performed on the KINASet 
collection of more than 12,000 drug-like molecules. 
 
4.3. RESULTS AND DISCUSSIONS 
4.3.1. REGRESSION MODELS 
The statistical results for all the regression models are summarized in Table 4.5. In order 
to systematically investigate the two cutting-edge machine learning algorithms (SVM and RF) in 
combination with feature selection, four models were built upon each group of compounds and 
the prediction abilities were validated both internally, using LOO and 5-fold cross-validation, 
and externally using an independent test set. The PSA-SVM model employed the SVM 
algorithm combined with the PS algorithm as feature selection; the RBE-RF model employed the 
RF algorithm with the RBE feature selection to remove the less important features.  In general, 
the SVM models without any feature selection were over-fitted to the training data and the over-
fitting problems are demonstrated by their low predictive ability (Table 4.5). For the worst case 
scenario, although the training R
2
 of the SVM models built upon the Group I and Group III data 
sets is ~0.9, the predictive R
2
 for both cross-validation and independent test sets are < 0.1. 
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However, by implementing feature selection the predictive power of the PSA-SVM models was 
significantly boosted. The majority of the models with the highest predictive R
2
 for both cross-
validation and independent test sets were produced using the PSA-SVM method. In contrast to 
SVM, RF is typically insensitive to the impact of redundant and irrelevant descriptors. This is 
supported by the high predictive R
2
 for the independent test sets, most of which are comparable 
to the ones obtained by the PSA-SVM method. Despite the good performance in external 
validation, the internal validations using cross-validation yielded relatively low predictions 
accuracies. The majority of the models built by RF without feature selection have cross-validated 
R
2 
< 0.5. The RBE feature selection can significantly boost the performance on internal 
validation while still retaining good predictive ability in external validation. In order to 
determine how many important descriptors are necessary for the RF models, the internal 
validation using 100 replications of 5-fold cross-validation was performed and the best median 
value was used to indicate the optimal size of the feature subset (Figure 4.3). 
  
  
 
9
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Table 4.5. The statistical results for the QSAR regression models. 
Models
a 
Training Set Cross Validation Test Set 
      
                       
             
              
                 
Group I 
PSA-SVM 0.997 0.006 29639 0.657 0.592 0.601 0.693 0.585 0.424 85.2 
SVM 0.991 0.046 4849.6 0.093 1.802 0.059 1.793 0.026 0.990 6.5 
RBE-RF 0.947 0.132 1516.3 0.533 0.810 0.526 0.828 0.734 0.248 111.8 
RF 0.948 0.143 1325.5 0.464 0.928 0.427 0.992 0.748 0.249 101.7 
Group II 
PSA-SVM 0.988 0.010 8685.1 0.798 0.150 0.768 0.172 0.828 0.144 149.5 
SVM 0.991 0.013 5753.6 0.259 0.556 0.242 0.571 0.468 0.324 10.9 
RBE-RF 0.945 0.064 923.6 0.471 0.392 0.499 0.374 0.768 0.145 53.3 
RF 0.950 0.063 915.7 0.429 0.424 0.411 0.437 0.784 0.137 56.8 
Group III 
PSA-SVM 0.998 0.004 31892 0.713 0.486 0.623 0.628 0.611 0.488 14.0 
SVM 0.989 0.067 1192.2 0.099 1.671 0.047 1.673 0.011 1.311 2.1 
RBE-RF 0.926 0.181 391.0 0.384 1.005 0.396 0.991 0.105 1.211 6.4 
RF 0.953 0.179 349.1 0.260 1.209 0.231 1.256 0.224 1.004 6.4 
Group IV 
PSA-SVM 0.921 0.092 738.2 0.613 0.465 0.551 0.558 0.641 0.521 46.5 
SVM 0.999 0.002 31060 0.253 0.876 0.215 0.919 0.513 0.722 4.9 
RBE-RF 0.952 0.109 400.8 0.499 0.614 0.433 0.685 0.680 0.447 11.8 
RF 0.964 0.136 268.7 0.258 0.883 0.210 0.932 0.763 0.415 11.2 
Group V 
  
 
9
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PSA-SVM 0.986 0.017 2749.9 0.869 0.142 0.851 0.164 0.771 0.168 43.4 
SVM 1.000 0.001 81620 0.231 0.833 0.214 0.853 0.821 0.104 27.3 
RBE-RF 0.954 0.061 624.5 0.654 0.371 0.660 0.366 0.719 0.157 36.8 
RF 0.949 0.074 479.8 0.568 0.467 0.550 0.490 0.750 0.129 38.1 
Group VI 
PSA-SVM 0.991 0.006 4631.7 0.689 0.205 0.594 0.276 0.846 0.081 64.7 
SVM 0.997 0.005 5294.5 0.198 0.545 0.148 0.569 0.586 0.268 1.8 
RBE-RF 0.846 0.112 173.7 0.406 0.401 0.561 0.290 0.679 0.180 22.4 
RF 0.945 0.057 343.3 0.413 0.387 0.399 0.397 0.676 0.148 17.4 
Group VII 
PSA-SVM 0.998 0.004 18282.0 0.838 0.323 0.836 0.328 0.681 0.513 24.9 
SVM 1.000 0.000 295840.0 0.416 1.179 0.379 1.244 0.546 0.839 2.0 
RBE-RF 0.931 0.148 402.2 0.674 0.604 0.679 0.595 0.198 1.174 5.4 
RF 0.959 0.128 418.4 0.541 0.866 0.521 0.917 0.614 0.588 7.9 
a
 The selected models are highlighted by bold. 
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Figure 4.3. The number of features selected by RBE-RF and the internal validation    
  (the 
median value from 100 replications of 5-fold cross-validation on the training set) for the various 
groups of compounds. The optimal number of features can be determined from the maximum 
   
 . 
The lack of correlation between the internal validation and external validation has been 
established earlier,
149
 and also has been demonstrated in the present study. Evidence showing 
this lack of correlation for the RF algorithm is found for the majority of the models. In the 
context of the PSA-SVM models, the model for Group VI has the best performance on external 
validation (R
2
test=0.846, RMSEtest=0.081, Ftest=64.7), but relatively poor performance on internal 
validation (R
2
LOO=0.689, RMSELOO=0.205, R
2
CV=0.594, RMSECV=0.276). However, the model 
for Group VII has the highest performance on internal validation (R
2
LOO=0.838, 
RMSELOO=0.323, R
2
CV=0.836, RMSECV=0.328), but relatively low prediction for external 
validation (R
2
test=0.681, RMSEtest=0.513, Ftest=24.9). Nevertheless, the low correlation is not 
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always found. By using the PSA-SVM method, the models for Group II and Group V performed 
consistently well on both internal and external validation, and the models for Group III and 
Group IV have consistently moderate predictions. Consequently, in order to make a reliable 
prediction, a set of criteria for both internal and external validation was formulated in the present 
study for model selection, namely: LOO cross-validated R
2 
> 0.5, median value for 100 
replications of 5-fold cross-validated R
2 
> 0.5, and predictive R
2  
> 0.6 for the independent test 
set. 
Based on the criteria, we selected the best predictive regression models for each group of 
compounds. For the Group I data set, the best predictive model is RBE-RF characterized by 
R
2
LOO=0.533, RMSELOO=0.810, R
2
CV=0.526, RMSECV=0.828, R
2
test=0.734, RMSEtest=0.248, and 
Ftest=111.8. This is the only group of compounds for which the RBE-RF method was able to 
produce a reliable prediction. The PSA-SVM method which was employed for the rest of the 
groups of compounds during the model selection cannot be used for the Group I data set, since 
the predictive R
2
 for the independent test set is < 0.6 even though the cross-validated R
2
 is > 0.6. 
This suggests that the RBE-RF algorithm compared to the PSA-SVM algorithm is less likely to 
be over-fitted, especially when it is used to deal with very large data sets consisting of 
structurally diverse compounds. The over-fitting problem of the PSA-SVM algorithm in certain 
cases may be attributed to the fact that the prediction performance of the selected feature subset 
is evaluated by interval validation using 5-fold cross-validation, which is a necessary but 
insufficient estimation of the predictive power. However, this over-fitting problem was only 
observed in certain cases. In general, the PSA-SVM method performed fairly well compared to 
other methods investigated in the present work, and indeed, it produced the best predictive 
models for the other group of compounds. 
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The best predictive models for Group II and Group V have high prediction performances: 
R
2
LOO=0.798, RMSELOO=0.150, R
2
CV=0.768, RMSECV=0.172, R
2
test=0.828, RMSEtest=0.144, and 
Ftest=149.5 for Group II, R
2
LOO=0.869, RMSELOO=0.142, R
2
CV=0.851, RMSECV=0.164, 
R
2
test=0.771, RMSEtest=0.168, and Ftest=43.4 for Group V. However, the best predictive models 
for Group III and Group IV have moderate prediction performances: R
2
LOO=0.713, 
RMSELOO=0.486, R
2
CV=0.623, RMSECV=0.628, R
2
test=0.611, RMSEtest=0.488, and Ftest=14.0 for 
Group III, R
2
LOO=0.613, RMSELOO=0.465, R
2
CV=0.551, RMSECV=0.558, R
2
test=0.641, 
RMSEtest=0.521, and Ftest=46.5 for Group IV. The moderate predictive power for the latter two 
groups of compounds may be caused by the Groups‘ intrinsic structural dissimilarity, which 
would translate into the lack of similar structural representations in the training set. It implies 
that the compounds in the training set cannot consistently reflect the influence of the structural 
modifications on the changes of the bioactivities. 
The final PSA-SVM models were refined by optimizing the tuning parameters. The 
optimal tuning parameters and the number of selected features are tabulated in Table 4.6. The 
final RBE-RF models were established based on the default tuning parameters, and the optimal 
number of features were determined as described above. The best predictive regression models 
were employed at the lower level of hierarchical QSAR model. The selected features and their 
descriptions for the RBE-RF model for Group I and optimized PSA-SVM models for Group II 
through VII are provided in the supporting information (Appendix: J−N). In addition to the 
internal and external validation, the Y-randomization test described above was carried out to 
ensure that the best predictive regression models did not merely capture noise. As expected, all 
the models built based on the randomized bioactivities yielded fairly low predictive R
2
 which 
was always < 0.1 for both LOO cross-validation and the independent test set (Table 4.7). These 
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results further confirmed the robustness and reliability of the selected regression models which 
uncovered legitimate correlations between the molecular descriptors and the biological activities. 
The strong correlations can be used to predict the bioactivities of structurally novel compounds 
as GSK-3 inhibitors. 
Table 4.6. The number of selected features and the optimal tuning parameters for PSA-SVM and 
SVM models. 
Group Model No. of feat. C γ ε 
multi-class classification model 
Whole Group 
PSA-SVM 10 40 0.060 – 
SVM 1357 42 0.010 – 
regression models 
Group I 
PSA-SVM 25 60 0.054 0.08 
SVM 1284 52 0.020 0.224 
Group II 
PSA-SVM 20 50 0.036 0.102 
SVM 1299 48 0.004 0.124 
Group III 
PSA-SVM 18 56 0.068 0.060 
SVM 1149 56 0.132 0.268 
Group IV 
PSA-SVM 20 20 0.038 0.018 
SVM 1218 40 0.004 0.048 
Group V 
PSA-SVM 9 48 0.100 0.112 
SVM 1108 20 0.004 0.024 
Group VI 
PSA-SVM 12 48 0.064 0.080 
SVM 1179 32 0.004 0.072 
Group VII 
PSA-SVM 11 40 0.064 0.060 
SVM 1161 32 0.004 0.016 
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Table 4.7. The statistical results for Y-randomization test. 
Group     
 a        
a      
 a         
a 
Group I
b 
0.009 
(0.014) 
2.423 
(0.247) 
0.021 
(0.032) 
1.253 
(0.148) 
Group II
c 
0.011 
(0.015) 
1.420 
(0.195) 
0.038 
(0.049) 
1.307 
(0.338) 
Group III
c 
0.024 
(0.029) 
2.923 
(0.565) 
0.063 
(0.082) 
2.960 
(1.127) 
Group IV
c 
0.034 
(0.043) 
1.916 
(0.371) 
0.057 
(0.083) 
2.084 
(0.534) 
Group V
c 
0.036 
(0.043) 
2.157 
(0.571) 
0.055 
(0.065) 
1.709 
(0.645) 
Group VI
c 
0.033 
(0.046) 
1.357 
(0.360) 
0.092 
(0.112) 
1.218 
(0.479) 
Group VII
c 
0.050 
(0.071) 
3.457 
(0.976) 
0.088 
(0.115) 
3.578 
(1.266) 
a
 The number represents the mean values of 100 replications. The number in the parentheses 
represents the standard deviation of 100 replications. 
b
 Model III based on RBE-RF method. 
c
 
Model I based on PSA-SVM method. 
 
4.3.2. MULTI-CLASS CLASSIFICATION MODELS 
The statistical results for all the multi-class classification models are summarized in 
Table 4.8. Three out of four models yielded predictive accuracies >0.9 for both internal and 
external validations. The high prediction of a multi-class classification model is derived from the 
fact that the chemical structures of a given group of molecules are unique and differ from those 
of other groups of molecules, and such structural diversity can be well described by the DragonX 
descriptors. RBE-RF model, which produced perfect prediction for both training and test set of 
compounds, was employed at the upper level of the hierarchical QSAR model. 42 selected 
features based on RBE approach and their descriptions are summarized in Appendix: P.  
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Table 4.8. The statistical results for the QSAR classification models. 
Model 
Accuracy on 
training set 
Cross-validation accuracy on 
training set Accuracy on test 
set 
LOO 5-fold 
PSA-SVM 0.997 0.995 0.992 0.986 
SVM 1.000 0.607 0.570 0.587 
RBE-RF 1.000 0.988 0.992 1.000 
RF 1.000 0.988 0.983 0.993 
 
4.3.3. HIERARCHICAL QSAR AND VIRTUAL SCREENING 
To evaluate the predicative performance of hierarchical QSAR model on the collection of 
728 GSK-3β inhibitors, a predictive model with multi-level structure was employed in a top-
down way. The same division of training and test set was made, which lead to the training set 
with 587 compounds and test set with 141 compounds. Since the selected multi-class 
classification model (RBE-RF model) at the upper level yielded perfect prediction for all of the 
compounds in both training and test set, the predicted pIC50 values can be obtained from the best 
predictive regression models selected for each group of compounds at the lower level (Figure 
4.4). The high predictive ability is indicated by the following statistical results: R
2
train=0.967, 
RMSEtrain=0.054, Ftrain=13630, R
2
test=0.752, RMSEtest=0.265, and Ftest=537.9. 
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Figure 4.4. Correlation of observed versus predicted pIC50 values based on hierarchical QSAR 
model for the whole collection of 728 compounds. Circles represent the compounds in the 
training set and triangles represent the compounds in the test set. 
To examine the predictive ability of the hierarchical QSAR in the mixed ligand/structure-
based virtual screening protocol from the experimental perspective, 5 compounds with high 
predicted pIC50 values (> 8.0) and acceptable docking scores were purchased from ChemBridge 
Corp., and the GSK-3β inhibitory activities of these compounds were tested according to the 
experiments described before. Their chemical structures and biological activities are listed in 
Table 4.9. Two compounds consisting of the same 1,2,4-triazole-3-thiol scaffold exhibit 
inhibition >50% at 10 μM concentration and low micromolar IC50 values. The new scaffold, 
which has not been identified before, can be employed to facilitate the discovery of structurally 
novel GSK-3β inhibitors. 
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Table 4.9. Biological activities of the hit compounds. 
ID Chemical structure QSAR 
Docking 
Score 
%inhibition 
(10 μM) 
Ki 
(μM) 
IC50 
(μM) 
Ref. 
 
  97% 0.07 0.13 
1 
 
8.526 
(Group VI) 
−9.788 
(3I4B) 
10%   
2 
 
8.647 
(Group II) 
−9.445 
(3DU8) 
73% 3.53 7.05 
3 
 
8.475 
(Group II) 
−9.090 
(3F88) 
64% 2.69 5.38 
4 
 
8.610 
(Group II) 
−8.911 
(3M1S) 
23%   
5 
 
8.854 
(Group V) 
−8.203 
(2JLD) 
22%   
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We also purchased and tested the inhibitory activities of 9 potential hit compounds with 
moderate predicted bioactivities (predicted pIC50 from 6 to 8). However, they are typically false 
positive hits with inhibitory percentage < 50% at 10 μM (Table 4.10), and we did not bioassay 
them for the exact IC50 values. The low prediction for those false positive hits can be attributed 
to the 3D conformations of those compounds, which did not undergo conformational search for 
global minimum and may be fairly different from the possible binding conformation. The 3D 
conformation may have impact on the QSAR predictions since a few 3D descriptors employed in 
the models are conformational dependent.  
Table 4.10. Biological activities of the false positive hits. 
ID Chemical structure QSAR Docking Score %inhibition (10 μM) 
1 
 
6.976 
(Group I) 
-10.068 
(3PUP) 
12% 
2 
 
6.899 
(Group I) 
-10.025 
(3L1S) 
39% 
3 
 
7.549 
(Group 
III) 
-9.996 
(1Q5K) 
32% 
4 
 
7.118 
(Group 
III) 
-9.454 
(3L1S) 
11% 
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5 
 
7.336 
(Group V) 
-9.436 
(1Q5K) 
8% 
6 
 
6.939 
(Group II) 
-9.370 
(3L1S) 
16% 
7 
 
7.849 
(Group 
VI) 
-8.808 
(3F88) 
6% 
8 
 
7.744 
(Group 
VI) 
-8.431 
(1R0E) 
14% 
9 
 
7.262 
(Group V) 
-8.248 
(1Q5K) 
29% 
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4.4. CONCLUSIONS 
In order to identify novel GSK-3 inhibitors, we successfully implemented a mixed 
ligand/structure-based virtual screening protocol. In terms of the ligand-based approach, we 
constructed a hierarchical QSAR model which adopts a multi-level structure applied to integrate 
and analyze complex data sets from multiple experimental sources. In terms of the structure-
based approach, we employed ensemble docking as an effective approach to evaluate the 
predicted binding affinities. The hit compounds obtained from virtual screening underwent 
experimental validation. The bioassay results showed that 2 out of 5 hit compounds are indeed 
GSK-3β inhibitors, exhibiting low micromolar activities. To build highly predicative 
classification and regression models in the multi-level structure, four different methods involving 
SVM and RF with or without feature selection were explored. The best regression models for the 
lower level were selected based on both internal and external validations, and the best 
classification model at the upper level yielded perfect prediction for the compounds in both 
training and set. The significance of feature selection in building predictive learning models was 
investigated, and there is no guarantee that a single approach can generate the best prediction for 
all the data set. Hence, systematic studies on different approaches are required to produce the 
best prediction for a particular data set. Based on the overall predictive performance and the 
successful virtual screening study, we can conclude that the proposed hierarchical QSAR model 
which makes predictions based on the most reliable models constructed using structurally similar 
compounds can be employed as an effective approach in virtual screening experiments. 
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5.1. INTRODUCTION 
In the context of molecular modeling and drug discovery research, it is imperative to 
specify which conformations of a given molecule are responsible for the observed biological 
activity. Due to structural flexibility, a molecule may adopt a wide range of conformers and the 
identification of the bioactive conformers is extremely important in order to understand the 
recognition mechanism between small molecules and proteins, which is crucial in drug discovery 
and development. Until now, the most reliable approach to obtain the bioactive conformer is to 
use the X-ray crystal structure of a ligand-protein complex; however, the number of such 
structures is limited because of the experimental difficulty in obtaining the crystals, especially 
for transmembrane proteins. We were interested to apply to this problem a machine-learning 
approach which does not require crystal structures, named multiple-instance learning (MIL) via 
embedded instance selection (MILES). MILES has been demonstrated as an efficient and 
accurate approach to solve different multiple-instance problems.
167
 In the context of drug activity 
prediction, MILES enables the construction of a quantitative structure-activity relationship 
(QSAR) model, and subsequently the identification of bioactive conformers. 
In the context of drug activity prediction, the observed biological activity is associated 
with a single molecule (bag) without knowing which conformer or conformers (instances) are 
responsible. Furthermore, a molecule is biologically active if and only if at least one of its 
conformers is responsible for the observed bioactivity; and the molecule is inactive if none of its 
conformers is responsible (Figure 5.1). A difficulty in implementation arises from the fact that 
different molecules have a different number of conformers, since some molecules having 
multiple rotatable bonds are highly flexible and others with rigid structures only have a small 
numbers of conformers. 
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Figure 5.1. Cartoon representation of the relationship between molecules and conformers. Mi, 
i=1, 2, 3, 4 represent the molecules (bags), circled by dashed lines. The solid triangles in M1, 
circles in M2, squares in M3, and stars in M4 represent conformers for different molecules. 
Molecules 2, 3, and 4 were biologically active since they had at least one bioactive conformer, 
whereas molecule 1 was inactive since none of its conformers was bioactive. The distance 
between two molecules, M1 and M3, was calculated by the minimum distance D(M1, M3). 
 
The overall strategy for structural and data mining using MILES (Figure 5.2) is 
summarized here. First of all, a complete sampling of conformational space provides a large 
number of conformers for each molecule. The molecules are themselves each already labelled as 
either positive or negative. However, the labels for the conformers are unavailable during the 
model generation. Each conformer is denoted by a unique pharmacophore fingerprint which is a 
superior feature-based 3D descriptor unveiling structural similarity and diversity.
168-171
 The 
pharmacophore fingerprint is encoded into a binary string which indicates the presence or 
absence of a match to individual pharmacophore models. Since the exhaustively enumerated 
fingerprints have millions of bits, which may be beyond computational limits, a significance 
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analysis of pharmacophore models
172
 is employed to determine the optimal subset of bits of the 
fingerprint. Subsequently, MILES converts the MIL to a standard supervised learning problem 
by embedding bags (molecules) into an instance-based (conformer-based) feature space via 
structural dissimilarity measures.
173
 Finally, 1-norm SVM is applied to select the most important 
features, identifying the highly significant conformers which help the most to distinguish active 
and inactive molecules, and, simultaneously, to construct a predictive classification model.  
 
 
Figure 5.2. Overview of the MILES approach: (1) Structure preprocessing and conformational 
sampling. (2) Creating pharmacophore fingerprints and significance analysis of pharmacophore 
models. (3) Instance-based feature mapping based on structural similarity measures. (4) Joint 
feature selection and classification using 1-norm SVM. 
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In the present work, MILES has been applied to study the biological activities of two sets 
of molecules: GSK-3 inhibition data set and GSK-3/CDK1 selective inhibition data set. The first 
data set was explored to identify conformers significant for potent GSK-3 binding affinity; and 
the second data set was explored to investigate the conformers contributing to GSK-3/CDK1 
binding selectivity. Based on our calculations, MILES is highly competitive with the classical 
QSAR approaches which do not include instance-based feature mapping in terms of predictive 
abilities.  Meanwhile, MILES has been validated as a useful approach to identify the bioactive 
conformers, which contribute to the classification of active and inactive molecules. 
5.2. METHODS 
5.2.1. DATA SET PREPARATION 
Two data sets were compiled through extensive literature search. Data set I included all 
molecules exhibiting inhibitory activities for GSK-3. Data set II included the compounds with 
reported inhibitory activities for both GSK-3 and CDK1. The datasets are publicly available 
(http://pars.cs.olemiss.edu/GangFu/MILES-project). The molecules collected for each data set 
were labelled as either positive or negative. A positive molecule either has a high binding affinity 
with GSK-3 in data set I, or has selective binding preference toward GSK-3 rather than CDK1 in 
data set II; whereas a negative molecule either has a low binding affinity with GSK-3, or does 
not exhibit selectivity toward GSK-3 over CDK1. A single cutoff value has been widely used in 
the development of classification models. However, it is inaccurate to use a single cutoff value 
for the separation of continuous biological activities in the context of drug activity prediction. 
The biological activities are represented by continuous numbers, and the small differences 
between the values above and below the cutoff value cannot imply the distinct nature of binding 
affinity. Furthermore, the small difference in the bioassay results may arise from systematic 
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errors introduced by different experimental protocols used in different labs, so it cannot be used 
as solid evidence for the classification of molecules. Therefore, multiple cutoff values were 
employed to separate molecules into positive and negative classes. For data set I, the molecules 
were categorized into positive and negative molecules using cutoff values of IC50 ≤ 50 nM and 
IC50 ≥ 500 nM, respectively. The molecules having inhibitory activities between the two cutoff 
values were considered as moderately active molecules, and were discarded from the data set. 
The wide margin between the two cutoff values was used to account for the variances in 
biological assays. This resulted in the selection of 260 positive and 258 negative compounds. For 
data set II, the molecules were considered as selective (positive) for GSK-3 over CDK1 if the 
inhibitory activity for GSK-3 is 10 times more than that for CDK1 and the molecules were 
considered as nonselective (negative) if the inhibitory activity for GSK-3 is less than that for 
CDK1. The cutoff values yielded 97 selective and 134 nonselective compounds. 
External validation was achieved using an independent test set. The split of the data set 
into training and test sets was carried out using Kohonen self-organizing maps (SOM) in Canvas 
1.4.
174
 The SOM is trained using unsupervised learning to produce a square 2D grid map from 
the high dimensional input space. Each grid cell (neuron) contains a cluster of structurally 
similar molecules defined by the input vectors. The SOM takes advantage of clustering 
capabilities so that the selected training set can represent the independent test set in terms of the 
input space and chemical domains. Molecular pharmacophore fingerprints were used to describe 
the relevant structural information of the molecules and were used as input variables to build the 
SOM. The grid size of the map depends on the number of molecules in the data set. For data sets 
I, the Kohonen maps built included 10 10 neurons and 500 epochs. For the data set II, a 
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Kohonen map consisting of 8 8 neurons and 500 epochs was built. The molecules were then 
stratified and sampled from each neuron to select the training and test set molecules. 
5.2.2. PREPROCESSING AND CONFORMATIONAL SAMPLING  
The molecules (bags) can be represented by Mi, i=1,···,l where l is the total number of 
molecules. The 3D molecular structures were generated using the Ligprep module from 
Schrödinger Suite 2011, and then subjected to preprocessing to enumerate all the possible 
tautomers. The protonation states of ionizable groups were set to match pH = 7.4, and the 
stereochemistry was retained from the original 3D structures. In order to explore the 
conformational space exhaustively, the mixed torsional/low mode sampling method was 
employed, using MacroModel from Schrödinger Suite 2011. The torsional sampling involves 
multiple Monte Carlo minimum searches for global exploration, and the low mode 
conformational search allows for automatic local exploration. The torsional increment for each 
rotatable bond was set to 15° and the maximum number of total steps for torsional sampling was 
1,000. The energy window for saving structures was set to 83.7 kJ/mol (20 kcal/mol). The small 
torsional increment and wide energy window were employed to provide a reasonable coverage of 
the conformational space. Each enumerated conformer was energy minimized using the Powell-
Reeves conjugate gradient method with default setup. To remove redundant conformations, the 
maximum atom deviation cutoff was set to 1.5 Å. So each molecule Mi has several possible 
conformers Cij, j=1,···,ni, where ni is the number of conformers (instances) for molecule i.  
In order to validate that MILES can identify the bioactive conformers, we seeded 12 co-
crystallized conformers, one for each of 12 molecules, in the set of sampled conformers for data 
set I. The validation process will be described in the following sections. 
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5.2.3. GENERATION OF PHARMACOPHORE FINGERPRINTS 
The pharmacophore fingerprint as a measure of molecular similarity and diversity based 
on 3D pharmacophoric shape was enumerated using Canvas 1.4. Each pharmacophore 
fingerprint associated with a unique conformer can be represented by a binary string, such as Pij 
= {p1,···,pk, ···,pm} and encodes quantitative structural information for conformer Cij, where 
each bit value pk, k=1,···,m indicates the presence or absence of a single pharmacophore model, 
representing a unique 3D arrangement of a number of pharmacophore features. If the conformer 
fits the pharmacophore model for a particular k, in other words the functional groups of the 
conformer fully overlap on all the pharmacophore features in the model, pk equals 1; otherwise, 
pk equals 0. As a result, each conformer is associated with a unique pharmacophore fingerprint as 
a conformational signature, which enables us to describe quantitatively the 3D structural 
information. In the present study, only four-feature based models were employed in order to 
allow a reasonable description of 3D orientation of the structures and retain information about 
molecular chirality, which is lost in three-feature based models. The pharmacophore features 
employed in the models consist of hydrogen bond donor (D), hydrogen bond acceptor (A), 
hydrophobic group (H), negatively charged group (N), positively charged group (P), and 
aromatic ring (A). The maximum distance between pharmacophore features was set to 20.0 Å in 
order to be able to cover the largest molecular structures in the databases. The originally 
enumerated fingerprints were subject to filtering to remove the pharmacophore models present in 
less than 5% of the total number of molecules, since the pharmacophore models with a very low 
occurrence are not useful for discriminating between positive and negative classes. 
 119 
 
5.2.4. SIGNIFICANCE ANALYSIS OF PHARMACOPHORE MODELS 
The post-filtered pharmacophore fingerprints still have too many bits that lack 
information content, as indicated by too many ‗0‘ values. Therefore a nonparametric supervised 
learning approach, motivated by the significance analysis of microarrays (SAM) algorithm 
proposed by Tibshirani et al.,
175
 was applied to elucidate a consistent pattern from the numerous 
bits of pharmacophore fingerprints. The detailed implementation and customization of the 
relevant procedures has been described in.
172
 The ranking score for each pharmacophore model 
was computed based on the occurrences of that model in each class, either positive or negative. 
That ranking score was then compared with a reference score computed from 500 random 
permutations of the class labels across all the molecules. If the difference between the true score 
and the reference score exceeds a cutoff threshold (called Δ) then that conveys statistical 
significance. The two-class t-statistic was used to estimate the percentile of truly significant 
pharmacophore models. 
5.2.5. INSTANCE-BASED FEATURE MAPPING 
MILES provides a framework to convert a MIL problem to a standard supervised 
learning problem via instance-based feature mapping. All the conformers (instances) belong to 
the instance-based feature space. For convenience, all conformers in all molecules were lined up 
together, and were re-indexed in the embedded feature space as C
r
, r=1,···,n where      
 
   . 
Instance-based feature mapping can be accomplished using calculated structural dissimilarities. 
Different binary string distance measures were tested, including the Soergel distance, Dice 
distance, Manhattan distance, and Rogers-Tanimoto distance (Table 5.1). The range of each 
dissimilarity measure was normalized to be [0, 1] by definition. Since one molecule is defined as 
a bag of multiple conformers (instances), the dissimilarity measure for a molecule is calculated 
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based on the minimum distance using the closest instance in the bag. The minimum distance 
calculation (Figure 5.1) extends the idea of the diverse density framework proposed for instance-
based learning.
176
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Table 5.1. Metrics used for dissimilarity measurements 
Dissimilarity Measure Definition
a 
Soergel 
   
     
 
Dice 
   
      
 
Manhattan 
   
       
 
Rogers-Tanimoto 
       
           
 
a 
Let P1 and P2 be two pharmacophore fingerprints, a be the count of bits which are set to 1 in 
both P1 and P2, b be the count of bits which are set to 1 in P1 but not in P2, c be the count of bits 
which are set to 1 in P2 but not in P1, and d be the count of bits which are set to 0 in both P1 and 
P2. So a is called the number of total matches, b and c are called the number of single matches, 
and d is called the number of no matches. 
 
5.2.6. JOINT FEATURE SELECTION AND CLASSIFICATION 
Since the molecules in the training sets are highly flexible, instance-based embedding, 
which provides a framework to convert a MIL problem to a traditional supervised learning 
problem, may produce a very high dimensional feature space. But many features are redundant 
or irrelevant, and do not play an important role in the classification of molecules as positive or 
negative. So an efficient feature selection model is required for selection of an optimal subset of 
instance-based features. Considering its excellent performance in many applications,
177
 the 1-
norm SVM method was chosen as a joint approach to construct classifiers and to select important 
features simultaneously.  
The features selected as important for the classification problem of interest are called 
prototype conformers. The plus or minus sign of the feature coefficient indicates the positive or 
negative contribution, respectively, of each prototype conformer to the putative bioactive 
conformers for each individual molecule. 
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5.2.7. IDENTIFICATION OF BIOACTIVE CONFORMERS 
One appealing advantage of the MILES algorithm is that it can identify the most 
significant instances in a bag according to their contributions to the classification of that bag. In 
the context of drug activity prediction, we can identify the most significant conformers, called 
the bioactive conformers, for each molecule. The putative bioactive conformers are the 
conformers that contributed the most to the classification of positive and negative molecules. The 
identification of bioactive conformers can be accomplished by calculating the contribution of 
each conformer of a given molecule. The contribution can be calculated with the assistance of 
the prototype conformers. Typically, the contribution is the total sum of the weighted distance 
between each conformer of a given molecule and the closest prototype conformers. 
In order to validate the ability of MILES to identify the bioactive conformers, the 
contributions for the 12 seeded conformers, which were taken directly from co-crystallized 
complex structures, were calculated and ranked among all the conformers sampled for those 12 
molecules. The PDB codes of 12 co-crystallized structures were 1Q5K, 2O5K, 2OW3, 1Q3W, 
1UV5, 1Q41, 1R0E, 3F7Z, 3GB2, 3L1S, 1Q4L, and 1Q3D.  
5.2.8. CLASSICAL QSAR METHODS WITHOUT INSTANCE-BASED EMBEDDING 
In order to examine the predictive performance of MILES, conventional classification 
approaches based on classical QSAR principles were tested for comparison. Without instance-
based embedding, the feature space for classical QSAR studies is based on the optimal subsets of 
the fingerprints selected through significance analysis of the pharmacophore models. The 
decision tree was constructed using the ‗classregtree‘ function implemented in Matlab R2011b. 
Gini‘s diversity index was used for recursive partitioning, and the minimal number of molecules 
per tree leaf was set as 3 to terminate tree growing. The MILES model was built in the 
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pharmacophore-based feature space. The ensemble learning method, random forests, developed 
by Leo Breiman 
163
, has been demonstrated as one of the most powerful tools available for data 
exploration 
164
. The Matlab implementation (randomforest-matlab v0.02) was used with default 
parameters. 
5.3. RESULTS AND DISCUSSION 
5.3.1. DATA SET PREPARATION AND CONFORMATIONAL SAMPLING 
According to the criteria used to label positive and negative molecules, the number of 
molecules in each of two classes was balanced for four data sets. Data set I has 266 positive 
compounds including 199 in training set and 67 in test set, as well as 258 negative compounds 
including 188 in training set and 70 in test set; data set II has 97 positive compounds including 
76 in training set and 21 in test set, as well as 134 negative compounds including 100 in training 
set and 34 in test set. The stratified sampling divided data sets into training and test sets at ratios 
around 3:1.  
The total number of conformers generated for data set I was 22,648, and the total number 
of conformers generated for data set II was 12,961. The feature space constructed through 
instance-based embedding only consisted of the instances from training bags, in other words, the 
conformers from the molecules in the training set. The molecules in the test set were not used in 
the construction of the instance-based feature space. So the number of instance-based features 
used for embedding molecules in data set I was 17,249, and the number of instance-based 
features used for embedding molecules in data set II was 9,972.  
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5.3.2. SIGNIFICANCE ANALYSIS OF PHARMACOPHORE MODELS 
Millions of pharmacophore models were originally enumerated for each data set 
(1,872,521 for data set I and 1,378,584 for data set II). After occurrence-based filtering, only a 
small portion of the pharmacophore models was retained for each data set (243,721 for data set I 
and 253,192 for data set II).  
Significance analysis was subsequently performed upon those retained pharmacophore 
models. The number of statistically significant pharmacophore models was computed at the 90th 
percentile among 500 permutations using the classical t-statistic. The threshold values were set to 
100 equally spaced intervals from 0 to the largest difference between the ranking scores and 
reference scores. As the threshold value increases in a bottom-up manner, the number of falsely 
significant pharmacophore models decreases, and the number of truly significant models remains 
roughly constant. So the optimal threshold values (Δ*=1.77 for data set I and Δ*=2.17 for data set 
II) for each data set can be obtained when the number of falsely significant pharmacophore 
models drops to zero. Subsequently, the optimal subsets of the pharmacophore fingerprint bits 
were obtained (2,979 for data set I and 10,010 for data set II). 
In the context of MIL, the optimal subsets of the binary strings were used to calculate the 
dissimilarity between two conformers for instance-based feature mapping. For the classical 
QSAR methods, the optimal subsets of the fingerprints were used as the 3D descriptors in the 
pharmacophore-based feature space for building classification models.   
5.3.3. PREDICTIVE PERFORMANCE OF MILES AND CLASSICAL QSAR METHODS 
In the MILES model, the only tuning parameter λ was determined by a grid search. Five 
replications of 5-fold cross-validation were performed to assess the classification accuracies at 
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each point over a fixed grid which ranged from 2
-8
 to 2
5
 with exponential increment in base 2. 
The median values for the 5 replications were used to find the optimal tuning parameters. During 
the cross-validation, the instance-based feature space was dynamically defined, which means that 
the conformers from the molecules in the internal test set, after random split of the training set, 
were excluded from the feature space. As a result, the optimal tuning parameters as well as the 
number of prototype conformers were obtained for four dissimilarity measures (Table 5.2).  
Table 5.2. Optimization of tuning parameter λ and predictive performance for four different 
dissimilarity measures used in MILES 
Data 
set 
Dissimilarity 
measure 
Cross-
validation
a 
λ nb 
Training set Test set 
Accu MCC Accu MCC 
I 
Soergel 0.777 8.000 196 0.972 0.944 0.854 0.714 
Dice 0.761 4.400 165 0.979 0.959 0.825 0.653 
Manhattan
c 
0.803 4.400 130 0.941 0.881 0.861 0.725 
Rogers-Tanimoto 0.801 4.000 153 0.961 0.923 0.861 0.725 
II 
Soergel 0.700 0.001 95 0.949 0.902 0.909 0.818 
Dice 0.709 0.002 81 0.949 0.902 0.927 0.851 
Manhattan
 
0.810 0.016 40 0.943 0.892 0.855 0.699 
Rogers-Tanimoto
c
 0.830 0.350 29 0.892 0.805 0.891 0.786 
a
 The median classification accuracy for 5 replications of 5-fold cross-validation; 
b
 the number of 
prototype conformers; 
c 
The model selected based on the number of prototype conformers. 
Based on the internal validation, the classification accuracies were similar within each 
data set using four different dissimilarity measures. However, the numbers of prototype 
conformers selected were much different. The dissimilarity measure which yielded the smallest 
number of selected prototype conformers was chosen as the best MILES model and used later for 
comparison with classical QSAR models without instance-based embedding. 
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After finding the optimal λ, a MILES model was identified from the training set and 
applied to the test set. In addition to comparing classification accuracy, denoted as the proportion 
of correct predictions, Mathews Correlation Coefficient (MCC)
178
 was also employed a 
complementary indicator for the predictive performance. MCC not only takes into account true 
positives and true negatives as classification accuracy does, but also false positives and false 
negatives. Thus it is considered as a balanced measure of the performance of binary 
classification (Figure 5.2). In accordance to classification accuracy and MCC, the performance 
of different dissimilarity measures was dataset-specific. For data set I, both the Manhattan and 
Rogers-Tanimoto distances were top-ranked and performed equally well on the test set, whereas 
on the training set, the Rogers-Tanimoto distance performed slightly better than the Manhattan 
distance. In addition, the results did not change after removing the 12 seeded conformers which 
were used for the validation of identifying bioactive conformers. For data set II, the Rogers-
Tanimoto distance which selected the minimum number of prototype conformers did not yield 
best predictive performance. However, the predictive abilities across different dissimilarity 
measures were similar.  
After comparing the predictive performance of different dissimilarity measures in the 
MILES model, the predictive performance of MILES models was compared with that of 
conventional classification approaches, which are based on classical QSAR principles without 
instance-based embedding (Table 5.3). To find the optimal λ for 1-norm SVM on the basis of 
classical QSAR principles, the same procedure was employed, which resulted in the minimal 
subset of the most important pharmacophore models. For data set I, optimal λ was 0.001 with 
223 selected pharmacophore models; for data set II, optimal λ was 0.8 with 50 selected 
pharmacophore models. 
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Table 5.3. Predictive performance for different models 
Data 
set 
Methods 
Training set Test set 
Accuracy MCC Accuracy MCC 
I 
MILES
a
 0.941 0.881 0.861 0.725 
Decision tree 0.915 0.830 0.781 0.569 
1-norm SVM 1.000 1.000 0.832 0.668 
Random forest 0.995 0.990 0.891 0.783 
II 
MILES
b 
0.892 0.805 0.891 0.786 
Decision tree 0.909 0.821 0.764 0.567 
1-norm SVM 0.955 0.912 0.891 0.767 
Random forest 0.897 0.810 0.873 0.755 
a
 Manhattan dissimilarity measure; 
b
 Rogers-Tanimoto dissimilarity measure. 
 
 
 
For data set I, the 1-norm SVM without instance-based embedding overfit the training 
set, producing perfect prediction on the training set and poor prediction on the test set. However, 
MILES performed fairly well on both the training and test sets without overfitting. MILES 
performed much better than decision trees and slightly worse than random forests in terms of the 
predictive power on the test set. For data set II, MILES outperformed all of the classical QSAR 
methods. It is noteworthy that the dissimilarity measure (Rogers-Tanimoto) used in comparison 
yielded slight lower prediction compared to Soergel and Dice distances. MILES performed fairly 
well on both training and test sets without overfitting, and its predictive power was highly 
comparable with other conventional QSAR approaches. It was interesting that the classification 
accuracy and MCC provided the same indications again, even for the comparison of different 
QSAR approaches. 
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5.3.4. IDENTIFICATION OF BIOACTIVE CONFORMERS 
After examining the predictive ability of MILES, we tested the ability of MILES in the 
pursuit of the bioactive conformers. We made use of 12 co-crystallized structures of GSK-3 with 
bound small molecules, which adopt bioactive conformers in the complex structures (Table 5.4). 
The direct comparison between the structures of the co-crystallized conformers and the ones 
from conformational sampling is difficult and sometimes impossible, since the conformational 
sampling plus structural minimization may not provide the exact same conformations found in 
the co-crystallized complex, due to the lack of protein environment in the conformational search 
process. So we adopted an indirect validation method. We seeded the 12 co-crystallized 
conformers in the set of sampled conformers generated through extensive exploration of 
conformational space. Then we calculated their contributions         to the classification of the 
relevant positive molecules as described above (Table 5.4). 
Three out of 12 molecules are highly flexible, adopting more than 100 conformers. For 
these three, MILES only correctly predicted one co-crystallized conformer as the third most 
significant conformer contributing to the classification of the molecule named AR. It incorrectly 
predicted the other two co-crystallized conformers as irrelevant conformers in terms of the 
contribution to the classification of benzoimidazole-1 and maleimide. 
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Table 5.4. Validations on the prediction of bioactive conformers 
ID
a 
Name
b 
PDB ID
 
Contribution
c 
Rank
d 
n
e 
23 AR 1Q5K 2.792 3 117 
37 Benzoimidazole-1 2O5K 0 N.A.
f 
138 
50 Jonjon-1 2OW3 2.827 6 38 
59 LM-4 1Q3W 0.858 1 2 
60 LM-5 1UV5 11.941 1 3 
77 LM-29 1Q41 8.576 2 7 
97 Maleimide 1R0E 0 N.A. 
f
 121 
98 OxaD-0 3F7Z 10.629 1 53 
99 OxaD-00 3GB2 4.637 2 9 
153 Pyzo-11 3L1S 10.371 1 11 
198 RM-0 1Q4L 5.568 2 25 
199 Staurosporine 1Q3D 22.359 1 5 
a
 Molecule index in the data set; 
b
 molecular name in the data set; 
c
 contribution calculated based 
on the weighted distance; 
d
 the rank in the set of contributions; 
e
 the number of conformers for 
each molecule; 
f
 the rank cannot be determined and the conformer was predicted to be irrelevant 
to classification based on the MILES method. 
 
But for the molecules adopting less than 100 conformers, which had relatively rigid 
structures, MILES correctly predicted all the co-crystallized conformers as significant 
conformers for the classification of positive molecules. Five co-crystallized conformers were 
predicted to be the most significant conformers, i.e., the bioactive conformers; three co-
crystallized conformers were predicted to be the second most significant conformers; and one co-
crystallized conformer was predicted to be the sixth most significant conformer, based on the 
calculations of        . So the pursuit of bioactive conformers is easy for relatively rigid 
molecules and relatively more difficult for the highly flexible ones.  
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5.4. CONCLUSIONS 
We have successfully implemented a multiple-instance learning (MIL) framework, 
multiple-instance learning via embedded instance selection (MILES), for drug activity 
prediction. The molecules and relevant conformers were described using superior 3D descriptors, 
pharmacophore fingerprints, encoded as binary strings. The instance-based embedding was 
accomplished using dissimilarity measures designed for calculations on binary strings. The joint 
feature selection and classification was accomplished using a wrapper model based on 1-norm 
SVM. We have used the approach for the prediction of the labels of molecules interacting with 
four therapeutic targets, including GSK-3, CBrs, and P-gp. Based on the predictive performance, 
our proposed approach was highly competitive with conventional classification approaches based 
on classical QSAR principle. Subsequently, we have validated that the proposed approach is 
highly useful in the pursuit of bioactive conformers using a set of 12 GSK-3 crystal structures 
with bound inhibitors. 
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The most active lead compound we identified through in silico virtual screening carries a 
phthalimide scaffold, and phthalimide compounds have been reported to have inhibitory 
activities against AGC family of protein kinases including AKT, PDK1, p70S6K, and ROCK 
kinases, which involve in proliferative and neurodegenerative disorders.
179
 The compounds can 
be easily synthesized through the Scheme I, and more structural analogs can be synthesized 
through the Scheme II. The GSK-3 inhibition of phthalimide has not been reported before. 
Hence, extensive structure-activity relationship can be explored to find promising drug 
candidates with potent inhibitory activities. 
 
Figure 6.1. Synthetic route to modify chemical structure of lead compound. 
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Appendix: A. Summary of the previous QSAR studies related 
to GSK-3 inhibitors. 
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et al.
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et al.
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2
 = 0.98, 
LOO-CV R
2
 = 0.53, 
test set R
2
 = 0.47 
best CoMSIA 
training set R
2
 = 0.92, 
LOO-CV R
2
 = 0.48 
test set R
2
 = 0.48 
Lather 
et al.
182
 
training set (36) 
test set (8) 
indirubins 
multiple linear 
correlation for 2D 
QSAR, 
atom-based PHASE 3D 
QSAR 
2D QSAR 
training set R
2
 = 0.93, 
test set R
2
 = 0.60 
3D QSAR 
training set R
2
 = 0.97, 
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test set R
2
 = 0.91 
Taha 
et al.
80
 
training set (123) 
test set (29) 
3-anilino-4-arylmaleimides, 
pyrozolopyridazines, 
pyrazolopyridines 
GFA-MLR-QSAR 
training set R
2
 = 0.663, 
LOO-CV R
2
 = 0.592, 
test set R
2
 = 0.695 
Prasanna 
et al.
183
 
training set (56) 
test set (18) 
3-anilino-4-arylmaleimides 
CoMFA 
CoMSIA 
best CoMFA 
training set R
2
 = 0.942, 
LOO-CV R
2
 = 0.844, 
test set R
2
 = 0.779 
best CoMSIA 
training set R
2
 = 0.932, 
LOO-CV R
2
 = 0.833 
test set R
2
 = 0.803 
Goodarzi 
et al.
81
 
training set (123) 
test set (29) 
3-anilino-4-arylmaleimides, 
pyrozolopyridazines, 
pyrazolopyridines 
linear/nonlinear 
regression methods 
best model obtained using SVM 
combining with fuzzy rough set ACO as 
variable selection method 
training set R
2
 = 0.960, 
test set R
2
 = 0.927 
Fang 
et al.
83
 
training set (30) 
test set (8) 
Benzofuran-3-yl-(indol-3-
yl)maleimides 
CoMFA 
CoMSIA 
best CoMFA 
training set R
2
 = 0.984, 
LOO-CV R
2
 = 0.602, 
test set R
2
 = 0.905 
best CoMSIA 
training set R
2
 = 0.983, 
LOO-CV R
2
 = 0.665 
test set R
2
 = 0.761 
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Appendix: B. Structures and bioactivities of the compounds 
in Group I. 
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6
3
 
 
No. R1
a 
R2
a 
R3
a 
R4
a 
X
a 
Y
 
pIC50 
Expt. Models 
I II III IV 
1 6-Br H H – NO(CH2) 2Piperazinyl – 8.481 8.402 8.258 8.119 8.102 
2 5,6-diCl H H – NOH – 8.398 8.318 8.174 8.082 8.040 
3 5,6-diCl H H – NOAc – 8.398 8.318 8.174 8.149 8.155 
4 6-Br H H – NOH – 8.301 8.221 8.077 7.881 7.766 
5 6-Br H H – NO(CH2) 2Piperazinyl-
N-EtOH 
– 8.301 8.330 8.077 8.119 8.088 
6 5-Me-6-Br H H – NOH – 8.222 8.302 7.998 7.931 7.962 
7 5-NO2-6-Br H H – NOAc – 8.222 8.302 7.998 7.989 7.997 
8 5-Me-6-Br H H – NOAc – 8.155 8.075 7.931 8.086 7.980 
9 5-NO2-6-Br H H – NOH – 8.155 8.075 7.931 7.963 7.871 
10 6-Br H H – NO(CH2) 2Piperazinyl- – 8.155 8.075 7.931 8.090 8.076 
  
 
1
6
4
 
N-Me 
11 5-I H H – NOH – 8.046 7.966 7.822 7.852 7.632 
12 6-Br H H – NOAc – 8.000 7.920 7.776 7.925 7.860 
13 6-I H H – NOAc – 7.886 7.927 7.662 7.816 7.710 
14 6-Br H H – NO(CH2) 2Piperazinyl-
N-EtOEtOH 
– 7.854 7.774 7.630 7.847 7.716 
15 6-Cl H H – NOAc – 7.770 7.747 7.546 7.781 7.743 
16 H H H – NOH – 7.658 7.578 7.434 7.325 7.266 
17 5-Me-6-Br H H – O – 7.602 7.682 7.378 7.192 7.256 
18 6-Br H H – NO(CH2)2N(CH2)4 – 7.585 7.665 7.361 7.538 7.542 
19 5,6-diCl H H – O – 7.523 7.443 7.299 7.294 7.233 
20 6-Br H H – NO(CH2)2NMe2 – 7.481 7.408 7.258 7.491 7.490 
21 6-Br H H – NOCH2CH(OH)CH2O
H 
– 7.469 7.389 7.244 7.461 7.472 
22 6-Br H H – NO(CH2)2NEt2 – 7.456 7.536 7.232 7.491 7.418 
23 5-NO2 H H – O – 7.377 7.297 7.153 7.234 7.242 
24 6-Br H H – O – 7.347 7.266 7.123 7.116 7.031 
25 6-I H H – O – 7.260 7.339 7.036 7.109 7.061 
26 5-Br H H – O – 7.260 7.180 7.036 7.129 7.094 
27 6-CH=CH2 H H – NOH – 7.222 7.302 6.998 7.299 7.156 
28 6-Br H H – NO(CH2) 2Morpholinyl – 7.222 7.302 6.998 7.498 7.447 
29 5-Me H H – O – 7.208 7.128 6.984 6.982 6.891 
30 6-CH=CH2 H H – NOAc – 7.187 7.268 6.963 7.277 7.269 
31 6-Br H H – NO(CH2)2NMe-2,3-
diOH-nPr 
– 7.174 7.094 6.949 7.441 7.408 
32 5-I H H – O – 7.167 7.247 6.943 7.142 7.019 
33 5-F H H – O – 7.108 7.028 6.884 7.030 6.937 
34 5-NO2-6-Br H H – O – 7.000 7.080 6.776 7.132 7.136 
35 6-Br 6‘-Br H – NOH – 6.921 7.001 6.697 7.082 7.079 
36 6-Cl H H – O – 6.854 6.934 6.630 6.896 6.757 
37 6-Br H H – NO(CH2)2Br – 6.854 6.934 6.630 7.013 7.069 
38 H H H – NOCH3 – 6.824 6.904 6.600 6.599 6.710 
39 H H H – NOAc – 6.699 6.779 6.475 6.986 6.950 
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40 H 6‘-Br H – NOH – 6.469 6.549 6.444 7.009 6.872 
41 H 5‘-Br H – O – 6.456 6.376 6.232 6.251 6.384 
42 H H H – O – 6.000 6.080 6.198 6.049 6.101 
43 6-Br 6‘-Br H – O – 5.347 5.427 5.571 5.742 5.815 
44 H 6‘-Br H – O – 4.658 4.738 4.882 5.627 5.512 
45 6-Br H Me – O – 4.000 4.080 4.224 4.411 4.448 
46 6-Br H Me – NOH – 4.000 4.080 4.224 5.057 5.103 
47 H H Me – O – 4.000 3.920 4.224 4.083 4.223 
48 H H Me – NOH – 4.000 4.080 4.224 4.591 4.728 
49 4-Cl H H – O – 4.000 4.080 4.224 4.824 4.887 
50 H H 9-NO2 H – – 8.398 8.318 8.174 7.831 7.720 
51 H H 9-CN H 1-N – 8.097 8.017 7.873 7.377 7.473 
52 H H 9-CF3 H 1-N – 8.097 8.017 7.873 7.289 7.220 
53 H H 9-CN H – – 8.000 7.920 7.776 7.391 7.520 
54 2,3-diOMe H 9-NO2 H – – 7.886 7.807 7.662 7.569 7.606 
55 H H 9-Cl H 2-N – 7.745 7.664 7.521 7.180 7.275 
56 2,3-diOMe H 9-CN H – – 7.745 7.665 7.521 7.382 7.444 
57 3-OH H 9-Br H – – 7.745 7.665 7.521 7.039 7.214 
58 H H 9-Br H – – 7.638 7.652 7.414 7.272 7.362 
59 H H 9-Cl H – – 7.620 7.540 7.395 7.304 7.235 
60 H H 9-I H 1-N – 7.602 7.522 7.378 7.148 7.188 
61 2-CN H 9-CN H – – 7.553 7.633 7.329 7.283 7.219 
62 H H 9-CF3 H – – 7.523 7.443 7.299 7.195 7.133 
63 3-O(CH2)4NH2
 
H 9-Br H – – 7.523 7.443 7.299 7.162 7.200 
64 2-CH2CH2CN H 9-CF3 H – – 7.481 7.401 7.257 7.147 7.100 
65 H H 9-F H 2-N – 7.292 7.373 7.068 7.023 6.953 
66 H H 9-Br H 2-N – 7.284 7.364 7.060 7.121 7.089 
67 H H 9-Cl H 1-N  7.201 7.280 6.977 6.760 6.805 
68 3-OMe H 9-NO2 H – – 7.155 7.075 6.931 7.253 7.251 
69 H H 9-Br CH2CO2-
Me 
– – 7.125 7.045 6.901 6.665 6.628 
70 2,3-diOMe H 9-CF3 H – – 7.125 7.045 6.901 6.857 6.913 
71 H H 9-F H – – 7.097 7.017 6.873 6.988 6.866 
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72 2-CH2COMe H 9-CF3 H – – 7.046 6.966 6.822 6.804 6.786 
73 2,3-diOMe H 9-Br H – – 7.000 6.920 6.776 6.712 6.714 
74 H H 9-Me H 1-N – 6.886 6.966 6.662 6.592 6.576 
75 H H 9-Me H – – 6.886 6.806 6.662 6.596 6.567 
76 H H 10-Br H – – 6.854 6.774 6.630 6.880 6.736 
77 2-Br H H H – – 6.699 6.779 6.475 6.743 6.552 
78 2-Br H 9-NO2 H – – 6.699 6.779 6.475 6.851 6.708 
79 3-OMe H 9-CF3 H – – 6.620 6.700 6.396 6.700 6.696 
80 2-I H H H – – 6.602 6.522 6.378 6.535 6.470 
81 H H 9-Br (CH2)2OH – – 6.523 6.443 6.299 6.275 6.378 
82 H H 9-OMe H 2-N – 6.409 6.329 6.186 6.347 6.302 
83 H H H Me 2-N – 6.398 6.317 6.194 6.129 6.205 
84 H H 9-Br Me – – 6.398 6.478 6.251 6.594 6.550 
85 2-CH=CHCN H 9-CF3 H – – 6.398 6.393 6.193 6.248 6.339 
86 H H H Bn 2-N – 6.387 6.307 6.193 5.980 5.972 
87 H H 11-Me H   6.301 6.221 6.257 6.203 6.225 
88 H H H H – – 6.208 6.288 6.154 6.059 6.030 
89 H H 8,10-
diCl 
H 1-N – 6.097 6.177 6.180 6.007 5.979 
90 2-Br H 9-Br H – – 6.097 6.017 6.193 6.176 6.063 
91 H H 11-Br H – – 6.046 6.126 6.225 6.210 6.185 
92 2,3-diOMe H H H – – 6.046 5.966 6.192 6.134 6.105 
93 2-CH=CHCO2-
Me 
H 9-CF3 H – – 6.046 6.126 6.190 6.202 6.197 
94 H H H Me 1-N – 6.000 5.920 6.132 5.873 5.915 
95 2-CN H H H – – 5.886 5.966 6.110 6.401 6.247 
96 H H 9-OH H 1-N  5.854 5.849 6.078 5.987 5.988 
97 2-
CH=CHCOMe 
H 9-CF3 H – – 5.854 5.774 6.078 6.116 6.106 
98 H H 9,11-
diF 
H 1-N – 5.745 5.665 5.969 6.020 5.960 
99 2-Br H 9-CF3 H – – 5.699 5.779 5.923 5.928 5.933 
100 2-CH=CH-1- H 9-CF3 H – – 5.699 5.779 5.923 5.902 5.962 
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OH-cyHe 
101 H Me 9-Br H – – 5.678 5.598 5.902 5.629 5.655 
102 H H 9-OMe H – – 5.658 5.738 5.882 5.709 5.732 
103 2-I H 9-CF3 H – – 5.658 5.578 5.881 5.775 5.927 
104 H H 9-Br CO2tBu – – 5.638 5.718 5.862 5.654 5.616 
105 2-Br H 9-CN H 1-N – 5.420 5.500 5.644 6.226 6.058 
106 H H 9-Br Allyl – – 5.398 5.478 5.622 5.536 5.613 
107 2-I H 9-Br H – – 5.377 5.457 5.601 5.777 5.759 
108 4-OH H 9-Br H – – 5.367 5.447 5.591 5.535 5.744 
109 H H 8,10-
diCl 
H – – 5.301 5.381 5.525 5.601 5.620 
110 H H 9-CF3 H 4-N  5.276 5.356 5.500 5.976 5.930 
111 H H H H – 11-
N 
5.260 5.179 5.484 5.322 5.502 
112 H H H Ph 1-N  5.000 5.080 5.224 5.248 5.299 
113 H Bn 9-Br H – – 5.000 4.976 5.224 4.728 4.845 
114 H H 9-NH2 H – – 4.921 5.001 5.145 5.591 5.494 
115 H H H Et 1-N – 4.886 4.966 5.110 5.328 5.321 
116 4-OMe H 9-Br H – – 4.796 4.876 5.019 5.160 5.341 
117 H Et 9-Br H – – 4.620 4.700 4.844 5.058 4.954 
118 H H 9-
NHAc 
H – – 4.387 4.467 4.611 5.321 5.309 
119 H H 9-
CO2H 
H 1-N – 4.000 4.080 4.224 5.181 5.277 
120 4-OMe H H H – – 3.854 3.934 4.078 4.672 4.695 
121 H H 9-Cl H 4-N – 3.301 3.381 3.525 4.834 4.947 
122 H CO2tBu 9-Br CO2tBu – – 3.194 3.274 3.418 3.530 3.681 
123 CN – – – – – 6.481 6.401 6.258 6.464 6.535 
124 Cl – – – – – 6.398 6.318 6.192 6.157 6.208 
125 Me – – – – – 5.886 5.966 6.110 6.014 6.032 
126 NO2 H H – NH C=
S 
6.222 6.202 6.212 6.141 6.173 
127 Br H CO2tB – N CO2tBu C= 3.886 3.966 4.110 4.041 4.103 
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u O 
128 Br H H – CH2 CH
2 
3.745 3.825 3.969 4.300 4.424 
129 Br CO2tBu CO2tB
u 
– N CO2tBu C=
O 
3.301 3.381 3.525 3.541 3.660 
130 Br H NHOH – – – 6.125 6.045 6.195 5.973 6.067 
131 Br H SMe – – – 5.921 5.841 6.145 5.672 5.651 
132 NO2 Me SMe – – – 3.000 3.080 3.224 4.025 3.988 
133 – – – – – – 6.387 6.307 6.191 6.072 5.998 
134 – – – – – – 5.000 5.080 5.224 5.056 5.177 
135 – – – – – – 3.456 3.536 3.680 3.846 3.857 
136 4-OMe-Ph (CH2)2Me H H – – 6.398 6.478 6.190 6.214 6.241 
137 4-OMe-Ph Me H H – – 6.337 6.257 6.193 6.135 6.139 
138 4-OMe-Ph CHMe2 H H – – 6.301 6.274 6.193 6.124 6.139 
139 4-OSO2NMe2-
Ph 
Me H H – – 6.301 6.221 6.193 5.768 5.894 
140 4-OH-Ph Me H H – – 6.284 6.364 6.192 6.140 6.116 
141 4-OH-Ph (CH2)3Me H H – – 6.187 6.107 6.191 6.024 6.054 
142 4-Cl-Ph CHMe2 H H – – 6.125 6.045 6.193 5.850 5.849 
143 3-Thienyl H H H – – 6.097 6.017 6.193 5.881 5.761 
144 4-OMe-Ph (CH2)3Me H H – – 6.036 5.956 6.193 5.984 5.940 
145 Ph Bn H H – – 6.000 5.920 6.193 5.623 5.582 
146 C(CH2)2-4-Cl-
Ph 
H H H – – 6.000 5.920 6.152 5.703 5.737 
147 4-OMe-Ph CH2cyPr H H – – 5.959 6.038 6.183 5.841 5.860 
148 4-OH-Ph H H H – – 5.921 6.001 6.145 5.860 5.838 
149 2-Thienyl H H H – – 5.921 5.841 6.144 5.734 5.666 
150 4-Cl-Ph Me H H – – 5.770 5.689 5.994 5.632 5.568 
151 4-F-Ph H H H – – 5.721 5.641 5.945 5.570 5.601 
152 3,4-diOMe-Ph Me H H – – 5.699 5.619 5.923 5.619 5.610 
153 Ph H H H – – 5.638 5.558 5.862 5.380 5.393 
154 4-OMe-Ph (CH2)3Cl H H – – 5.602 5.682 5.826 5.792 5.745 
155 4-OH-Ph CH2cyPr H H – – 5.523 5.603 5.747 5.738 5.703 
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156 3-OMe-Ph H H H – – 5.495 5.415 5.719 5.391 5.372 
157 2-OMe-Ph H H H – – 5.481 5.437 5.705 5.605 5.544 
158 4-CN-Ph H H H – – 5.319 5.399 5.543 5.400 5.334 
159 4-Cl-Ph (CH2)3Me H H – – 5.229 5.309 5.453 5.425 5.321 
160 4-Br-Ph H H H – – 5.222 5.302 5.446 5.167 5.247 
161 4-OMe-Ph CH2cyHe H H – – 5.167 5.087 5.392 5.236 5.185 
162 4-CF3-Ph H H H – – 5.143 5.223 5.367 5.206 5.247 
163 4-Cl-Ph CH2cyHe H H – – 5.097 5.093 5.321 5.148 5.120 
164 4-OMe-Ph (CH2)6Me H H – – 5.000 5.080 5.224 4.858 4.908 
165 4-NMe2-Ph H H H – – 4.921 5.001 5.145 5.062 5.084 
166 2-Furanyl H H H – – 4.824 4.904 5.048 5.063 5.065 
167 2-Pyridyl H H H – – 4.824 4.904 5.048 4.980 4.990 
168 C(CH2)2-4-Cl-
Ph 
Me H H – – 4.745 4.825 4.969 5.204 5.122 
169 3,5-diOMe-Ph H H H – – 4.222 4.302 4.446 4.471 4.521 
170 3,4,5-triOMe-
Ph 
H H H – – 4.071 4.150 4.295 4.217 4.352 
171 3,5-diCl-Ph H H H – – 4.000 4.080 4.224 4.588 4.511 
172 Ph H Me H – – 4.000 4.080 4.224 4.373 4.385 
173 Ph H H Me – – 4.000 4.080 4.224 4.586 4.488 
174 – – – – – – 4.000 3.920 4.224 4.274 4.243 
175
b 
6-I H H – NOH – 8.000 8.052 6.194 7.814 7.476 
176
b
 6-Br H H – NO(CH2) 2Piperazinyl-
N-EtOMe 
– 7.959 7.778 6.230 7.891 7.837 
177
b
 6-Cl H H – NOH – 7.699 8.200 6.204 7.589 7.523 
178
b
 6-Br H H – NOCH3 – 7.523 7.526 6.148 6.962 7.282 
179
b
 6-Br H H – NO(CH2)2OH – 7.523 7.320 6.228 7.302 7.490 
180
b
 6-Br H H – NOCONEt2 – 7.523 6.866 6.193 7.613 7.629 
181
b
 6-Br H H – NO(CH2)2N(EtOH)2 – 7.398 6.631 6.197 7.592 7.431 
182
b
 5-Cl H H – O – 7.301 6.740 6.291 6.937 6.855 
183
b
 6-F H H – NOAc – 7.046 7.150 6.199 7.826 7.417 
184
b
 6-F H H – NOH – 6.886 8.092 6.200 7.793 7.35 
185
b
 6-CH=CH2 H H – O – 6.620 6.308 6.198 6.703 6.641 
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186
b
 5-Br 5‘-Br H – O – 6.602 6.114 6.193 6.108 6.367 
187
b
 6-F H H – O – 6.187 6.851 6.447 6.961 6.729 
188
b
 H H 9-CF3 H 2-N – 7.886 7.016 6.086 6.843 6.669 
189
b
 H H 9-CN H 2-N – 7.678 8.602 6.348 6.976 7.094 
190
b
 2-OMe H 9-NO2 H – – 7.658 7.051 6.223 6.980 7.108 
191
b
 H H 9-F H 1-N – 7.097 6.582 6.236 6.687 6.204 
192
b
 H H 9-CN-
11-I 
H 1-N – 6.921 7.703 6.193 6.546 6.599 
193
b
 2,3-diOH H 9-Br H – – 6.921 6.501 6.314 6.664 6.719 
194
b
 3-OMe H 9-CN H – – 6.886 6.912 6.202 7.078 7.065 
195
b
 H H 11-Cl H – – 6.699 6.512 6.343 6.395 6.195 
196
b
 2-C≡CCH2OH H 9-CF3 H – – 6.699 6.474 6.194 6.474 6.488 
197
b
 H CH2CO2Me 9-Br H – – 6.301 4.542 6.193 4.989 5.083 
198
b
 H H 11-Et H – – 6.155 6.423 6.197 6.110 5.972 
199
b
 H H H H 1-N – 6.097 6.874 6.193 6.117 6.029 
200
b
 H H 9-OMe H 1-N – 6.097 5.204 6.176 5.812 5.853 
201
b
 H H H Et 2-N – 6.097 5.661 6.157 5.918 5.926 
202
b
 H H 9-Br Et – – 5.824 5.980 6.152 5.705 5.759 
203
b
 H H H Bn 1-N – 5.678 5.501 6.190 5.574 5.527 
204
b
 NO2 – – – – – 7.456 7.063 6.193 6.769 6.557 
205
b
 Br – – – – – 6.921 6.671 6.193 6.192 6.369 
206
b
 Br H H – NH C=
S 
5.699 5.773 6.195 5.796 5.845 
207
b
 4-OMe-Ph CH2CH= 
CH2 
H H – – 6.222 6.352 6.192 5.980 6.013 
208
b
 4-OMe-Ph H H H – – 5.959 5.304 6.191 5.674 5.589 
209
b
 4-OH-Ph (CH2)2Me H H – – 5.745 5.994 6.191 6.033 6.027 
210
b
 4-Me-Ph H H H – – 5.585 5.055 6.045 5.290 5.151 
211
b
 2-OH-Ph H H H – – 5.187 5.299 6.193 5.761 5.693 
212
b
 4-Cl-Ph Bn H H – – 5.167 5.524 6.193 5.273 5.292 
213
b
 4-(2-1,3-
dioxolano)-Ph 
H H H – – 4.699 5.030 6.193 4.832 5.074 
214
b
 1-Naphthyl H H H – – 4.569 6.308 6.193 5.398 5.330 
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a
 Ac = Acetyl, Br = Bromo, Bu = Butyl, Bn = Benzyl, Cl = Chloro, Et = Ethyl, Me = Methyl, Ph = Phenyl, Pr = Propyl, n = normal, cy 
= cyclo, t = tert; 
b
 Test set. 
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Appendix: C. Structures and bioactivities of the compounds 
in Group II. 
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No. R1
a 
R2
a 
R3
a 
X
a 
Y pIC50 
Expt. Model 
I II III IV 
1 3-NO2 3,5,-di-Cl-4-OH H – – 7.699 7.597 7.575 7.414 7.456 
2 2-NO2 4-Cl-3-CO2H H – – 7.553 7.451 7.429 7.286 7.445 
3 3-Cl 3,5,-di-Cl-4-OH H – – 7.237 7.135 7.113 7.140 7.149 
4 3-NO2 3-Cl-4-OH H – – 7.229 7.170 7.105 7.197 7.202 
5 3-NO2 3-Cl H – – 7.155 7.053 7.031 6.918 6.984 
6 4-NO2 3,5,-di-Cl-4-OH H – – 7.149 7.251 7.173 7.183 7.173 
7 2-Cl 4-Cl-3-CO2H H – – 7.131 7.031 7.007 7.001 7.078 
8 3-Cl 4-Cl-3-CO2H H – – 7.119 7.205 6.995 7.071 7.104 
9 3-NO2 3-CO2H H – – 7.102 7.084 6.979 6.938 7.026 
10 2-OMe 3,5,-di-Cl-4-OH H – – 7.086 6.985 6.962 7.039 7.075 
11 3-OMe 4-Cl-3-CO2H H – – 7.071 7.043 6.946 7.081 7.102 
12 4-Cl 3,5,-di-Cl-4-OH H – – 7.041 7.143 7.028 7.014 7.043 
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13 2-Cl 3,5,-di-Cl-4-OH H – – 7.032 7.134 6.952 6.923 7.111 
14 2-NO2 3-Cl H – – 6.983 7.085 6.885 6.878 6.916 
15 2-NO2 3-Cl-4-OH H – – 6.983 7.085 7.027 7.002 7.031 
16 2-OMe 4-SMe H – – 6.959 7.060 6.835 6.769 6.814 
17 2-OMe 3-Cl H – – 6.943 7.045 6.819 6.777 6.832 
18 3-NO2 4-OH H – – 6.910 6.808 6.849 6.820 6.795 
19 3-Cl 3-CO2H H – – 6.873 6.900 6.760 6.860 6.843 
20 2-Cl 3-CO2H H – – 6.866 6.895 6.810 6.818 6.856 
21 3-OMe 3,5,-di-Cl-4-OH H – – 6.848 6.950 6.972 6.981 6.984 
22 H 4-Cl-3-CO2H H – – 6.845 6.947 6.823 6.847 6.816 
23 H 3,5,-di-Cl-4-OH H – – 6.827 6.752 6.842 6.845 6.831 
24 2-Cl 3-Cl-4-OH H – – 6.818 6.811 6.847 6.794 6.846 
25 3-NO2 4-SMe H – – 6.818 6.716 6.751 6.768 6.772 
26 4-OMe 3-Cl H – – 6.807 6.705 6.683 6.713 6.679 
27 2-Cl 4-SMe H – – 6.793 6.752 6.674 6.758 6.711 
28 4-Cl 3-Cl-4-OH H – – 6.762 6.743 6.757 6.798 6.766 
29 4-Cl 3-CO2H H – – 6.730 6.833 6.798 6.745 6.751 
30 2-Cl 3-Cl H – – 6.710 6.644 6.633 6.629 6.643 
31 3-OMe 3-CO2H H – – 6.710 6.639 6.748 6.705 6.724 
32 4-OMe 3-CO2H H – – 6.670 6.772 6.794 6.672 6.689 
33 2-Cl H H – – 6.666 6.563 6.561 6.513 6.580 
34 2-OMe H H – – 6.666 6.768 6.542 6.532 6.522 
35 3-NO2 3-OH H – – 6.627 6.568 6.738 6.614 6.656 
36 4-OMe 4-SMe H – – 6.614 6.716 6.738 6.668 6.598 
37 2-NO2 3-OH H – – 6.600 6.679 6.724 6.654 6.672 
38 3-OMe 3-Cl H – – 6.590 6.692 6.532 6.658 6.574 
39 H 3-CO2H H – – 6.536 6.522 6.633 6.530 6.542 
40 4-Cl 4-OH H – – 6.499 6.464 6.500 6.444 6.471 
41 2-Cl 3-OH H – – 6.427 6.325 6.551 6.407 6.465 
42 4-OMe H H – – 6.409 6.511 6.424 6.338 6.375 
43 4-NO2 4-SMe H – – 6.407 6.508 6.530 6.546 6.561 
44 4-Cl 3-Cl H – – 6.350 6.452 6.474 6.372 6.407 
45 3-OMe 3-OH H – – 6.326 6.224 6.432 6.386 6.371 
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46 4-OMe 3-OH H – – 6.318 6.420 6.442 6.370 6.392 
47 4-Cl H H – – 6.289 6.391 6.413 6.284 6.285 
48 H H H – – 6.277 6.358 6.400 6.225 6.273 
49 4-Cl 4-SMe H – – 6.277 6.360 6.400 6.389 6.370 
50 3-Cl 4-SMe H – – 6.274 6.376 6.398 6.393 6.412 
51 H 3-OH H – – 6.152 6.255 6.277 6.249 6.202 
52 3-NO2 H Me – – 5.854 5.956 5.978 6.098 6.143 
53 3-Cl 3-OH H – – 5.830 5.933 5.954 6.165 6.084 
54 3-OMe H Me – – 5.347 5.449 5.471 5.681 5.774 
55 2-NO2 – – – – 6.883 6.781 6.827 6.712 6.815 
56 2-OMe – – – – 6.728 6.626 6.722 6.458 6.581 
57 2-Cl – – – – 6.472 6.371 6.570 6.488 6.552 
58 4-Cl – – – – 5.850 5.952 5.974 6.110 6.120 
59 – – – – – 5.301 5.403 5.425 5.703 5.727 
60 Ph H COnPr N N 8.398 8.500 8.274 8.039 7.963 
61 Ph H COnBu N N 8.398 8.296 8.274 8.255 8.191 
62 Ph H CO(CH2)3Morpholinyl N N 8.301 8.199 8.177 7.839 7.932 
63 2,3-diF-Ph H CO(CH2)3NMe2 N N 8.301 8.199 8.177 8.197 8.104 
64 Ph H COcyPent CH N 8.301 8.199 8.177 8.096 8.108 
65 Ph H COnPr N CH 8.155 8.052 8.031 7.912 7.863 
66 Ph H CO(CH2)3Piperazinyl-N-Et N N 8.155 8.053 8.031 8.101 8.055 
67 2,3-diF-Ph H COnPr CH N 8.155 8.053 8.031 7.916 7.919 
68 Ph H CO(CH2)3Pyrrolidine N N 7.959 8.061 7.835 8.049 7.966 
69 3-Pyridyl H COnPr CH N 7.959 7.856 7.835 7.469 7.488 
70 Ph H COiPr CH N 7.721 7.794 7.597 7.392 7.391 
71 3-F-Ph H COnPr CH N 7.699 7.801 7.601 7.498 7.526 
72 Ph H CO(CH2)3NMe2 N N 7.658 7.760 7.534 7.863 7.789 
73 2-Cl-Ph H COnPr CH N 7.569 7.540 7.445 7.511 7.458 
74 Ph H COEt CH N 7.367 7.264 7.243 7.134 7.004 
75 Ph H COnPr CH N 7.252 7.300 7.376 7.291 7.257 
76 Ph H COnPr CH CH 7.004 7.106 7.129 6.940 6.936 
77 2-Naphthyl H COnPr CH N 6.772 6.874 6.896 6.961 6.958 
78 Ph Ph H N N 6.602 6.704 6.726 6.536 6.470 
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79 B(OCMe2CMe2O) H COnPr CH N 6.449 6.522 6.573 6.887 6.901 
80 Ph H H CH N 6.367 6.264 6.243 6.154 6.146 
81 4-Pyridyl H COnPr CH N 6.354 6.456 6.478 6.638 6.630 
82 Ph H H N N 6.276 6.318 6.390 6.160 6.171 
83 Ph Ph COnPr N N 6.161 6.262 6.284 6.458 6.483 
84 4-Ph-Ph H COnPr CH N 6.070 6.088 6.194 6.606 6.614 
85 Ph H H N CH 5.900 5.923 6.024 6.030 5.964 
86 H H COnPr CH N 5.630 5.704 5.754 6.006 5.952 
87 Ph H CONHEt CH N 5.551 5.653 5.675 6.193 6.171 
88 Ph H SO2Me CH N 5.447 5.549 5.571 5.862 5.923 
89 COMe – – NH N 6.536 6.638 6.660 6.410 6.421 
90 H – – NMe N 5.301 5.403 5.425 5.623 5.520 
91 H – – O N 5.301 5.403 5.425 5.702 5.668 
92 H – – NH CH 5.301 5.403 5.426 5.551 5.511 
93 – – – – – 5.569 5.671 5.693 6.174 6.215 
94 4-HO-Ph Br COcyPr N – 9.097 8.995 8.973 8.402 8.363 
95 4-HO-Ph Cl COcyPr N – 9.000 8.898 8.876 8.499 8.573 
96 4-HO-Ph Br CO-4-Piperidine-N-Me N – 9.000 8.898 8.876 8.555 8.649 
97 4-HO-Ph Br CO(CH2)3Piperazinyl-N-Et N – 8.398 8.473 8.274 8.270 8.265 
98 3-Br-4-HO-Ph H COcyPr N – 8.301 8.199 8.177 8.194 8.168 
99 4-HO-Ph Me COcyPr N – 8.222 8.324 8.098 7.862 7.817 
100 2-Thienyl Br COcyPent N – 8.155 8.159 8.031 7.912 7.876 
101 2-Furanyl Br COcyPr N – 8.155 8.053 8.031 7.858 7.821 
102 4-HO-Ph H COcyPr N – 8.097 8.121 7.973 7.903 7.901 
103 3,4-diHO-Ph H COcyPr N – 8.097 8.199 7.973 8.032 8.045 
104 3-HO-Ph H COcyPr N – 7.921 8.023 7.797 7.826 7.825 
105 2-Furanyl Br CO-(±)-3-Pyrrolidine-N-Bn N – 7.854 7.860 7.730 7.884 7.837 
106 4-HO-Ph H COcyPr CH – 7.824 7.722 7.700 7.149 7.150 
107 2-Thienyl Br CO-CH2-4-Piperidine-N-Et N – 7.745 7.643 7.621 7.745 7.684 
108 4-HO-Ph Ph COcyPr N – 7.620 7.722 7.496 7.527 7.528 
109 2-Thienyl Br COcyPr N – 7.409 7.402 7.285 7.410 7.378 
110 5-Indolyl H COcyPr CH – 7.377 7.275 7.252 7.183 7.217 
111 2-Furanyl H COcyPr CH – 7.301 7.199 7.177 7.137 7.059 
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112 Ph Br COcyPr N – 7.125 7.023 7.249 7.122 7.146 
113 Ph CN COcyPr N – 7.060 6.959 6.990 7.122 7.091 
114 2-Thiazolyl Br COcyPr N – 7.004 7.107 7.080 7.269 7.211 
115 3-MeO-Ph H COcyPr N – 6.903 6.454 6.779 6.695 6.794 
116 2-Thienyl H COcyPr CH – 6.668 6.753 6.792 6.888 6.750 
117 Ph Cl COcyPr N – 6.631 6.704 6.755 6.923 6.879 
118 2-Pyrrolyl H COcyPr CH – 6.495 6.597 6.619 6.789 6.744 
119 Ph Br CO-4-Piperidine-N-Me N – 6.417 6.518 6.540 6.974 6.924 
120 Ph H COcyPr N – 6.372 6.474 6.495 6.439 6.435 
121 Ph-3-SO2NH2 H COcyPr CH – 6.318 6.216 6.442 6.443 6.532 
122 3-F-Ph H COcyPr CH – 6.082 6.015 6.158 6.151 6.224 
123 6-Quinolyl H COcyPr CH – 6.000 5.983 6.124 6.394 6.353 
124 Ph-4-SO2NH2 H COcyPr CH – 6.000 6.027 6.124 6.311 6.417 
125 2-F-Ph H COcyPr CH – 6.000 5.937 6.124 6.258 6.251 
126 4-F-Ph H COcyPr CH – 6.000 6.102 6.124 6.230 6.272 
127 2-MeO-Ph H COcyPr N – 5.798 5.900 5.922 6.422 6.427 
128 4-MeO-Ph H COcyPr N – 5.301 5.403 5.425 5.918 6.005 
129
b 
3-NO2 4-Cl-3-CO2H H – – 7.585 7.523 7.059 7.142 7.265 
130
b
 2-NO2 3,5,-di-Cl-4-OH H – – 7.284 7.373 7.032 7.103 7.298 
131
b
 4-OMe 3,5,-di-Cl-4-OH H – – 7.081 7.131 6.990 6.966 7.060 
132
b
 3-Cl 3-Cl-4-OH H – – 7.027 6.417 6.748 6.781 6.796 
133
b
 4-Cl 4-Cl-3-CO2H H – – 6.963 7.314 6.973 6.933 7.021 
134
b
 2-OMe 3-Cl-4-OH H – – 6.857 7.074 6.888 6.844 6.983 
135
b
 3-NO2 H H – – 6.851 6.635 6.588 6.428 6.441 
136
b 
3-OMe 4-SMe H – – 6.693 6.613 6.749 6.682 6.588 
137
b 
2-OMe 3-OH H – – 6.587 6.830 6.699 6.479 6.580 
138
b 
H 3-Cl H – – 6.521 6.370 6.421 6.379 6.311 
139
b 
H 4-SMe H – – 6.394 6.522 6.677 6.398 6.395 
140
b 
4-Cl 3-OH H – – 6.390 5.952 6.291 6.331 6.327 
141
b 
H H Me – – 5.583 5.283 6.464 6.234 6.115 
142
b 
3-NO2 – – – – 6.793 6.651 6.730 6.573 6.714 
143
b 
3-Cl – – – – 6.337 5.913 6.349 6.432 6.315 
144
b 
4-OMe – – – – 6.159 6.375 6.712 6.396 6.577 
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145
b 
Ph H CO(CH2)4Piperazinyl-N-Et N N 8.301 8.767 7.251 7.512 7.532 
146
b
 Ph H CO-4-Piperidine-N-Me N N 8.046 7.802 7.232 7.881 7.909 
147
b
 2-F-Ph H COnPr CH N 7.745 7.431 7.775 7.468 7.492 
148
b
 Ph H COnPr CH N 7.252 7.310 7.377 7.286 7.254 
149
b
 1-Naphthyl H COnPr CH N 6.618 6.922 6.901 7.206 7.087 
150
b
 H Ph H CH H 5.301 6.252 6.913 6.018 6.155 
151
b
 3-Cl-4-HO-Ph H COcyPr N – 8.155 8.753 7.468 7.462 7.441 
152
b
 4-HO-Ph H CO-4-Piperidine-N-Me N – 7.921 8.455 6.969 7.924 7.902 
153
b
 2-Thiazolyl Br COcyPent N – 7.796 8.190 7.241 7.782 7.735 
154
b
 2-HO-Ph H COcyPr N – 7.444 7.952 6.910 7.269 7.077 
155
b
 2-Furanyl H COcyPr N – 6.851 6.806 7.121 7.058 7.038 
156
b
 Ph Ph COcyPr N – 6.382 6.371 7.107 7.223 7.107 
157
b
 Ph H COcyPr CH – 6.303 5.836 6.394 6.439 6.237 
a
 Ac = Acetyl, Br = Bromo, Bu = Butyl, Bn = Benzyl, Cl = Chloro, Et = Ethyl, Me = Methyl, Pent = Pentyl, Ph = Phenyl, Pr = Propyl, 
n = normal, cy = cyclo,  i = iso, (±) = racemic mixture; 
b
 Test set. 
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Appendix: D. Structures and bioactivities of the compounds 
in Group III. 
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No. R1
a 
R2
a 
R3
a 
R4
a 
R5
a 
pIC50 
Expt. Model 
I II III IV 
1 H H 7-Benzimidazole 4-CONH(CH2)2NMe2-Ph H 8.8 8.740 8.532 8.440 8.355 
2 H H 3-OMe-Ph 4-NH2-Ph H 8.6 8.525 8.332 8.189 8.135 
3 H H 3-OMe-Ph 4-SO2Me-Ph H 8.6 8.540 8.332 7.994 8.039 
4 H H 4-Pyridyl 4-Pyridyl H 8.5 8.440 8.232 7.898 7.780 
5 H H 3-OMe-Ph 4-CH2NHEt-Ph H 8.4 8.340 8.132 8.202 8.112 
6 H H 7-Benzimidazole 4-Pyridyl H 8.4 8.460 8.132 7.581 7.612 
7 H H 3-OMe-Ph 4-CH2NMe2-Ph H 8.3 8.326 8.032 8.217 8.201 
8 H H 3-OMe-Ph 4-NHC(O)(CH2)2NMe2-Ph H 8.3 8.240 8.032 8.134 8.205 
9 H H 7-Benzimidazole 4-SO2Me-Ph H 8.3 8.240 8.032 7.669 7.823 
10 H H 7-Benzimidazole 4-COOH-Ph H 8.3 8.240 8.032 7.775 7.783 
11 H H 3-OMe-Ph 4-Pyridyl H 8.2 8.260 7.932 7.846 7.853 
12 H H 7-Benzimidazole 4-F-Ph H 8.2 8.140 7.932 7.598 7.628 
13 H H 3-OMe-Ph 3-F-Ph H 8.1 8.122 7.832 7.849 7.817 
14 H H 3-OMe-Ph 4-CONH(CH2)2SO2Me-Ph H 8.1 8.040 7.832 7.969 7.702 
15 H H 3-OMe-Ph 4-Pyridyl Me 8.0 7.940 7.732 7.715 7.509 
16 H H 3-OMe-Ph 4-Pyridyl nPr 8.0 7.940 7.732 7.843 7.606 
17 H H 3-OMe-Ph 3-NH2-Ph H 8.0 8.060 7.732 7.952 7.850 
18 H H 3-OMe-Ph 4-SO2NH(CH2)2NMe2-Ph H 8.0 7.989 7.732 7.750 7.919 
19 H H 3-OMe-Ph 4-OH-Ph H 7.9 7.960 7.632 7.640 7.684 
20 H H 3-OMe-Ph 4-NHAc-Ph H 7.9 7.880 7.632 7.995 7.811 
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21 H H 3-OMe-Ph 3,4-diF-Ph H 7.8 7.740 7.532 7.411 7.516 
22 H H 3-OMe-Ph 4-NHSO2Me-Ph H 7.8 7.860 7.532 7.883 7.835 
23 H H 3-OMe-Ph 4-CN-Ph H 7.8 7.740 7.532 7.843 7.822 
24 H H 3-OMe-Ph 4-CONH(CH2)2NMe2-Ph H 7.8 7.860 7.532 7.576 7.829 
25 H H Ph 4-CONH(CH2)2NMe2-Ph H 7.7 7.760 7.432 7.696 7.547 
26 H H 3-OMe-Ph 3-OMe-Ph H 7.6 7.660 7.332 7.683 7.462 
27 H H 3-Pyridyl 4-Pyridyl H 7.5 7.560 7.232 7.520 7.271 
28 H H 3-OMe-Ph 4-OMe-Ph H 7.5 7.440 7.232 7.113 7.154 
29 H H 3-OMe-Ph 4-Pyridyl iPr 7.5 7.440 7.232 7.134 7.131 
30 H Me 3-OMe-Ph 4-Pyridyl H 7.2 7.140 6.932 7.311 7.004 
31 H H Ph 4-Pyridyl H 7.0 6.940 6.785 6.579 6.749 
32 H H 3-OEt-Ph 4-Pyridyl H 7.0 7.060 6.785 7.428 7.195 
33 H H Ph 3-OMe-4-OH-Ph H 7.0 7.060 6.785 6.334 6.520 
34 H H 3-OMe-Ph 2-F-Ph H 6.9 6.840 6.785 6.241 6.543 
35 H H 2-Me-Ph 4-Pyridyl H 6.8 6.740 6.785 6.481 6.533 
36 H H 3-OMe-Ph 4-OAllyl-Ph H 6.8 6.740 6.785 6.458 6.557 
37 H H 3-Br-Ph 4-Pyridyl H 6.6 6.540 6.785 6.507 6.541 
38 H H 3-OCF3-Ph 4-Pyridyl H 6.5 6.560 6.768 6.167 6.247 
39 H H 3-NHCOnPr-Ph 4-Pyridyl H 6.2 6.260 6.468 6.069 6.194 
40 H H Ph 4-F-Ph H 6.2 6.260 6.468 6.312 6.340 
41 H H 4-OMe-Ph 4-Pyridyl H 6.0 5.940 6.268 6.148 6.038 
42 H H 2-Pyridyl 4-Pyridyl H 5.9 5.959 6.168 6.394 6.458 
43 H H 3-NHCH2cyPr-Ph 4-Pyridyl H 5.7 5.640 5.968 5.904 5.847 
44 H H 2-OMe-Ph 4-Pyridyl H 5.6 5.660 5.868 5.812 6.054 
45 H H iPr 3-OMe-4-OH-Ph H 5.6 5.660 5.868 6.127 5.986 
46 H H 3-OMe-Ph 4-O(4-F)Bn-Ph H 5.6 5.660 5.868 5.582 5.717 
47 H H 3-OMe-Ph 4-NEt2-Ph H 5.6 5.660 5.868 5.952 6.015 
48 H H H 3-OMe-4-OH-Ph H 5.5 5.560 5.768 5.827 6.104 
49 H H 3-NHnPr-Ph 4-Pyridyl H 5.4 5.340 5.668 5.883 5.875 
50 H Me 3-OMe-Ph 4-Pyridyl Me 5.2 5.260 5.468 6.376 6.143 
51 Cl H Ph 3-OMe-4-OH-Ph H 5.0 5.060 5.268 5.382 5.436 
52 Ph H Ph 3-OMe-4-OH-Ph H 5.0 5.060 5.268 5.473 5.795 
53 H Me Ph 3-OMe-4-OH-Ph H 5.0 5.060 5.268 5.129 5.402 
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54 H H Bn 3-OMe-4-OH-Ph H 5.0 5.060 5.268 5.367 5.362 
55 H H 3-OMe-Ph 2-OMe-Ph H 4.6 4.660 4.868 5.278 5.191 
56 H H 4-Me-Ph 4-Pyridyl H 4.5 4.560 4.768 5.039 5.299 
57 H H 3-NO2-Ph 4-Pyridyl H 4.5 4.560 4.768 5.097 5.110 
58 H H 3-OMe-Ph 4-Me-Ph H 4.5 4.560 4.768 5.982 5.811 
59 H H 3-OMe-Ph 4-Ph-Ph H 4.5 4.560 4.768 5.050 5.172 
60 cyPent 3-Pyridyl – – – 8.3 8.240 8.032 8.029 7.797 
61 cyPent Ph – – – 7.6 7.540 7.332 7.137 7.278 
62 cyPent 4-OMe-Ph – – – 7.5 7.440 7.232 6.931 7.142 
63 CHMe2 4-OMe-Ph – – – 6.9 6.840 6.785 6.773 6.758 
64 cyPr Ph – – – 6.8 6.740 6.785 6.585 6.935 
65 cyPent 4-Me-Ph – – – 6.6 6.660 6.785 6.712 6.600 
66 cyPr 4-OMe-Ph – – – 6.5 6.560 6.768 6.672 6.592 
67 (CH2)4Me 4-OMe-Ph – – – 6.4 6.340 6.668 6.185 6.413 
68 (CH2)2SMe 4-OMe-Ph – – – 6.3 6.360 6.568 6.332 6.372 
69 cyPent 4-Cl-Ph – – – 6.3 6.360 6.568 6.358 6.363 
70 cyPr 4-Me-Ph – – – 6.2 6.260 6.468 6.352 6.474 
71 cyPr 4-Cl-Ph – – – 6.0 6.060 6.268 6.117 6.248 
72 cyHe 4-OMe-Ph – – – 5.7 5.760 5.968 5.958 5.857 
73 Pyrrolidinyl 4-OMe-Ph – – – 5.7 5.760 5.968 6.005 6.074 
74 2-Furanyl 4-OMe-Ph – – – 5.6 5.660 5.868 5.831 5.953 
75 3-F-Ph 4-OMe-Ph – – – 4.5 4.560 4.768 4.932 5.086 
76
b 
H H 3-OMe-Ph 3-SO2Me-Ph H 8.4 7.570 6.785 5.921 6.353 
77
b
 H H 3-OMe-Ph 4-O(CH2)2NMe2-Ph H 8.2 7.781 6.785 6.574 6.507 
78
b
 H H 3-OMe-Ph 4-F-Ph H 8.1 7.329 6.785 7.157 7.334 
79
b
 H H 3-OMe-Ph Ph H 8.0 7.782 6.785 7.371 6.851 
80
b
 H H 3-OMe-Ph 4-Pyridyl Et 7.9 7.188 6.785 7.786 7.299 
81
b
 H H 3-OMe-Ph 4-COOH-Ph H 7.5 7.787 6.785 7.024 7.440 
82
b
 H H 3-OMe-2-Pyridyl 4-Pyridyl H 7.4 6.945 6.785 7.767 7.480 
83
b
 H H 2-Thiazolyl 4-Pyridyl H 7.4 6.258 6.785 6.648 7.091 
84
b
 H H 3-Me-Ph 4-Pyridyl H 6.8 6.472 6.785 6.225 5.986 
85
b
 H H 3-NHAc-Ph 4-Pyridyl H 6.8 7.396 6.785 6.461 6.541 
86
b
 H H 3-F-Ph 4-Pyridyl H 6.5 7.402 6.785 7.619 7.439 
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87
b
 cyPr 3-Pyridyl – – – 8.3 7.394 6.785 7.949 7.673 
88
b
 cyPent 4-F-Ph – – – 6.7 6.786 6.785 6.534 6.763 
89
b
 CH2cyPent 4-OMe-Ph – – – 6.5 6.592 6.785 6.184 6.274 
90
b
 cyPr 4-F-Ph – – – 6.2 6.313 6.785 6.554 6.650 
91
b
 Morpholinyl 4-OMe-Ph – – – 4.5 5.545 6.785 6.467 6.038 
a
 Ac = Acetyl, Br = Bromo, Bu = Butyl, Bn = Benzyl, Cl = Chloro, Et = Ethyl, He = Hexyl, Me = Methyl, Pent = Pentyl, Ph = Phenyl, 
Pr = Propyl, n = normal, cy = cyclo; 
b
 Test set. 
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Appendix: E. Structures and bioactivities of the compounds 
in Group IV. 
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No. R1
a 
R2
a 
R3
a 
R4
a 
pIC50 
Expt. Model 
I II III IV 
1 5-Br H Me H 8.456 7.477 8.408 7.818 7.736 
2 5-F H H H 7.943 6.648 7.895 7.543 7.415 
3 5-F H (CH2)2OMe H 7.444 7.426 7.396 7.145 7.127 
4 5-F H Me H 7.310 7.292 7.358 7.271 7.150 
5 5-NO2 H (CH2)2OMe H 7.284 7.302 7.236 7.295 7.255 
6 5-CN H H H 7.092 7.073 7.043 6.892 6.921 
7 5-OBn H (CH2)3OH H 7.000 6.982 6.952 6.757 6.865 
8 H H Me Me 6.921 6.903 6.873 6.495 6.768 
9 5-OBn H (CH2)2OMe H 6.886 6.868 6.838 6.787 6.820 
10 5-F 5-Cl (CH2)2OMe H 6.783 6.801 6.802 6.665 6.703 
11 5-Cl H (CH2)2OMe H 6.420 6.402 6.372 6.540 6.464 
12 6-F H H H 6.272 6.253 6.320 6.486 6.570 
13 5-OBn 5-Cl (CH2)2OMe H 6.125 6.143 6.173 6.243 6.260 
14 5-Br H H H 6.071 6.088 6.119 6.376 6.400 
15 5-Cl H Me H 5.959 6.263 5.910 6.141 6.174 
16 5-OBn H Me H 5.921 5.939 5.969 6.025 6.133 
17 6-NO2 H Me H 5.886 5.904 5.934 5.987 6.212 
18 H H (CH2)3OH H 5.745 5.727 5.793 5.684 5.967 
19 H H (CH2)2OMe H 5.602 6.122 5.650 6.109 6.071 
20 H H Me H 5.585 5.573 5.633 5.680 5.817 
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21 6-Cl H Me H 5.509 5.347 5.556 5.673 5.735 
22 H 5-Cl Me H 5.509 5.527 5.556 5.728 5.816 
23 H 5-Cl (CH2)3OH H 5.444 5.462 5.492 5.555 5.647 
24 5-Cl H (CH2)3OH H 5.301 5.283 5.349 5.787 5.791 
25 H H H H 4.921 4.939 4.969 5.411 5.615 
26 7-CH2OMe H Me – 9.638 8.838 9.591 8.718 8.612 
27 5-F 6-CH2OH Me – 9.456 9.438 9.408 8.590 8.572 
28 7-CH2OMe 6-CH2OH Me – 9.137 9.119 9.089 8.710 8.667 
29 5-F-6-Cl 6-CH2OH Me – 9.022 9.004 8.974 8.289 8.037 
30 5-F 6-OH Me – 8.456 8.438 8.408 7.954 7.928 
31 7-CH2OH H Me – 8.268 8.250 8.220 8.223 8.132 
32 5-Br H Me – 8.155 8.137 8.107 7.766 7.752 
33 5-C≡CH H Me – 8.018 8.036 7.970 7.586 7.580 
34 7-(CH2)2COOEt H Me – 7.991 8.009 7.943 8.072 7.819 
35 5-CN 6-CH2OH Me – 7.879 7.897 7.832 7.807 7.759 
36 6-OH 5-F Me – 7.854 7.872 7.831 7.701 7.738 
37 6-OH H Me – 7.824 7.806 7.776 7.754 7.628 
38 5-C≡CcyPr 5-F Me – 7.793 7.811 7.745 7.571 7.496 
39 5-F 6-CH2OMe Me – 7.623 8.746 7.672 7.848 7.676 
40 5-F H Me – 7.585 7.567 7.537 7.570 7.405 
41 5-Cl 5-F Me – 7.377 7.359 7.329 7.211 7.258 
42 5-Br 6-OCH2CH=CH2 Me – 7.316 7.298 7.268 7.228 7.194 
43 7-OH H Me – 7.260 7.242 7.212 7.269 7.206 
44 5,7-diBr 7-OMe Me – 7.052 7.070 7.004 7.274 7.157 
45 5-OMe H Me – 6.903 6.885 6.951 6.826 6.959 
46 6-OBn 5-F Me – 6.796 6.778 6.773 6.692 6.722 
47 H 7-OMe Me – 6.745 6.763 6.793 7.058 6.963 
48 5-F-6-Cl H Me – 6.735 6.753 6.783 6.865 6.802 
49 7-OBn H Me – 6.658 6.639 6.638 6.650 6.626 
50 5-F-6-I 7-OMe Me – 6.607 6.590 6.655 6.641 6.780 
51 5-F-6-Cl 7-OMe Me – 6.585 6.567 6.633 6.586 6.627 
52 5-Br 6-O-(4-OMe)-Bn Me – 6.475 6.493 6.523 6.644 6.601 
53 5-F H H – 6.444 6.448 6.492 6.715 6.524 
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a 
Br = Bromo, Bu 
= Butyl, Bn = 
Benzyl, Cl = 
Chloro, Et = 
Ethyl, Me = 
Methyl, Ph = 
Phenyl, Pr = 
Propyl, cy = cyclo 
; 
b
 Test set. 
 
  
54 5-OMe-6-Cl H Me – 6.357 6.339 6.405 6.445 6.496 
55 5-OBn H Me – 6.301 6.319 6.253 6.215 6.325 
56 H 5-Br Me – 6.260 6.671 6.308 6.689 6.789 
57 H 5-F H – 6.174 6.192 6.222 6.402 6.412 
58 5-OH H Me – 6.161 7.051 6.209 6.479 6.600 
59 5,6-methylenedioxy 5-F Me – 6.149 6.167 6.197 6.634 6.553 
60 6-CF3 7-OMe Me – 6.081 6.099 6.129 6.239 6.569 
61 5-F-6-Cl 6-OMe Me – 6.060 6.079 6.109 6.434 6.492 
62 5-OBn H H – 5.783 5.800 5.830 6.026 6.035 
63 5-F-6-Cl 6-OCH2cyBu Me – 5.388 5.407 5.436 6.080 6.008 
64 5-F-6-(4-Cl)-Ph 7-OMe Me – 5.145 5.163 5.193 5.656 5.736 
65 – – – – 7.379 7.361 7.331 7.350 7.227 
66 – – – – 7.301 7.283 7.253 7.165 7.109 
67
b
 H H Me (CH2)2OMe 7.310 7.488 6.445 6.395 6.724 
68
b
 7-OBn H (CH2)2OMe H 6.398 6.495 6.789 7.059 6.748 
69
b
 6-OBn H (CH2)2OMe H 6.347 6.525 6.768 6.939 6.775 
70
b
 5-NO2 H Me H 6.337 7.122 6.529 6.725 6.705 
71
b
 6-Me 5-Cl (CH2)2OMe H 5.620 5.974 6.515 6.250 6.194 
72
b
 5-Br 6-CH2OH Me – 9.292 9.547 7.234 7.915 7.893 
73
b
 7-(CH2)2COOH H Me – 8.921 8.541 7.313 8.285 8.040 
74
b
 7-CH2OH 6-CH2OH Me – 8.292 9.003 7.939 7.899 8.113 
75
b
 5-Br 7-OMe Me – 8.125 8.735 7.118 7.353 7.190 
76
b
 5-Br 6-OCH2C≡CH Me – 7.597 7.192 7.054 7.325 7.144 
77
b
 5-I H Me – 7.462 6.346 6.860 6.863 7.197 
78
b
 H H Me – 7.456 5.717 6.427 6.803 6.793 
79
b
 5-I 5-F Me – 6.745 6.715 6.829 7.056 7.228 
80
b
 5-OBn H (CH2)3OH – 6.658 7.062 6.801 6.904 6.889 
81
b
 5-OMe-6-I H Me – 6.652 5.873 6.813 6.561 6.765 
82
b
 5-cyPr H Me – 6.629 7.712 6.830 6.902 7.086 
83
b
 1H-benzo[g] 5,6-diF Me – 6.503 6.902 6.816 7.242 7.061 
84
b
 6-OBn H Me – 6.046 6.503 6.562 6.516 6.621 
85
b
 5-F-6-Cl 6-OCH2cyPr Me – 5.889 5.429 6.354 6.604 6.544 
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Appendix: F. Structures and bioactivities of the compounds in 
Group V. 
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No. R1
a 
R2
a 
pIC50 
Expt. Model 
I II III IV 
1 3,4-(OMe)2-Ph 3-Cl-Ph 9.398 9.286 9.374 9.025 9.043 
2 3,4-(OMe)2-Ph 3-OMe-Ph 9.398 9.286 9.374 9.112 9.075 
3 4-OMe-Ph 3-OMe-Ph 9.097 8.985 9.073 8.864 8.840 
4 4-OMe-Ph 3-Cl-Ph 8.721 8.833 8.697 8.521 8.574 
5 4-OMe-Ph 4-OMe-Ph 8.699 8.329 8.675 8.366 8.384 
6 4-OMe-3-Pyridyl 4-OMe-Ph 8.699 8.705 8.675 8.687 8.650 
7 4-OMe-Ph 4-Cl-Ph 8.699 8.587 8.675 8.547 8.512 
8 4-OMe-Ph 3-Pyridyl 8.699 8.587 8.675 8.684 8.601 
9 3,4-(OMe)2-Ph 4-Cl-Ph 8.699 8.587 8.675 8.535 8.472 
10 3,4-(OMe)2-Ph 4-CN-Ph 8.699 8.750 8.675 8.544 8.551 
11 3,4-(OMe)2-Ph 4-NEt2-Ph 8.699 8.587 8.675 8.514 8.551 
12 3,4-(OMe)2-Ph 4-Morpholinyl-Ph 8.523 8.411 8.499 8.488 8.436 
13 3,4-(OMe)2-Ph Ph 8.456 8.568 8.432 8.486 8.437 
14 3,4-(OMe)2-Ph 4-Pyridyl 8.456 8.568 8.432 8.328 8.337 
15 4-OMe-3-Pyridyl Ph 8.347 8.235 8.323 8.183 8.170 
16 3-OMe-Ph 3-OMe-Ph 8.301 8.405 8.325 8.372 8.331 
17 3-OMe-Ph 4-COOH-Ph 8.187 8.076 8.163 8.166 8.165 
18 4-OMe-3-Pyridyl 4-COOH-Ph 8.114 8.226 8.090 8.269 8.244 
19 3-OMe-Ph 3-Cl-Ph 8.097 8.209 8.072 8.127 8.077 
20 3-OMe-Ph 2-Pyridyl 8.097 7.988 8.073 7.976 8.015 
21 4-OMe-Ph 4-Morpholinyl-Ph 8.097 7.985 8.073 7.887 7.947 
22 3-OMe-Ph 4-Cl-Ph 8.046 8.158 8.022 7.968 8.012 
23 3-OMe-Ph 4-NMe2-Ph 8.046 7.934 8.022 8.040 7.945 
24 4-OMe-Ph 4-Pyridyl 7.854 8.199 7.878 7.839 7.875 
25 4-OMe-3-Pyridyl 4-Pyridyl 7.796 7.908 7.772 7.695 7.715 
26 3-OMe-Ph 4-OMe-Ph 7.745 7.857 7.768 7.999 7.977 
27 Ph 4-OMe-Ph 7.699 7.587 7.675 7.702 7.695 
28 3-Pyridyl 4-OMe-Ph 7.699 7.811 7.675 7.673 7.714 
29 Ph 4-Cl-Ph 7.638 7.526 7.614 7.264 7.322 
30 3-OMe-Ph 4-Pyridyl 7.638 7.527 7.662 7.507 7.458 
31 4-OMe-3-Pyridyl 3-Pyridyl 7.638 7.750 7.662 7.828 7.815 
32 3-OMe-Ph Ph 7.409 7.516 7.404 7.571 7.537 
33 3,4-(OMe)2-Ph 2-Cl-Ph 7.357 7.363 7.381 7.585 7.761 
34 4-OMe-3-Pyridyl 4-Morpholinyl-Ph 7.301 7.413 7.325 7.635 7.628 
35 3-OMe-Ph 4-Morpholinyl-Ph 7.229 7.341 7.254 7.512 7.546 
36 3,4-(OMe)2-Ph 4-NMe2-Ph 7.060 7.173 7.085 7.645 7.788 
37 Ph Ph 7.004 7.116 7.028 6.784 6.777 
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38 4-OMe-Ph 4-NMe2-Ph 6.959 7.070 6.983 7.360 7.551 
39 Ph 3-Cl-Ph 6.921 7.033 6.944 6.925 6.972 
40 3-Pyridyl 2-Cl-Ph 6.699 6.586 6.675 6.483 6.558 
41 4-OMe-3-Pyridyl 2-OMe-Ph 6.569 6.615 6.592 6.875 6.974 
42 Me 2-Cl-Ph 6.337 6.439 6.361 6.058 6.159 
43 2-Pyridyl 4-OMe-Ph 6.194 6.306 6.218 6.695 6.755 
44 2-Pyridyl 2-Cl-Ph 6.187 6.142 6.211 6.263 6.277 
45 Ph 2-Cl-Ph 6.143 6.255 6.167 6.208 6.319 
46 3-OMe-Ph 2-Cl-Ph 6.071 6.183 6.095 6.497 6.529 
47 H 2-Cl-Ph 5.827 5.715 5.851 5.874 5.994 
48 iPr 2-Cl-Ph 5.432 5.544 5.456 5.826 5.815 
49 Ph 2-OMe-Ph 5.398 5.510 5.422 5.916 5.949 
50
b 
3,4-(OMe)2-Ph 4-OMe-Ph 8.699 9.291 8.636 8.740 8.730 
51
b
 4-OMe-Ph 4-CN-Ph 8.699 8.460 8.464 8.523 8.407 
52
b
 4-OMe-3-Pyridyl 4-Cl-Ph 8.523 8.541 8.043 7.893 7.853 
53
b
 3,4-(OMe)2-Ph 3-Pyridyl 8.456 8.956 8.057 8.426 8.334 
54
b
 4-OMe-3-Pyridyl 3-OMe-Ph 8.432 9.106 8.259 8.546 8.431 
55
b
 3-OMe-Ph 4-CN-Ph 8.398 8.024 7.921 7.977 7.999 
56
b
 4-OMe-3-Pyridyl 4-CN-Ph 8.081 8.463 7.982 7.661 7.710 
57
b
 3,4,5-(OMe)3-Ph 4-OMe-Ph 8.046 8.043 7.607 8.798 8.625 
58
b
 4-OMe-Ph 4-NEt2-Ph 7.796 7.452 7.571 7.374 7.521 
59
b
 4-Pyridyl 4-OMe-Ph 7.523 7.205 7.769 7.249 7.321 
60
b
 3-OMe-Ph 3-Pyridyl 7.523 7.979 7.742 7.751 7.707 
61
b
 Ph 3-OMe-Ph 7.456 7.487 7.689 7.619 7.684 
62
b
 4-Pyridyl 2-Cl-Ph 6.602 6.732 6.761 6.415 6.425 
a 
Cl = Chloro, Et = Ethyl, Me = Methyl, Ph = Phenyl, i = iso; 
b 
Test set. 
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Appendix: G. Structures and bioactivities of the compounds 
in Group VI. 
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No. R1
a 
R2
a 
Ar1 Ar2 X Y Z pIC50 
Expt. Model 
I II III IV 
1 -S-CH2-(3-CN)-Ph 4-OMe-Ph r – N – – 8.638 8.558 8.566 8.378 8.429 
2 -S-CH2-(3-CF3)-Ph 4-OMe-Ph r – N – – 8.602 8.522 8.530 8.408 8.426 
3 -S-CH2-(3-CF3-4-OMe)-Ph – r – S – – 8.509 8.429 8.437 8.265 8.314 
4 -S-CH2-(3-CN)-Ph 4-OMe-Ph q – O CH C 8.456 8.504 8.384 8.397 8.336 
5 -S-CH2-(3-CF3-4-OMe)-Ph H q – O CH C 8.310 8.390 8.238 8.171 8.207 
6 -S-CH2-(3-CF3-4-OMe)-Ph H t – – – – 8.187 8.107 8.115 7.987 7.984 
7 -S-CH2-(3-CF3-4-OMe)-Ph 4-OMe-Ph r – N – – 8.066 7.986 7.994 8.031 8.087 
8 -S-CH2-(3-CF3)-Ph Me r – N – – 8.027 7.947 7.955 7.721 7.877 
9 -S-CH2-(3-Cl-4-OMe)-Ph H p – CH – – 7.886 7.806 7.814 7.778 7.521 
10 NH2 4-S(O)Me-Ph q – O CH C 7.886 7.806 7.814 7.257 7.446 
11 -S-CH2-(3-CF3-4-OMe)-Ph – s – – – – 7.745 7.664 7.672 7.970 7.850 
12 -S-CH2-(3-CF3-4-OMe)-Ph 4-OMe-Ph q – O CH C 7.602 7.682 7.530 7.990 7.854 
13 -S-CH2-(3-CN-4-OMe)-Ph H p – CH – – 7.553 7.473 7.481 7.877 7.470 
14 Me 4-S(O)Me-Ph q – O CH C 7.456 7.376 7.384 7.030 7.094 
15 Me 4-S(O)Et-Ph q – O CH C 7.456 7.376 7.384 7.106 7.198 
16 Me 4-S(O)2Me-Ph q – O CH C 7.377 7.296 7.305 6.882 7.226 
17 -S-CH2-(3-F-4-OMe)-Ph H p – CH – – 7.357 7.437 7.285 7.442 7.185 
18 Me 4-CO2H-Ph q – O CH C 7.301 7.221 7.229 6.881 7.146 
19 -S-CH2-(3-F)-Ph H p – CH – – 7.268 7.187 7.196 6.761 6.953 
20 Me 4-OMe-Ph q – O CH C 7.268 7.187 7.195 7.091 7.083 
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21 -S-CH2-(3-F-4-OMe)-Ph – p – O – – 7.187 7.267 7.169 7.054 7.128 
22 Me 4-SMe-Ph q – O CH C 7.18 7.26 7.108 6.689 7.054 
23 -S-CH2-(3-CF3)-Ph H p – CH – – 7.167 7.247 7.239 6.980 7.209 
24 Me 4-CONH2-Ph q – O CH C 7.161 7.081 7.092 6.909 7.100 
25 Me 3-OMe-Ph q – O CH C 7.131 7.211 7.141 6.862 7.025 
26 SH 4-S(O)Me-Ph q – O CH C 7.027 7.107 7.067 6.980 6.935 
27 Me 4-F-Ph q – O CH C 6.959 7.039 7.031 6.866 6.929 
28 OH 4-S(O)Me-Ph q – O CH C 6.886 6.966 6.958 6.976 6.953 
29 Me 4-C(OH)Me-Ph q – O CH C 6.796 6.876 6.868 6.933 6.858 
30 Me 4-OH-Ph q – O CH C 6.745 6.825 6.817 6.801 6.808 
31 -S-CH2-(2-Cl)-Ph H p – CH – – 6.699 6.779 6.771 6.551 6.708 
32 Me 4-CO2Me-Ph q – O CH C 6.699 6.779 6.771 6.688 6.854 
33 Me 4-S(O)Me-Ph r – N – – 6.699 6.619 6.771 6.746 6.628 
34 -S-CH2-Ph H p – CH – – 6.678 6.597 6.750 6.760 6.689 
35 -S-CH2-(4-OMe)-Ph H p – CH – – 6.658 6.612 6.730 6.891 6.741 
36 Me 4-S(O)Me-Ph u – N CH CH 6.569 6.489 6.641 6.752 6.586 
37 -S-CH2-(4-Cl)-Ph H p – CH – – 6.553 6.472 6.625 6.517 6.647 
38 Me 4-P(O)(OMe)2-Ph q – O CH C 6.553 6.633 6.625 6.712 6.867 
39 -NH-CH2-(3-F)-Ph H p – CH – – 6.481 6.402 6.418 6.523 6.537 
40 -S-CH2-(3-CO2Me)-Ph H p – CH – – 6.201 6.281 6.273 6.560 6.638 
41 -CH2-S-(3-F)-Ph H p – CH – – 6.167 6.136 6.239 6.429 6.383 
42 Me 4-S(O)Me-Ph t – – – – 6.000 6.080 6.072 6.609 6.320 
43 Me 4-S(O)Me-Ph u – CH CH N 6.000 6.007 6.072 6.280 6.366 
44 Me 4-S(O)Me-Ph u – CH N CH 6.000 5.920 6.072 6.330 6.305 
45 -O-CH2-(3-F)-Ph H p – CH – – 5.000 5.080 5.072 6.104 5.755 
46 4-S(O)Me-Ph – – v S N N 7.143 7.063 7.070 6.728 6.947 
47 4-S(O)Me-Ph – – v N O N 6.167 6.247 6.239 6.474 6.369 
48 4-S(O)Me-Ph – – w – – – 6.000 6.080 6.072 6.364 6.386 
49 4-S(O)Me-Ph – – v N N O 6.000 6.080 6.072 6.459 6.306 
50
b 
-S-CH2-(3-CF3-4-OMe)-Ph H p – CH – – 8.244 8.116 7.329 7.826 7.702 
51
b
 -S-CH2-(3-CF3)-Ph 4-OMe-Ph q – O CH C 8.076 8.538 7.497 8.362 8.167 
52
b
 -S-CH2-(3-CF3-4-OMe)-Ph H q – NH N C 7.796 8.010 7.368 7.430 7.655 
53
b
 Me 4-S(O)2Et-Ph q – O CH C 7.420 7.109 7.255 6.862 7.209 
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54
b
 Me 4-Pyridyl q – O CH C 7.114 6.798 7.137 6.857 6.797 
55
b
 -S-CH2-(3-CN)-Ph H p – CH – – 7.041 6.763 7.058 6.621 6.874 
56
b
 -S-CH2-(3-Cl)-Ph H p – CH – – 7.027 7.010 6.963 6.591 6.706 
57
b
 Me 4-COMe-Ph q – O CH C 7.000 7.111 7.001 6.634 7.054 
58
b
 Me 3-S(O)Me-Ph q – O CH C 6.678 6.873 7.091 6.812 6.968 
59
b
 -CH2-CH2-(3-F)-Ph H p – CH – – 6.469 6.268 6.748 6.419 6.714 
60
b
 Me 4-S(O)Me-Ph q – S CH C 6.102 6.482 7.114 6.759 6.850 
61
b
 4-S(O)Me-Ph – – v NH N N 7.092 6.932 6.967 6.804 6.676 
a 
Cl = Chloro, Et = Ethyl, Me = Methyl, Ph = Phenyl; 
b 
Test set. 
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Appendix: H. Structures and bioactivities of the compounds 
in Group VII. 
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No. R1
a 
R2
a 
R3
a 
pIC50 
Expt. Model 
I II III IV 
1 Br 4-OH-Ph H 8.301 8.241 8.285 8.015 7.839 
2 Ph F F 8.222 8.162 8.206 7.782 7.760 
3 Ph Cl H 8.155 8.095 8.139 7.938 7.731 
4 4-NH2-Ph Cl H 8.097 8.037 8.081 7.861 7.982 
5 4-OH-Ph Cl H 8.000 8.060 7.984 7.942 7.948 
6 Ph Cl Cl 7.921 8.060 7.904 7.895 7.835 
7 4-Me-Ph Cl H 7.854 7.794 7.838 7.333 7.481 
8 2-Furanyl 4-OH-Ph H 7.854 7.794 7.838 7.878 7.769 
9 4-NO2-Ph Cl H 7.745 7.778 7.729 7.680 7.601 
10 4-F-Ph Cl H 7.658 7.718 7.641 7.833 7.736 
11 4-OBn-Ph Cl H 7.638 7.578 7.622 7.697 7.394 
12 H 3,4-diOH-Ph H 7.569 7.508 7.553 7.292 7.066 
13 H 4-OH-Ph H 7.357 7.296 7.341 6.843 6.695 
14 4-Et-Ph 4-OH-Ph H 7.310 7.370 7.294 6.614 6.849 
15 4-Pyridyl Cl H 7.301 7.241 7.285 7.528 7.478 
16 H 2-Cl-4-OH-Ph H 7.260 7.320 7.244 7.352 7.240 
17 Ph 4-OH-Ph H 7.260 7.200 7.244 7.085 7.099 
18 H 4-NH2-Ph H 7.119 7.179 7.103 6.673 6.517 
19 H 3-OH-Ph H 7.027 7.087 7.043 6.994 6.854 
20 3-Furanyl 4-OH-Ph H 7.009 7.069 6.992 6.901 6.996 
21 3-Pyridyl 4-OH-Ph H 6.827 6.767 6.811 6.299 6.689 
22 H CF3 H 6.710 6.770 6.694 6.573 6.518 
23 H Br H 6.703 6.643 6.687 6.571 6.533 
24 H 3-Furanyl H 6.585 6.525 6.569 6.483 6.343 
25 H 4-Pyridyl H 6.180 6.240 6.163 5.878 6.008 
26 H 4-OBn-Ph H 5.927 5.867 5.943 5.373 5.610 
27 H Ph H 5.892 5.952 5.909 6.123 5.747 
28 Ph Ph H 5.764 5.825 5.78 6.250 6.200 
29 H (E)-CH=CHMe H 5.609 5.669 5.626 5.652 5.832 
30 H 3,5-diF-Ph H 5.539 5.498 5.554 5.217 5.636 
31 H 4-tBu-Ph H 5.419 5.479 5.435 5.152 5.302 
32 H 4-F-Ph H 5.300 5.346 5.316 5.555 5.635 
33 H 3,5-diCl-Ph H 5.267 5.207 5.282 5.014 5.598 
34 H CH2Bn H 5.069 5.009 5.085 5.521 5.439 
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35 4-OBn-Ph 4-OBn-Ph H 5.000 5.060 5.016 5.086 5.572 
36 H 4-CF3-Ph H 4.977 4.917 4.993 4.928 5.072 
37 H 3-Pyridyl H 4.963 4.903 4.979 5.605 5.376 
38 H 4-NMe2-Ph H 4.912 4.852 4.928 4.828 4.979 
39 H 2-OH-5-Pyridyl H 4.775 4.835 4.791 5.812 5.537 
40 H 4-Me-Ph H 4.767 4.706 4.783 4.878 4.846 
41 H 4-CN-Ph H 4.688 4.747 4.704 5.270 5.111 
42 H 4-NO2-Ph H 4.000 4.060 4.016 4.559 4.619 
43 H 4-OMe-Ph H 4.000 4.060 4.016 4.469 4.518 
44 H 4-Et-Ph H 4.000 4.060 4.016 4.741 4.466 
45 H 4-Cl-Ph H 4.000 4.137 4.016 4.458 4.571 
46
 – – – 5.928 5.989 5.944 5.734 6.005 
47
b
 3-Furanyl Cl H 7.959 6.917 6.475 6.437 6.775 
48
b
 4-Et-Ph Cl H 7.921 7.721 6.823 6.748 7.145 
49
b
 Br Cl H 7.260 6.796 6.266 6.478 6.891 
50
b
 4-OH-Ph 4-OH-Ph H 7.252 6.862 6.665 7.271 7.120 
51
b
 H Cl H 6.451 6.204 6.291 5.821 6.152 
52
b
 H 3-Thienyl H 6.029 6.926 6.186 7.334 6.334 
53
b
 H 2-NH2-5-Pyridyl H 5.963 4.856 5.954 5.939 5.844 
54
b
 H 2-Cl-Ph H 5.869 6.404 6.209 6.169 6.499 
55
b
 H Bn H 5.383 4.656 5.554 5.467 5.555 
56
b
 H 4-OCF3-Ph H 5.260 4.684 6.192 5.618 5.933 
57
b
 H 4-SMe-Ph H 5.145 5.244 5.507 4.808 5.003 
58
b
 H 3,4-methylenedioxy-Ph H 4.601 5.228 6.170 6.836 6.223 
a 
Br = Bromo, Bn = Benzyl, Cl = Chloro, Et = Ethyl, Me = Methyl, Ph = Phenyl; 
b 
Test set. 
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Appendix: I. Features selected for Group I by RBE-RF.  
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Name Block Description 
J Topological 
descriptors 
Balaban distance connectivity index 
MAXDP Topological 
descriptors 
maximal electrotopological positive variation 
D/Dr05 Topological 
descriptors 
distance/detour ring index of order 5 
D/Dr09 Topological 
descriptors 
distance/detour ring index of order 9 
T(N..N) Topological 
descriptors 
sum of topological distances between N..N 
SIC1 Information indices structural information content (neighborhood symmetry of 
1-order) 
IC2 Information indices information content index (neighborhood symmetry of 2-
order) 
SIC2 Information indices structural information content (neighborhood symmetry of 
2-order) 
IC3 Information indices information content index (neighborhood symmetry of 3-
order) 
MATS1v 2D autocorrelations Moran autocorrelation − lag 1 / weighted by atomic van 
der Waals volumes 
MATS1e 2D autocorrelations Moran autocorrelation − lag 1 / weighted by atomic 
Sanderson electronegativities 
MATS3e 2D autocorrelations Moran autocorrelation − lag 3 / weighted by atomic 
Sanderson electronegativities 
MATS5e 2D autocorrelations Moran autocorrelation − lag 5 / weighted by atomic 
Sanderson electronegativities 
MATS1p 2D autocorrelations Moran autocorrelation − lag 1 / weighted by atomic 
polarizabilities 
GATS4e 2D autocorrelations Geary autocorrelation − lag 4 / weighted by atomic 
Sanderson electronegativities 
EEig06x Edge adjacency 
indices 
Eigenvalue 06 from edge adj. matrix weighted by edge 
degrees 
EEig07x Edge adjacency 
indices 
Eigenvalue 07 from edge adj. matrix weighted by edge 
degrees 
EEig01r Edge adjacency 
indices 
Eigenvalue 01 from edge adj. matrix weighted by 
resonance integrals 
ESpm01d Edge adjacency 
indices 
Spectral moment 01 from edge adj. matrix weighted by 
dipole moments 
HOMA Geometrical 
descriptors 
Harmonic Oscillator Model of Aromaticity index 
HOMT Geometrical 
descriptors 
HOMA total (trial) 
G(N..N) Geometrical 
descriptors 
sum of geometrical distances between N..N 
RDF105u RDF descriptors Radial Distribution Function − 10.5 / unweighted 
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RDF035m RDF descriptors Radial Distribution Function − 3.5 / weighted by atomic 
masses 
RDF105v RDF descriptors Radial Distribution Function − 11.5 / weighted by atomic 
van der Waals volumes 
RDF105e RDF descriptors Radial Distribution Function − 10.5 / weighted by atomic 
Sanderson electronegativities 
RDF105p RDF descriptors Radial Distribution Function − 10.5 / weighted by atomic 
polarizabilities 
Mor16u 3D-MoRSE 
descriptors 
3D-MoRSE − signal 16 / unweighted 
Mor16e 3D-MoRSE 
descriptors 
3D-MoRSE − signal 16 / weighted by atomic Sanderson 
electronegativities 
Ds WHIM descriptors D total accessibility index / weighted by atomic 
electrotopological states 
HATS4m GETAWAY 
descriptors 
leverage-weighted autocorrelation of lag 4 / weighted by 
atomic masses 
nRCONHR Functional group 
counts 
number of secondary amides (aliphatic) 
nHDon Functional group 
counts 
number of donor atoms for H-bonds (N and O) 
H–050 Atom-centered 
fragments 
H attached to heteroatom 
Hy Molecular properties hydrophilic factor 
TPSA(NO) Molecular properties topological polar surface area using N, O polar 
contributions 
TPSA(Tot) Molecular properties topological polar surface area using N, O, S, P polar 
contributions 
B01[N–O] 2D binary 
fingerprints 
presence/absence of N–O at topological distance 1 
B06[O–O] 2D binary 
fingerprints 
presence/absence of O–O at topological distance 6 
F06[O–O] 2D frequency 
fingerprints 
frequency of O–O at topological distance 6 
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Appendix: J. Features selected for Group II using PSA-SVM. 
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Name Block Description 
Ss Constitutional 
descriptors 
sum of Kier–Hall electrotopological states 
Ms Constitutional 
descriptors 
mean electrotopological state 
nR05 Constitutional 
descriptors 
number of 5-membered rings 
CSI Topological 
descriptors 
eccentric connectivity index 
ATS2p 2D autocorrelation 
indices 
Broto–Moreau autocorrelation of a topological structure − 
lag 2 / weighted by atomic polarizabilities 
MATS1p 2D autocorrelation 
indices 
Moran autocorrelation − lag 1 / weighted by atomic 
polarizabilities 
MATS3p 2D autocorrelation 
indices 
Moran autocorrelation − lag 3 / weighted by atomic 
polarizabilities 
GATS1v 2D autocorrelation 
indices 
Geary autocorrelation − lag 1 / weighted by atomic van der 
Waals volumes 
ESpm15u Edge adjacency 
indices 
Spectral moment 15 from edge adjacent matrix 
BEHv5 Burden eigenvalue 
descriptors 
highest eigenvalue n. 5 of Burden matrix / weighted by 
atomic van der Waals volumes 
VRA1 Eigenvalue-based 
indices 
Randic-type eigenvector-based index from adjacency 
matrix 
G(O..Cl) Geometrical 
descriptors 
sum of geometrical distances between O..Cl 
Mor27e 3D-MoRSE 
descriptors 
3D-MoRSE − signal 27 / weighted by atomic Sanderson 
electronegativities 
Tu WHIM descriptors T total size index / unweighted 
R6p GETAWAY 
descriptors 
R autocorrelation of lag 6 / weighted by atomic 
polarizabilities 
nArOH Functional group 
counts 
number of aromatic hydroxyls 
nHBonds Functional group 
counts 
number of intramolecular H-bonds 
F02[C–O] 2D frequency 
fingerprints 
frequency of C–O at topological distance 2 
F02[N–N] 2D frequency 
fingerprints 
frequency of N–N at topological distance 2 
F06[C–N] 2D frequency 
fingerprints 
frequency of C–N at topological distance 6 
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Appendix: K. Features selected for Group III using PSA-
SVM. 
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Name Block Description 
CIC1 Information indices complementary information content (neighborhood 
symmetry of 1-order) 
ATS6m 2D autocorrelation 
indices 
Broto–Moreau autocorrelation of a topological structure − 
lag 6 / weighted by atomic masses 
ATS7p 2D autocorrelation 
indices 
Broto–Moreau autocorrelation of a topological structure − 
lag 7 / weighted by atomic polarizabilities 
MATS8e 2D autocorrelation 
indices 
Moran autocorrelation − lag 8 / weighted by atomic 
Sanderson electronegativities 
GATS8m 2D autocorrelation 
indices 
Geary autocorrelation − lag 8 / weighted by atomic masses 
ESpm14x Edge adjacency 
indices 
Spectral moment 14 from edge adjacent matrix weighted 
by edge degrees 
QYYp Geometrical 
descriptors 
Qyy COMMA2 value / weighted by atomic polarizabilities 
RDF020u RDF descriptors Radial Distribution Function − 2.0 / unweighted 
Mor10e 3D-MoRSE 
descriptors 
3D-MoRSE − signal 10 / weighted by atomic Sanderson 
electronegativities 
G3u WHIM descriptors 3rd component symmetry directional WHIM index / 
unweighted 
HATS4u GETAWAY 
descriptors 
leverage-weighted autocorrelation of lag 4 / unweighted 
R4u GETAWAY 
descriptors 
R autocorrelation of lag 4 / unweighted 
C–037 Atom-centered 
fragments 
Ar–CH=X (Ar represents aromatic groups; X represents 
any electronegative atom) 
H–046 Atom-centered 
fragments 
H attached to C (sp3) no X attached to next C 
H–051 Atom-centered 
fragments 
H attached to alpha–C (a C attached through a single bond 
with –C=X, –C#X, –C–X) 
Hypertens-
80 
Molecular 
properties 
Ghose–Viswanadhan–Wendoloski antihypertensive-like 
index at 80% 
B10[C–N] 2D binary 
fingerprints 
presence/absence of C–N at topological distance 10 
F04[C–C] 2D frequency 
fingerprints 
frequency of C–C at topological distance 4 
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Appendix: L. Features selected for Group IV using PSA-
SVM. 
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Name Block Description 
JhetZ Topological 
descriptors 
Balaban-type index from Z weighted distance matrix 
(Barysz matrix) 
BAC Topological 
descriptors 
Balaban centric index 
piPC10 Walk and path counts molecular multiple path count of order 10 
EEig01d Edge adjacency 
indices 
Eigenvalue 01 from edge adjacent matrix weighted by 
dipole moments 
ESpm04u Edge adjacency 
indices 
Spectral moment 04 from edge adjacent matrix 
BELm6 Burden eigenvalue 
descriptors 
lowest eigenvalue n. 6 of Burden matrix / weighted by 
atomic masses 
QXXe Geometrical 
descriptors 
Qxx COMMA2 value / weighted by atomic Sanderson 
electronegativities 
RDF025e RDF descriptors Radial Distribution Function − 2.5 / weighted by atomic 
Sanderson electronegativities 
Mor07u 3D-MoRSE 
descriptors 
3D-MoRSE − signal 07 / unweighted 
Mor12u 3D-MoRSE 
descriptors 
3D-MoRSE − signal 12 / unweighted 
Mor29m 3D-MoRSE 
descriptors 
3D-MoRSE − signal 29 / weighted by atomic masses 
Mor02v 3D-MoRSE 
descriptors 
3D-MoRSE − signal 02 / weighted by atomic van der 
Waals volumes 
Mor19p 3D-MoRSE 
descriptors 
3D-MoRSE − signal 19 / weighted by atomic 
polarizabilities 
Ks WHIM descriptors K global shape index / weighted by atomic 
electrotopological states 
HATS0p GETAWAY 
descriptors 
leverage-weighted autocorrelation of lag 0 / weighted by 
atomic polarizabilities 
nArOR Functional group 
counts 
number of ethers (Ar represents aromatic group; R 
represents any group) 
C–024 Atom-centered 
fragments 
R–CH–R (R represents any group linked through carbon) 
Hypertens-
80 
Molecular properties Ghose–Viswanadhan–Wendoloski antihypertensive-like 
index at 80% 
F05[O–O] 2D frequency 
fingerprints 
frequency of O–O at topological distance 5 
F08[C–Cl] 2D frequency 
fingerprints 
frequency of C–Cl at topological distance 8 
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Appendix: M. Features selected for Group V using PSA-
SVM. 
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Name Block Description 
BEHv1 Burden eigenvalue 
descriptors 
highest eigenvalue n. 1 of Burden matrix / weighted by 
atomic van der Waals volumes 
JGI8 Topological charge 
indices 
mean topological charge index of order8 
RDF085u RDF descriptors Radial Distribution Function − 8.5 / unweighted 
RDF110v RDF descriptors Radial Distribution Function − 11.0 / weighted by atomic 
van der Waals volumes 
RDF105p RDF descriptors Radial Distribution Function − 10.5 / weighted by atomic 
polarizabilities 
Mor02m 3D-MoRSE 
descriptors 
3D-MoRSE − signal 02 / weighted by atomic masses 
Mor11v 3D-MoRSE 
descriptors 
3D-MoRSE − signal 11 / weighted by atomic van der 
Waals volumes 
Ts WHIM descriptors T total size index / weighted by atomic electrotopological 
states 
F09[C–C] 2D frequency 
fingerprints 
frequency of C–C at topological distance 9 
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Appendix: N. Features selected for Group VI using PSA-
SVM. 
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Name Block Description 
GMTIV Topological 
descriptors 
Gutman MTI by valence vertex degrees 
ATS4v 2D autocorrelation 
indices 
Broto–Moreau autocorrelation of a topological structure − 
lag 4 / weighted by atomic van der Waals volumes 
EEig04d Edge adjacency 
indices 
Eigenvalue 04 from edge adjacent matrix weighted by dipole 
moments 
EEig01r Edge adjacency 
indices 
Eigenvalue 01 from edge adjacent matrix weighted by 
resonance integrals 
DP04 Randic molecular 
profiles 
molecular profile no. 04 
RDF010m RDF descriptors Radial Distribution Function − 1.0 / weighted by atomic 
masses 
RDF070m RDF descriptors Radial Distribution Function − 7.0 / weighted by atomic 
masses 
Mor26u 3D-MoRSE 
descriptors 
3D-MoRSE − signal 26 / unweighted 
Mor24m 3D-MoRSE 
descriptors 
3D-MoRSE − signal 24 / weighted by atomic masses 
P1e WHIM descriptors 1st component shape directional WHIM index / weighted by 
atomic Sanderson electronegativities 
nSO Functional group 
counts 
number of sulfoxides 
H–051 Atom-centered 
fragments 
H attached to alpha–C (a C attached through a single bond 
with –C=X, –C#X, –C–X) 
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Appendix: O. Features selected for Group VII using PSA-
SVM. 
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Name Block Description 
MSD Topological 
descriptors 
mean square distance index (Balaban) 
BIC2 Information indices bond information content (neighborhood symmetry of 2-
order) 
SIC3 Information indices structural information content (neighborhood symmetry of 3-
order) 
RDF135v RDF descriptors Radial Distribution Function − 13.5 / weighted by atomic 
van der Waals volumes 
RDF150v RDF descriptors Radial Distribution Function − 15.0 / weighted by atomic 
van der Waals volumes 
Mor13u 3D-MoRSE 
descriptors 
3D-MoRSE − signal 13 / unweighted 
L1m WHIM descriptors 1st component size directional WHIM index / weighted by 
atomic masses 
nHDon Functional group 
counts 
number of donor atoms for H-bonds (N and O) 
B10[N–S] 2D binary 
fingerprints 
presence/absence of N–S at topological distance 10 
B10[N–F] 2D binary 
fingerprints 
presence/absence of N–F at topological distance 10 
F06[N–N] 2D frequency 
fingerprints 
frequency of N–N at topological distance 6 
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Appendix: P. Features selected for multi-class classification 
using RBE-RF. 
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Name Block Description 
nCIR Constitutional 
descriptors 
number of circuits 
RBN Constitutional 
descriptors 
number of rotatable bonds 
nAB Constitutional 
descriptors 
number of aromatic bonds 
TI2 Topological 
descriptors 
second Mohar index TI2 
Rww Topological 
descriptors 
reciprocal hyper-detour index 
D/D Topological 
descriptors 
distance/detour index 
D/Dr05 Topological 
descriptors 
distance/detour ring index of order 5 
D/Dr06 Topological 
descriptors 
distance/detour ring index of order 6 
SRW09 Walk and path counts self-returning walk count of order 09 
piPC05 Walk and path counts molecular multiple path count of order 05 
piPC06 Walk and path counts molecular multiple path count of order 06 
piPC08 Walk and path counts molecular multiple path count of order 08 
IDE Information indices mean information content on the distance equality 
HVcpx Information indices graph vertex complexity index 
EEig01x Edge adjacency 
indices 
Eigenvalue 01from edge adj. matrix weighted by edge 
degrees 
EEig01r Edge adjacency 
indices 
Eigenvalue 01 from edge adj. matrix weighted by 
resonance integrals 
BEHv1 Burden eigenvalue 
descriptors 
highest eigenvalue n. 1 of Burden matrix / weighted by 
atomic van der Waals volumes 
BEHv2 Burden eigenvalue 
descriptors 
highest eigenvalue n. 2 of Burden matrix / weighted by 
atomic van der Waals volumes 
BEHv3 Burden eigenvalue 
descriptors 
highest eigenvalue n. 3 of Burden matrix / weighted by 
atomic van der Waals volumes 
BEHe1 Burden eigenvalue 
descriptors 
lowest eigenvalue n. 1 of Burden matrix / weighted by 
atomic Sanderson electronegativities 
BEHe2 Burden eigenvalue 
descriptors 
lowest eigenvalue n. 2 of Burden matrix / weighted by 
atomic Sanderson electronegativities 
BEHe3 Burden eigenvalue 
descriptors 
lowest eigenvalue n. 3 of Burden matrix / weighted by 
atomic Sanderson electronegativities 
BEHp1 Burden eigenvalue 
descriptors 
highest eigenvalue n. 1 of Burden matrix / weighted by 
atomic polarizabilities 
BEHp2 Burden eigenvalue 
descriptors 
highest eigenvalue n. 2 of Burden matrix / weighted by 
atomic polarizabilities 
BEHp3 Burden eigenvalue 
descriptors 
highest eigenvalue n. 3 of Burden matrix / weighted by 
atomic polarizabilities 
LP1 Eigenvalue-based Lovasz–Pelikan index (leading eigenvalue) 
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indices 
E3u WHIM descriptors 3rd component accessibility directional WHIM index / 
unweighted 
nR=Ct Functional group 
counts 
number of aliphatic tertiary C(sp2) 
nC=N–N< Functional group 
counts 
number of amidine derivatives 
nPyrroles Functional group 
counts 
number of Pyrroles 
nPyrimidines Functional group 
counts 
number of Pyrimidines 
nHDon Functional group 
counts 
number of donor atoms for H-bonds (N and O) 
C–017 Atom-centered 
fragments 
=CR2 (R represents any group linked through carbon) 
C–030 Atom-centered 
fragments 
X–CH–X (X represents any electronegative atom (O, N, 
S, P, Se, halogens)) 
N–074 Atom-centered 
fragments 
R#N/R=N– (R represents any group linked through 
carbon) 
Hy Molecular properties hydrophilic factor 
B01[N–N] 2D binary fingerprints presence/absence of N–N at topological distance 1 
F01[N–N] 2D frequency 
fingerprints 
frequency of N–N at topological distance 1 
F02[N–N] 2D frequency 
fingerprints 
frequency of N–N at topological distance 2 
F03[C–N] 2D frequency 
fingerprints 
frequency of C–N at topological distance 3 
F04[N–N] 2D frequency 
fingerprints 
frequency of N–N at topological distance 4 
F09[C–C] 2D frequency 
fingerprints 
frequency of C–C at topological distance 5 
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